# US 2021/0330869 A1 · SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330869 A1
- Document ID: US20210330869A1
- Status: Published application
- Kind: A1
- Application number: 17/306,621
- Filed: 2021-05-03
- Published: 2021-10-28
- Earliest claimed: 2012-07-03
- Assignees: Sio2 Medical Products, Inc.
- Applicants: SiO2 Medical Products, Inc.
- Inventors: Christopher Weikart; John T. Felts; Thomas E. Fisk; Robert S. Abrams; John Ferguson; Jonathan R. Freedman; Robert J. Pangborn; Peter J. Sagona
- Web page: https://patentgrep.com/patent/US20210330869A1

## CPC

- A61L 31/088: {Other specific inorganic materials not covered by A61L31/084 or A61L31/086}
- A61J 1/035: {Blister-type containers (blisters in general B65D75/36)}
- A61J 1/05: for collecting, storing or administering blood, plasma or medical fluids {(multiple bags systems for separating or storing blood components A61M1/0209); Infusion or perfusion containers}
- A61L 29/106: {Inorganic materials other than carbon}
- A61M 5/3129: {Syringe barrels (A61M5/3205, A61M5/50 take precedence)}
- C23C 16/401: {containing silicon}
- A61F 9/0008: {Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00)}
- A61J 1/1468: {Containers characterised by specific material properties}
- A61L 2420/02: Methods for coating medical devices
- A61M 15/0001: {Details of inhalators; Constructional features thereof}
- A61M 2202/048: Anaesthetics
- A61M 2205/0238: the material being a coating or protective layer
- A61M 2205/19: Constructional features of carpules, syringes or blisters
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- C23C: COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL (making metal-coated products by extrusion B21C23/22; covering with metal by connecting pre-existing layers to articles, see the relevant places, e.g. B21D39/00, B23K; metallising of glass C03C; metallising mortars, concrete, artificial stone, ceramics or natural stone C04B41/00; enamelling of, or applying a vitreous layer to, metals C23D; treating metal surfaces or coating of metals by electrolysis or electrophoresis C25D; single-crystal film growth C30B; by metallising textiles D06M11/83; decorating textiles by locally metallising D06Q1/04)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

A vessel including a thermoplastic wall enclosing a lumen is disclosed. The wall supports an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, between the wall and the lumen. High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the wall or substrate. In one aspect, the interface has at least 1 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding. In another aspect, the interface has an Si 2p chemical shift to lower binding energy (eV), compared to the binding energy of SiO4 bonding. The result is a tightly adherent composite barrier coating or layer having a high degree of adhesion to the substrate under practical use conditions. Methods of applying the composite barrier coating or layer are also disclosed.

## Claims

### Claim 1

A vessel comprising a thermoplastic wall enclosing a lumen and an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, in which the SiOx composite barrier coating or layer is formed by PECVD from an organosilicon monomer and oxidizing gas, in at least bonding and buildup stages, under the following conditions:
during the bonding stage, a feed ratio of organosilicon monomer to oxidizing gas, in sccm, of from 2.5 to 10; and
during the buildup stage, a feed ratio of organosilicon monomer to oxidizing gas of from 0.1 to 0.05.

### Claim 2

A vessel comprising a thermoplastic wall enclosing a lumen and an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, in which the SiOx composite barrier coating or layer is formed by RF PECVD from an organosilicon monomer and oxidizing gas, at an initial RF power level from 20 to 4 W and a highest RF power level of from 300 to 30 W.

### Claim 3

A vessel comprising a thermoplastic wall enclosing a lumen and an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 95% by the Article Deformation/Tape Test Method.

### Claim 4

A vessel comprising a thermoplastic wall enclosing a lumen and an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 90% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 5

A vessel comprising a thermoplastic wall enclosing a lumen and an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 1 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 6

A vessel comprising a thermoplastic wall enclosing a lumen and an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an Si 2p chemical shift to lower binding energy (eV), compared to the binding energy of SiO4 bonding.

### Claim 7

A method of making a vessel comprising:
providing a thermoplastic wall enclosing a lumen; and
applying to the thermoplastic wall an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, by PECVD from an organosilicon monomer and oxidizing gas, in at least bonding and buildup stages, under the following conditions:
during the bonding stage, a feed ratio of organosilicon monomer to oxidizing gas, in sccm, of from 2.5 to 10; and
during the buildup stage, a feed ratio of organosilicon monomer to oxidizing gas of from 0.1 to 0.05.

### Claim 8

A method of making a vessel comprising:
providing a thermoplastic wall enclosing a lumen; and
applying to the thermoplastic wall an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, by PECVD from an organosilicon monomer and oxidizing gas, in at least bonding and buildup stages, at an initial RF power level from 20 to 4 W and a highest RF power level of from 300 to 30 W.

### Claim 9

A method of making a vessel comprising:
providing a thermoplastic wall enclosing a lumen; and
applying to the thermoplastic wall an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, by PECVD from an organosilicon monomer and oxidizing gas, in at least bonding and buildup stages,
in which the degree of retention of the composite barrier coating or layer on the substrate is at least 95% by the Article Deformation/Tape Test Method.

### Claim 10

A method of making a vessel comprising:
providing a thermoplastic wall enclosing a lumen; and
applying to the thermoplastic wall an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, by PECVD from an organosilicon monomer and oxidizing gas, in at least bonding and buildup stages,
in which the degree of retention of the composite barrier coating or layer on the substrate is at least 90% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 11

A method of making a vessel comprising:
providing a thermoplastic wall enclosing a lumen; and
applying to the thermoplastic wall an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, by PECVD from an organosilicon monomer and oxidizing gas, in at least bonding and buildup stages,
in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 1 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 12

A method of making a vessel comprising:
providing a thermoplastic wall enclosing a lumen; and
applying to the thermoplastic wall an SiOx composite barrier coating or layer, for which x is from 1.8 to 2.4, supported by the wall between the wall and the lumen, by PECVD from an organosilicon monomer and oxidizing gas, in at least bonding and buildup stages,
in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an Si 2p chemical shift to lower binding energy (eV), compared to the binding energy of SiO4 bonding.

### Claim 13

The invention of any preceding claim, formed during the bonding stage at a feed ratio of organosilicon monomer to oxidizing gas of from 2.5 to 10.

### Claim 14

The invention of any preceding claim, formed during the buildup stage at a feed ratio of organosilicon monomer to oxidizing gas of from 0.1 to 0.05.

### Claim 15

The invention of any preceding claim, in which the SiOx composite barrier coating or layer is formed by RF PECVD from an organosilicon monomer and oxidizing gas, at an initial RF power level from 20 to 4 W and a highest RF power level of from 300 W to 30 W.

### Claim 16

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 95% by the Article Deformation/Tape Test Method.

### Claim 17

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 90% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 18

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 2 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 19

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an Si 2p chemical shift to lower binding energy (eV), compared to the binding energy of SiO4 bonding.

### Claim 20

The invention of any preceding claim, in which
the SiOx composite barrier coating or layer is formed by RF PECVD from an organosilicon monomer and oxidizing gas, at an initial RF power level from 20 W to 4 W and a highest RF power level of from 300 to 30 W; and
the power level is increased uniformly from the initial RF power level to the highest RF power level.

### Claim 21 (depends on 20)

The vessel of claim 20, in which the RF power level is not pulsed.

### Claim 22

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 96% by the Article Deformation/Tape Test Method.

### Claim 23

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 97% by the Article Deformation/Tape Test Method.

### Claim 24

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 98% by the Article Deformation/Tape Test Method.

### Claim 25

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 99% by the Article Deformation/Tape Test Method.

### Claim 26

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is 100% by the Article Deformation/Tape Test Method.

### Claim 27

The invention of any preceding claim, in which the Article Deformation/Tape Test Method is carried out using axial deformation.

### Claim 28

The invention of any preceding claim, in which the Article Deformation/Tape Test Method is carried out using diametric deformation.

### Claim 29

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 91% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 30

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 92% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 31

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 93% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 32

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 94% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 33

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 95% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 34

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 96% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 35

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 97% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 36

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 98% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 37

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is at least 99% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 38

The invention of any preceding claim, in which the degree of retention of the composite barrier coating or layer on the substrate is 100% by the Coated Article Cross-Scratch Tape Test Method.

### Claim 39

The invention of any preceding claim, in which the Coated Article Cross-Scratch Tape Test Method is carried out using an X scratch pattern.

### Claim 40

The invention of any preceding claim, in which the Coated Article Cross-Scratch Tape Test Method is carried out using a rectangular scratch pattern.

### Claim 41

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 2 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 42

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 3 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 43

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 4 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 44

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 5 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 45

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 6 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 46

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 7 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 47

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 8 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 48

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 9 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 49

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 10 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 50

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 11 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 51

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 12 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 52

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 13 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 53

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 14 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 54

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 15 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 55

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 16 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 56

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 17 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 57

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 18 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 58

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 19 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 59

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at least 20 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 60 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The invention of any preceding claim 41-59, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at most 25 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 61 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The invention of any preceding claim 41-59, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at most 20 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 62 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The invention of any preceding claim 41-59, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at most 15 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 63 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The invention of any preceding claim 41-59, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having at most 10 mol. % O3—Si—C covalent bonding, as a proportion of the O3—Si—C covalent bonding plus SiO4 bonding.

### Claim 64

The invention of any preceding claim, in which High Resolution X-ray Photoelectron Spectroscopy (XPS) shows the presence of an interface between the composite barrier coating or layer and the substrate having Si 2p peak broadening of at least 0.2 eV, compared to the binding energy of SiO4 bonding.

### Claim 65

The invention of any preceding claim, in which the SiOx composite barrier coating or layer is formed by PECVD from an organosilicon monomer and oxidizing gas, in at least substrate ablation, SiOx bonding and SiOx buildup stages.

### Claim 66

The invention of any preceding claim, in which the vessel has a rated volume between 0.2 and 50 ml.

### Claim 67

The invention of any preceding claim, in which the vessel has a rated volume between 2 and 50 ml.

### Claim 68

The invention of any preceding claim, in which the vessel has a rated volume between 2 and 20 ml.

### Claim 69

The invention of any preceding claim, in which the vessel has a rated volume between 2 and 6 ml.

### Claim 70

The invention of any preceding claim, in which the vessel has a rated volume between 3 and 5 ml.

### Claim 71

The invention of any preceding claim, in which the vessel has a rated volume between 0.25 and 20 ml.

### Claim 72

The invention of any preceding claim, in which the vessel has a rated volume between 0.5 and 5 ml.

### Claim 73

The invention of any preceding claim, in which the vessel has a rated volume between 1 and 2 ml.

### Claim 74

The invention of any preceding claim, in which the vessel has a fill volume between 0.3 and 75 ml.

### Claim 75

The invention of any preceding claim, in which the vessel has a fill volume between 3 and 75 ml.

### Claim 76

The invention of any preceding claim, in which the vessel has a fill volume between 3 and 30 ml.

### Claim 77

The invention of any preceding claim, in which the vessel has a fill volume between 4 and 9 ml.

### Claim 78

The invention of any preceding claim, in which the vessel has a fill volume between 4 and 8 ml.

### Claim 79

The invention of any preceding claim, in which the vessel has a fill volume between 0.4 and 35 ml.

### Claim 80

The invention of any preceding claim, in which the vessel has a fill volume between 0.8 and 9 ml.

### Claim 81

The invention of any preceding claim, in which the vessel has a fill volume between 1.7 and 3.5 ml.

### Claim 82

The invention of any preceding claim, in which the vessel is a vial.

### Claim 83

The invention of any preceding claim, in which the vessel is a syringe.

### Claim 84

The invention of any preceding claim, in which the vessel is a prefilled syringe.

### Claim 85

The invention of any preceding claim, in which the vessel is a cartridge.

### Claim 86

The invention of any preceding claim, in which the vessel is a sample tube.

### Claim 87

The invention of any preceding claim, in which the vessel is an evacuated blood sample tube.

### Claim 88

The invention of any preceding claim, in which the power density at the initial RF power level is from 3 to 1 W/mL.

### Claim 89

The invention of any preceding claim, in which the power density at the highest RF power level is from 60 to 4 W/mL.

### Claim 90

The invention of any preceding claim, in which the organosilicon monomer is an organosiloxane having from 2 to 6 silicon atoms per molecule.

### Claim 91

The invention of any preceding claim, in which the organosilicon monomer is hexamethyldisiloxane.

### Claim 92

The invention of any preceding claim, in which the organosilicon monomer is an organosiloxazane having from 2 to 6 silicon atoms per molecule.

### Claim 93

The invention of any preceding claim, in which the organosilicon monomer is hexamethyldisiloxazane.

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The invention of any preceding claim 1-6 or 13-93, in which the lumen contains a pharmaceutical agent.

### Claim 95 (depends on 94)

The invention of claim 94, in which the pharmaceutical agent has a pH between 5 and 9.

### Claim 96 (depends on 1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The invention of any preceding claim 1-6 or 13-95, further comprising an opening between the lumen and the exterior of the vessel.

### Claim 97 (depends on 96)

The invention of claim 96, further comprising a closure seated in the opening.

### Claim 98 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The invention of any preceding claim 7-93, further comprising introducing a pharmaceutical agent into the lumen.

### Claim 99 (depends on 98)

The invention of claim 98, in which the pharmaceutical agent has a pH between 5 and 9.

### Claim 100 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The invention of any preceding claim 7-99, further comprising providing an opening between the lumen and the exterior of the vessel.

### Claim 101 (depends on 100)

The invention of claim 100, further comprising seating a closure in the opening.

### Claim 102 (depends on 1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The invention of any preceding claim 1-6 or 13-97, further comprising an interior surface of the composite barrier coating or layer facing the lumen and a pH protective coating or layer of SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the pH protective coating or layer having an interior surface facing the lumen and an outer surface facing the interior surface of the composite barrier coating or layer, the pH protective coating or layer being effective to increase the calculated shelf life of the vessel (total Si/Si dissolution rate).

### Claim 103 (depends on 1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The invention of any preceding claim 1-6 or 13-97, in which the wall has an interior surface comprising glass facing the lumen and an outer surface, further comprising a pH protective coating or layer of SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the pH protective coating or layer having an interior surface facing the lumen and an outer surface facing the interior surface of the composite barrier coating or layer, the pH protective coating or layer being effective to decrease the Si dissolution rate of the glass interior surface.

### Claim 104 (depends on 1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The invention of any preceding claim 1-6 or 13-97, further comprising an interior surface of the composite barrier coating or layer facing the lumen and a pH protective coating or layer of SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, on the composite barrier coating or layer, the pH protective coating or layer being formed by chemical vapor deposition of a precursor selected from a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors

### Claim 105

The invention of any preceding claim, wherein the SiOx composite barrier coating or layer is formed by PECVD from a gas feed comprising an organosilicon monomer, an oxidizing gas, and a carrier gas.

### Claim 106 (depends on 105)

The invention of claim 105, wherein the carrier gas consists essentially of inert gas under the PECVD conditions employed.

### Claim 107 (depends on 105, 106)

The invention of claim 105 or 106, wherein the carrier gas comprises a noble gas.

### Claim 108 (depends on 105, 106)

The invention of claim 105, 106, or 107, wherein the carrier gas comprises helium.

### Claim 109 (depends on 105, 106, 107, 108)

The invention of any preceding claims 105 to 108, wherein the carrier gas comprises neon.

### Claim 110 (depends on 105, 106, 107, 108, 109)

The invention of any preceding claims 105 to 109, wherein the carrier gas comprises argon.

### Claim 111 (depends on 105, 106, 107, 108, 109, 110)

The invention of any preceding claims 105 to 110, wherein the carrier gas comprises krypton.

### Claim 112 (depends on 105, 106, 107, 108, 109, 110, 111)

The invention of any preceding claims 105 to 111, wherein the carrier gas comprises xenon.

### Claim 113

The invention of any preceding claim, in which the SiOx is formed from an organosilicon monomer and an oxidizing gas.

### Claim 114 (depends on 113)

The invention of claim 113, in which the oxidizing gas comprises oxygen.

### Claim 115 (depends on 113, 114)

The invention of claim 113 or 114, in which the oxidizing gas comprises O2.

### Claim 116 (depends on 113, 114, 115)

The invention of any preceding claims 113 to 115, in which the oxidizing gas comprises H2O2.

### Claim 117 (depends on 113, 114, 115, 116)

The invention of any preceding claims 113 to 116, in which the oxidizing gas comprises O3.

### Claim 118 (depends on 113, 114, 115, 116, 117)

The invention of any preceding claims 113 to 117, in which the oxidizing gas comprises H2O.

### Claim 119

The invention of any preceding claim, in which the composite barrier coating or layer is applied by PECVD of a precursor feed comprising an organosiloxane, an organosilane, or an organosilazane.

### Claim 120

The invention of any preceding claim, in which the composite barrier coating or layer is applied by PECVD of a precursor feed comprising a linear or branched siloxane having from 1 to 5 silicon atoms, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim 121

The invention of any preceding claim, in which in which the composite barrier coating or layer is applied by PECVD of a precursor feed comprising a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a silatrane, a silquasilatrane, a silproatrane, or a combination of any two or more of these precursors.

### Claim 122

The invention of any preceding claim, in which the composite barrier coating or layer is applied by PECVD of a precursor feed comprising a monocyclic siloxane.

### Claim 123

The invention of any preceding claim, in which the composite barrier coating or layer is applied by PECVD of a precursor feed comprising octamethylcyclotetrasiloxane (OMCTS).

### Claim 124

The invention of any preceding claim, in which the composite barrier coating or layer is applied by PECVD of a precursor feed consisting essentially of octamethylcyclotetrasiloxane (OMCTS).

### Claim 125

The invention of any preceding claim, in which the composite barrier coating or layer is applied by PECVD of a precursor feed comprising a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim 126

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises:
a polyolefin,
a polyester or
a combination of a polyolefin and a polyester.

### Claim 127

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a polyolefin.

### Claim 128

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a polyolefin.

### Claim 129

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a cyclic olefin polymer.

### Claim 130

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a cyclic olefin polymer.

### Claim 131

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a cyclic olefin copolymer.

### Claim 132

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a cyclic olefin copolymer.

### Claim 133

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises polypropylene.

### Claim 134

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of polypropylene.

### Claim 135

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a polyester.

### Claim 136

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a polyester.

### Claim 137

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises polyethylene terephthalate.

### Claim 138

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of polyethylene terephthalate.

### Claim 139

The invention of any preceding claim, in which the vessel comprises a syringe barrel.

### Claim 140

The invention of any preceding claim, in which the vessel comprises a vial.

### Claim 141

The invention of any preceding claim, in which the vessel comprises a blister package.

### Claim 142

The invention of any preceding claim, further comprising a fluid contained in the lumen of the vessel, in which the fluid composition has a pH between 5 and 6.

### Claim 143

The invention of any preceding claim, further comprising a fluid contained in the lumen of the vessel, in which the fluid composition has a pH between 6 and 7.

### Claim 144

The invention of any preceding claim, further comprising a fluid contained in the lumen of the vessel, in which the fluid composition has a pH between 7 and 8.

### Claim 145

The invention of any preceding claim, further comprising a fluid contained in the lumen of the vessel, in which the fluid composition has a pH between 8 and 9.

### Claim 146

The invention of any preceding claim, further comprising a fluid contained in the lumen of the vessel, in which the fluid composition has a pH between 6.5 and 7.5.

### Claim 147

The invention of any preceding claim, further comprising a fluid contained in the lumen of the vessel, in which the fluid composition has a pH between 7.5 and 8.5.

### Claim 148

The invention of any preceding claim, further comprising a fluid contained in the lumen of the vessel, in which the fluid composition has a pH between 8.5 and 9.

### Claim 149

The invention of any preceding claim, further comprising a fluid contained in the lumen of the vessel, in which the fluid composition is a liquid at 20° C. and 760 mm Hg. atmospheric pressure.

### Claim 150

The invention of any preceding claim, further comprising a fluid contained in the lumen of the vessel, in which the fluid composition is an aqueous liquid.

### Claim 151

The invention of any preceding claim, in which the composite barrier coating or layer is from 4 nm to 500 nm thick.

### Claim 152

The invention of any preceding claim, in which the composite barrier coating or layer is from 7 nm to 400 nm thick.

### Claim 153

The invention of any preceding claim, in which the composite barrier coating or layer is from 10 nm to 300 nm thick.

### Claim 154

The invention of any preceding claim, in which the composite barrier coating or layer is from 20 nm to 200 nm thick.

### Claim 155

The invention of any preceding claim, in which the composite barrier coating or layer is from 30 nm to 100 nm thick.

### Claim 156 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which the pH protective coating or layer comprises SiOxCy.

### Claim 157 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which the pH protective coating or layer consists essentially of SiOxCy.

### Claim 158 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which the pH protective coating or layer comprises SiNxCy.

### Claim 159 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which the pH protective coating or layer consists essentially of SiNxCy.

### Claim 160 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim 161 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a silatrane, a silquasilatrane, a silproatrane, or a combination of any two or more of these precursors.

### Claim 162 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising a monocyclic siloxane.

### Claim 163 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising octamethylcyclotetrasiloxane (OMCTS).

### Claim 164 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which the pH protective coating or layer is applied by PECVD of a precursor feed consisting essentially of octamethylcyclotetrasiloxane (OMCTS).

### Claim 165 (depends on 102, 103, 104)

The invention of any preceding claims 102 to 104, in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim 166 (depends on 165)

The invention of claim 165, in which the precursor feed further comprises oxidizing gas.

### Claim 167 (depends on 165)

The invention of claim 165 or 165A, in which the precursor feed further comprises a carrier gas.

### Claim 168 (depends on 165, 165167)

The invention of any preceding claims 165 to 165167, in which the carrier gas comprises argon.

### Claim 169 (depends on 165, 165168)

The invention of any preceding claims 165 to 165168, in which the precursor feed comprises:
from 0.5 to 10 standard volumes of the organosilicon precursor;
from 0.1 to 10 standard volumes of oxidizing gas; and
from 1 to 100 sccm of a carrier gas.

### Claim 170 (depends on 165, 165169)

The invention of any preceding claims 165 to 165169, in which the precursor feed comprises:
from 0.5 to 10 standard volumes of octamethylenecyclotetrasiloxane;
from 0.1 to 10 standard volumes of oxidizing gas; and
from 1 to 100 sccm of argon.

### Claim 171 (depends on 165, 165170)

The invention of any preceding claims 165 to 165170, in which the pH protective coating or layer as applied is between 10 and 1000 nm thick.

### Claim 172 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171)

The invention of any preceding claims 102 to 171, in which the pH protective coating or layer as applied is between 50 and 800 nm thick.

### Claim 173 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172)

The invention of any preceding claims 102 to 172, in which the pH protective coating or layer as applied is between 100 and 700 nm thick.

### Claim 174 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The invention of any preceding claims 102 to 173, in which the pH protective coating or layer as applied is between 300 and 600 nm thick.

### Claim 175 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174)

The invention of any preceding claims 102 to 174, in which the pH protective coating or layer contacting the fluid composition is between 10 and 1000 nm thick two years after the invention is assembled.

### Claim 176 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175)

The invention of any preceding claims 102 to 175, in which the pH protective coating or layer contacting the fluid composition is between 20 and 700 nm thick two years after the invention is assembled.

### Claim 177 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The invention of any preceding claims 102 to 176, in which the pH protective coating or layer contacting the fluid composition is between 50 and 500 nm thick two years after the invention is assembled.

### Claim 178 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177)

The invention of any preceding claims 102 to 177, in which the pH protective coating or layer contacting the fluid composition is between 100 and 400 nm thick two years after the invention is assembled.

### Claim 179 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178)

The invention of any preceding claims 102 to 178, in which the pH protective coating or layer contacting the fluid composition is between 150 and 300 nm thick two years after the invention is assembled.

### Claim 180 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179)

The invention of any preceding claims 102 to 179, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 20% of the rate of erosion of the composite barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 181 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180)

The invention of any preceding claims 102 to 180, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 15% of the rate of erosion of the composite barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 182 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)

The invention of any preceding claims 102 to 181, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 10% of the rate of erosion of the composite barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 183 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The invention of any preceding claims 102 to 182, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 7% of the rate of erosion of the composite barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 184 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183)

The invention of any preceding claims 102 to 183, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 20% of the rate of erosion of the composite barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 185 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184)

The invention of any preceding claims 102 to 184, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 15% of the rate of erosion of the composite barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 186 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185)

The invention of any preceding claims 102 to 185, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 10% of the rate of erosion of the composite barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 187 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186)

The invention of any preceding claims 102 to 186, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 7% of the rate of erosion of the composite barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 188 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187)

The invention of any preceding claims 102 to 187, in which the pH protective coating or layer is at least coextensive with the composite barrier coating or layer.

### Claim 189 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188)

The invention of any preceding claims 102 to 188, having a shelf life, after the invention is assembled, of at least one year.

### Claim 190 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The invention of any preceding claims 102 to 189, having a shelf life, after the invention is assembled, of at least two years.

### Claim 191 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The invention of any preceding claims 102 to 189, having a shelf life, after the invention is assembled, of at least three years.

### Claim 192 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The invention of any preceding claims 102 to 189, having a shelf life, after the invention is assembled, of at least four years.

### Claim 193 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The invention of any preceding claims 102 to 189, having a shelf life, after the invention is assembled, of at least five years.

### Claim 194 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The invention of any preceding claims 102 to 189, having a shelf life, after the invention is assembled, of at least six years.

### Claim 195 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The invention of any preceding claims 102 to 189, having a shelf life, after the invention is assembled, of at least seven years.

### Claim 196 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The invention of any preceding claims 102 to 189, having a shelf life, after the invention is assembled, of at least eight years.

### Claim 197 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The invention of any preceding claims 102 to 189, having a shelf life, after the invention is assembled, of at least nine years.

### Claim 198 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The invention of any preceding claims 102 to 189, having a shelf life, after the invention is assembled, of at most ten years.

### Claim 199 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198)

The invention of any preceding claims 102 to 198, in which the shelf life is determined at 3° C.

### Claim 200 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198)

The invention of any preceding claims 102 to 198, in which the shelf life is determined at 4° C.

### Claim 201 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198)

The invention of any preceding claims 102 to 198, in which the shelf life is determined at 20° C.

### Claim 202 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198)

The invention of any preceding claims 102 to 198, in which the shelf life is determined at 23° C.

### Claim 203 (depends on 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198)

The invention of any preceding claims 102 to 198, in which the shelf life is determined at 40° C.

### Claim 204 (depends on 102, 203)

The invention of any preceding claims 102 to 203, in which the pH of the fluid composition is between 5 and 6 and the thickness of the pH protective coating or layer is at least 80 nm at the end of the shelf life.

### Claim 205 (depends on 102, 203)

The invention of any preceding claims 102 to 203, in which the pH of the fluid composition is between 6 and 7 and the thickness of the pH protective coating or layer is at least 80 nm at the end of the shelf life.

### Claim 206 (depends on 102, 203)

The invention of any preceding claims 102 to 203, in which the pH of the fluid composition is between 7 and 8 and the thickness of the pH protective coating or layer is at least 80 nm at the end of the shelf life.

### Claim 207 (depends on 102, 203)

The invention of any preceding claims 102 to 203, in which the pH of the fluid composition is between 8 and 9 and the thickness of the pH protective coating or layer is at least 80 nm at the end of the shelf life.

### Claim 208 (depends on 102, 203)

The invention of any preceding claims 102 to 203, in which the pH of the fluid composition is between 5 and 6 and the thickness of the pH protective coating or layer is at least 150 nm at the end of the shelf life.

### Claim 209 (depends on 102, 203)

The invention of any preceding claims 102 to 203, in which the pH of the fluid composition is between 6 and 7 and the thickness of the pH protective coating or layer is at least 150 nm at the end of the shelf life.

### Claim 210 (depends on 102, 203)

The invention of any preceding claims 102 to 203, in which the pH of the fluid composition is between 7 and 8 and the thickness of the pH protective coating or layer is at least 150 nm at the end of the shelf life.

### Claim 211 (depends on 102, 203)

The invention of any preceding claims 102 to 203, in which the pH of the fluid composition is between 8 and 9 and the thickness of the pH protective coating or layer is at least 150 nm at the end of the shelf life.

### Claim 212 (depends on 102, 211)

The invention of any preceding claims 102 to 211, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 44 hours of contact with the fluid composition.

### Claim 213 (depends on 102, 211)

The invention of any preceding claims 102 to 211, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 88 hours of contact with the fluid composition.

### Claim 214 (depends on 102, 211)

The invention of any preceding claims 102 to 211, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 175 hours of contact with the fluid composition.

### Claim 215 (depends on 102, 211)

The invention of any preceding claims 102 to 211, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 250 hours of contact with the fluid composition.

### Claim 216 (depends on 102, 211)

The invention of any preceding claims 102 to 211, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 350 hours of contact with the fluid composition.

### Claim 217 (depends on 102, 216)

The invention of any preceding claims 102 to 216, in which the pH protective coating or layer is effective to provide a lower frictional resistance than the uncoated interior surface.

### Claim 218 (depends on 217)

The invention of claim 217 wherein the frictional resistance is reduced by at least 25% in comparison to the uncoated interior surface.

### Claim 219 (depends on 217)

The invention of claim 217 wherein the frictional resistance is reduced by at least 45% in comparison to the uncoated interior surface.

### Claim 220 (depends on 217)

The invention of claim 217 wherein the frictional resistance is reduced by at least 60% in comparison to the uncoated interior surface.

### Claim 221 (depends on 102, 220)

The invention of any preceding claims 102 to 220, in which the pH protective coating or layer is effective to reduce the frictional resistance between a portion of the wall contacted by the fluid composition and a relatively sliding part after the invention is assembled.

### Claim 222 (depends on 102, 220)

The invention of any preceding claims 102 to 220, in which the pH protective coating or layer is effective to reduce the frictional resistance between the wall and a relatively sliding part at least two years after the invention is assembled.

### Claim 223

The invention of any preceding claim, in which the invention is a syringe.

### Claim 224

The invention of any preceding claim, in which the invention is a syringe comprising a syringe barrel.

### Claim 225

The invention of any preceding claim, in which the invention is a syringe comprising a plunger.

### Claim 226

The invention of any preceding claim, in which the invention is a syringe comprising a syringe barrel and a plunger.

### Claim 227

The invention of any preceding claim, in which the invention is a syringe comprising a syringe barrel and a plunger and the wall defines at least a portion of the syringe barrel.

### Claim 228

The invention of any preceding claim, in which the invention is a syringe comprising a syringe barrel and a plunger, the wall defines at least a portion of the syringe barrel, and the relatively sliding part comprises the syringe plunger.

### Claim 229 (depends on 102, 228)

The invention of any preceding claims 102 to 228, further comprising
a lubricity coating applied between the pH protective coating or layer and the lumen;
optionally, a further coating applied adjacent to the inner surface of the pH protective coating or layer, the further coating having an outer surface facing the interior surface of the thermoplastic wall and an inner surface facing the lumen; and
fluid in contact with the pH protective coating or layer.

### Claim 230 (depends on 102, 229)

The invention of any preceding claims 102 to 229, in which an FTIR absorbance spectrum of the pH protective coating or layer has a ratio greater than 0.75 between:
the maximum amplitude of the Si—O—Si symmetrical stretch peak between about 1000 and 1040 cm−1, and
the maximum amplitude of the Si—O—Si assymmetric stretch peak between about 1060 and about 1100 cm−1.

### Claim 231 (depends on 230)

The invention of claim 230, in which the ratio is at least 0.8.

### Claim 232 (depends on 230)

The invention of claim 230, in which the ratio is at least 0.9.

### Claim 233 (depends on 230)

The invention of claim 230, in which the ratio is at least 1.

### Claim 234 (depends on 230)

The invention of claim 230, in which the ratio is at least 1.1.

### Claim 235 (depends on 230)

The invention of claim 230, in which the ratio is at least 1.2.

### Claim 236 (depends on 230, 231, 232, 233, 234, 235)

The invention of any preceding claims 230 to 235, in which the ratio is at most 1.7.

### Claim 237 (depends on 230, 231, 232, 233, 234, 235)

The invention of any preceding claims 230 to 235, in which the ratio is at most 1.6.

### Claim 238 (depends on 230, 231, 232, 233, 234, 235)

The invention of any preceding claims 230 to 235, in which the ratio is at most 1.5.

### Claim 239 (depends on 230, 231, 232, 233, 234, 235)

The invention of any preceding claims 230 to 235, in which the ratio is at most 1.4.

### Claim 240 (depends on 230, 231, 232, 233, 234, 235)

The invention of any preceding claims 230 to 235, in which the ratio is at most 1.3.

### Claim 241 (depends on 102, 240)

The invention of any preceding claims 102 to 240, in which the pH protective coating or layer has a non-oily appearance.

### Claim 242 (depends on 102, 241)

The invention of any preceding claims 102 to 241, in which the silicon dissolution rate by a 50 mM potassium phosphate buffer diluted in water for injection, adjusted to pH 8 with concentrated nitric acid, and containing 0.2 wt. % polysorbate-80 surfactant from the vessel is less than 170 ppb/day.

### Claim 243 (depends on 242)

The invention of claim 242, in which the silicon dissolution rate is less than 160 ppb/day.

### Claim 244 (depends on 242)

The invention of claim 242, in which the silicon dissolution rate is less than 140 ppb/day.

### Claim 245 (depends on 242)

The invention of claim 242, in which the silicon dissolution rate is less than 120 ppb/day.

### Claim 246 (depends on 242)

The invention of claim 242, in which the silicon dissolution rate is less than 100 ppb/day.

### Claim 247 (depends on 242)

The invention of claim 242, in which the silicon dissolution rate is less than 90 ppb/day.

### Claim 248 (depends on 242)

The invention of claim 242, in which the silicon dissolution rate is less than 80 ppb/day.

### Claim 249 (depends on 102, 248)

The invention of any preceding claims 102 to 248, in which the total silicon content of the pH protective coating and composite barrier coating or layer, upon dissolution into 0.1 N potassium hydroxide aqueous solution at 40° C. from the vessel, is less than 66 ppm.

### Claim 250 (depends on 249)

The invention of claim 249, in which the total silicon content is less than 60 ppm.

### Claim 251 (depends on 249)

The invention of claim 249, in which the total silicon content is less than 50 ppm.

### Claim 252 (depends on 249)

The invention of claim 249, in which the total silicon content is less than 40 ppm.

### Claim 253 (depends on 249)

The invention of claim 249, in which the total silicon content is less than 30 ppm.

### Claim 254 (depends on 249)

The invention of claim 249, in which the total silicon content is less than 20 ppm.

### Claim 255

The invention of any preceding claim, in which the calculated shelf life (total Si/Si dissolution rate) is more than 1 year.

### Claim 256 (depends on 255)

The invention of claim 255, in which the calculated shelf life (total Si/Si dissolution rate) is more than 18 months.

### Claim 257 (depends on 255)

The invention of claim 255, in which the calculated shelf life (total Si/Si dissolution rate) is more than 2 years.

### Claim 258 (depends on 255)

The invention of claim 255, in which the calculated shelf life (total Si/Si dissolution rate) is more than 2½ years.

### Claim 259 (depends on 255)

The invention of claim 255, in which the calculated shelf life (total Si/Si dissolution rate) is more than 3 years.

### Claim 260

The invention of any preceding claim, in which the calculated shelf life (total Si/Si dissolution rate) is less than 4 years.

### Claim 261

The invention of any preceding claim, in which the calculated shelf life (total Si/Si dissolution rate) is less than 5 years.

### Claim 262 (depends on 102, 261)

The invention of any preceding claims 102 to 261, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 22,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 263 (depends on 262)

The invention of any preceding claim 262, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 30,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 264 (depends on 262)

The invention of any preceding claim 262, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 40,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 265 (depends on 262)

The invention of any preceding claim 262, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 50,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 266 (depends on 262)

The invention of any preceding claim 262, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 60,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 267 (depends on 262)

The invention of any preceding claim 262, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 62,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 268 (depends on 262)

The invention of any preceding claim 262, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 70,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 269 (depends on 262)

The invention of any preceding claim 262, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 80,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 270 (depends on 102, 269)

The invention of any preceding claims 102 to 269, in which the pH protective coating or layer is applied by PECVD at a power level per of less than 100,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 271 (depends on 102, 270)

The invention of any preceding claims 102 to 270, in which the pH protective coating or layer is applied by PECVD at a power level per of less than 90,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 272 (depends on 102, 271)

The invention of any preceding claims 102 to 271, in which the pH protective coating or layer is applied by PECVD at a power level per of from 0.1 to 500 W.

### Claim 273 (depends on 272)

The invention of claim 272, in which the pH protective coating or layer is applied by PECVD at a power level per of from 0.1 to 400 W.

### Claim 274 (depends on 272)

The invention of claim 272, in which the pH protective coating or layer is applied by PECVD at a power level per of from 1 to 300 W.

### Claim 275 (depends on 272)

The invention of claim 272, in which the pH protective coating or layer is applied by PECVD at a power level per of from 1 to 250 W.

### Claim 276 (depends on 272)

The invention of claim 272, in which the pH protective coating or layer is applied by PECVD at a power level per of from 10 to 200 W.

### Claim 277 (depends on 272)

The invention of claim 272, in which the pH protective coating or layer is applied by PECVD at a power level per of from 20 to 150 W.

### Claim 278 (depends on 272)

The invention of claim 272, in which the pH protective coating or layer is applied by PECVD at a power level per of from 40 to 150 W.

### Claim 279 (depends on 272)

The invention of claim 272, in which the pH protective coating or layer is applied by PECVD at a power level per of from 60 to 150 W.

### Claim 280 (depends on 102, 279)

The invention of any preceding claims 102 to 279, in which the ratio of the electrode power to the plasma volume is from 1 W/ml to 100 W/ml.

### Claim 281 (depends on 280)

The invention of claim 280, in which the ratio of the electrode power to the plasma volume is from 5 W/ml to 75 W/ml.

### Claim 282 (depends on 280)

The invention of claim 280, in which the ratio of the electrode power to the plasma volume is from 6 W/ml to 60 W/ml.

### Claim 283 (depends on 280)

The invention of claim 280, in which the ratio of the electrode power to the plasma volume is from 10 W/ml to 50 W/ml.

### Claim 284 (depends on 280)

The invention of claim 280, in which the ratio of the electrode power to the plasma volume is from 20 W/ml to 40 W/ml.

### Claim 285 (depends on 102, 284)

The invention of any preceding claims 102 to 284, in which the pH protective coating or layer has an RMS surface roughness value (measured by AFM) of from about 5 to about 9.

### Claim 286 (depends on 102, 284)

The invention of any preceding claims 102 to 284, in which the pH protective coating or layer has an RMS surface roughness value (measured by AFM) of from about 6 to about 8.

### Claim 287 (depends on 102, 284)

The invention of any preceding claims 102 to 284, in which the pH protective coating or layer has an RMS surface roughness value (measured by AFM) of from about 4 to about 6.

### Claim 288 (depends on 102, 284)

The invention of any preceding claims 102 to 284, in which the pH protective coating or layer has an RMS surface roughness value (measured by AFM) of from about 4.6 to about 5.8.

### Claim 289 (depends on 102, 288)

The invention of any preceding claims 102 to 288, in which the pH protective coating or layer has an Rmax surface roughness value of the pH protective coating or layer, measured by AFM, from about 70 to about 160.

### Claim 290 (depends on 102, 288)

The invention of any preceding claims 102 to 288, in which the pH protective coating or layer has an Rmax surface roughness value of the pH protective coating or layer, measured by AFM, from about 84 to about 142.

### Claim 291 (depends on 102, 288)

The invention of any preceding claims 102 to 288, in which the pH protective coating or layer has an Rmax surface roughness value of the pH protective coating or layer, measured by AFM, from about 90 to about 130.

### Claim 292 (depends on 102, 291)

The invention of any preceding claims 102 to 291, comprising a syringe barrel coated on its interior wall with the pH protective layer, the invention further comprising a plunger positioned for sliding in the barrel and a lubricity coating or layer on at least a portion of the plunger.

### Claim 293 (depends on 292)

The invention of claim 292, in which the lubricity coating or layer is configured to provide a lower piston sliding force or breakout force than the uncoated substrate

### Claim 294

SiNxCy s formula is from about 0.5 to 2.4, and y is from about 0.6 to about 3.

### Claim 295 (depends on 292)

The invention of claim 292, in which the lubricity coating or layer the lubricity layer having a thickness by transmission electron microscopy (TEM) between 10 and 500 nm;

### Claim 296 (depends on 292)

The invention of claim 292, in which the lubricity coating or layer the lubricity layer deposited by plasma enhanced chemical vapor deposition (PECVD).

### Claim 297 (depends on 292)

The invention of claim 292, in which the lubricity coating or layer is deposited under conditions effective to form a coating from a precursor selected from a linear siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a linear silazane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim 298 (depends on 292)

The invention of claim 292, in which the precursor comprises a linear siloxane.

### Claim 299 (depends on 292)

The invention of claim 292, in which the precursor comprises a monocyclic siloxane.

### Claim 300 (depends on 292)

The invention of claim 292, in which the precursor comprises a polycyclic siloxane.

### Claim 301 (depends on 292)

The invention of claim 292, in which the precursor comprises a polysilsesquioxane.

### Claim 302 (depends on 292)

The invention of claim 292, in which the precursor comprises a linear silazane.

### Claim 303 (depends on 292)

The invention of claim 292, in which the precursor comprises a monocyclic silazane.

### Claim 304 (depends on 292)

The invention of claim 292, in which the precursor comprises a polycyclic silazane.

### Claim 305 (depends on 292)

The invention of claim 292, in which the precursor comprises a polysilsesquiazane.

### Claim 306 (depends on 292)

The invention of claim 292, in which the precursor comprises a silatrane.

### Claim 307 (depends on 292)

The invention of claim 292, in which the precursor comprises a silquasilatrane.

### Claim 308 (depends on 292)

The invention of claim 292, in which the precursor comprises a silproatrane.

### Claim 309 (depends on 292)

The invention of claim 292, in which the precursor comprises an azasilatrane.

### Claim 310 (depends on 292)

The invention of claim 292, in which the precursor comprises an azasilquasiatrane.

### Claim 311 (depends on 292)

The invention of claim 292, in which the precursor comprises an azasilproatrane.

### Claim 312 (depends on 102, 311)

The invention of any preceding claims 102 to 311, wherein the pH protective layer shows an O-Parameter measured with attenuated total reflection (ATR) of less than 0.4, measured as:
O
⁢
-
⁢
Parameter
=
Intensity
⁢
⁢
at
⁢
⁢
1253
⁢
⁢
cm
-
1
Maximum
⁢
⁢
intensity
⁢
⁢
in
⁢
⁢
the
⁢
⁢
range
⁢
⁢
1000
⁢
⁢
to
⁢
⁢
1100
⁢
⁢
cm
-
1
.

### Claim 313 (depends on 312)

The invention of claim 312, in which the O-parameter has a value of from 0.1 to 0.39.

### Claim 314 (depends on 312)

The invention of claim 312, in which the O-parameter has a value of from 0.15 to 0.37.

### Claim 315 (depends on 312)

The invention of claim 312, in which the O-parameter has a value of from 0.17 to 0.35.

### Claim 316 (depends on 102, 315)

The invention of any preceding claims 102 to 315, wherein the pH protective layer shows an N-Parameter measured with attenuated total reflection (ATR) of less than 0.7, measured as:
N
⁢
-
⁢
Parameter
=
Intensity
⁢
⁢
at
⁢
⁢
840
⁢
⁢
cm
-
1
Intensity
⁢
⁢
at
⁢
⁢
799
⁢
⁢
cm
-
1
.

### Claim 317 (depends on 316)

The invention of claim 316, in which the N-parameter has a value of at least 0.3.

### Claim 318 (depends on 316)

The invention of claim 316, in which the N-parameter has a value of 0.4 to 0.6.

### Claim 319

A composite material comprising:
a substrate,
a composite barrier coating or layer according to any preceding claim over the substrate, and
a passivation layer over the composite barrier coating or layer, wherein the passivation layer shows an FTIR absorbance ratio of greater than 0.75 between:
the maximum amplitude of the Si—O—Si symmetrical stretch peak of an FTIR spectrum between about 1000 and 1040 cm−1, and
the maximum amplitude of the Si—O—Si assymmetric stretch peak of the FTIR spectrum between about 1060 and about 1100 cm−1.

### Claim 320

The invention of any preceding claim, in which x for the pH protective layer is between 0.5 and 1.5 and y is between 0.9 and 2.

### Claim 321 (depends on 320)

The invention of claim 320, in which x is between 0.7 and 1.3 and y is between 0.9 and 2.

### Claim 322 (depends on 320)

The invention of claim 320, in which x is between 0.8 and 1.2 and y is between 0.9 and 1.5.

### Claim 323 (depends on 320)

The invention of claim 320, in which x is between 0.9 and 1.2 and y is between 0.9 and 1.4.

### Claim 324 (depends on 320)

The invention of claim 320, in which x is between 0.92 and 1.07 and y is between 1.16 and 1.33.

### Claim 325 (depends on 102, 324)

The invention of any preceding claims 102 to 324, in which the RMS surface roughness value of the pH protective coating or layer, measured by atomic force microscopy, is from about 5 to about 9, optionally from about 6 to about 8, optionally from about 6.4 to about 7.8.

### Claim 326 (depends on 325, 1021)

The invention of any preceding claims 1021 to 325, in which the Ra surface roughness value of the pH protective coating or layer, measured by atomic force microscopy, is from about 4 to about 6, optionally from about 4.6 to about 5.8.

### Claim 327 (depends on 326, 1021)

The invention of any preceding claims 1021 to 326, in which the R max surface roughness value of the pH protective coating or layer, measured by atomic force microscopy, is from about 70 to about 160, optionally from about 84 to about 142, optionally from about 90 to about 130.

### Claim 328

The invention of any preceding claim, in which the lumen contains a fluid composition comprising a member selected from the group consisting of:
Inhalation Anesthetics
Aliflurane
Chloroform
Cyclopropane
Desflurane (Suprane)
Diethyl Ether
Enflurane (Ethrane)
Ethyl Chloride
Ethylene
Halothane (Fluothane)
Isoflurane (Forane, Isoflo)
Isopropenyl vinyl ether
Methoxyflurane
methoxyflurane,
Methoxypropane
Nitrous Oxide
Roflurane
Sevoflurane (Sevorane, Ultane, Sevoflo)
Teflurane
Trichloroethylene
Vinyl Ether
Xenon
Injectable Drugs
Ablavar (Gadofosveset Trisodium Injection)
Abarelix Depot
Abobotulinumtoxin A Injection (Dysport)
ABT-263
ABT-869
ABX-EFG
Accretropin (Somatropin Injection)
Acetadote (Acetylcysteine Injection)
Acetazolamide Injection (Acetazolamide Injection)
Acetylcysteine Injection (Acetadote)
Actemra (Tocilizumab Injection)
Acthrel (Corticorelin Ovine Triflutate for Injection)
Actummune
Activase
Acyclovir for Injection (Zovirax Injection)
Adacel
Adalimumab
Adenoscan (Adenosine Injection)
Adenosine Injection (Adenoscan)
Adrenaclick
AdreView (Iobenguane I 123 Injection for Intravenous Use)
Afluria
Ak-Fluor (Fluorescein Injection)
Aldurazyme (Laronidase)
Alglucerase Injection (Ceredase)
Alkeran Injection (Melphalan Hcl Injection)
Allopurinol Sodium for Injection (Aloprim)
Aloprim (Allopurinol Sodium for Injection)
Alprostadil
Alsuma (Sumatriptan Injection)
ALTU-238
Amino Acid Injections
Aminosyn
Apidra
Apremilast
Alprostadil Dual Chamber System for Injection (Caverject Impulse)
AMG 009
AMG 076
AMG 102
AMG 108
AMG 114
AMG 162
AMG 220
AMG 221
AMG 222
AMG 223
AMG 317
AMG 379
AMG 386
AMG 403
AMG 477
AMG 479
AMG 517
AMG 531
AMG 557
AMG 623
AMG 655
AMG 706
AMG 714
AMG 745
AMG 785
AMG 811
AMG 827
AMG 837
AMG 853
AMG 951
Amiodarone HCl Injection (Amiodarone HCl Injection)
Amobarbital Sodium Injection (Amytal Sodium)
Amytal Sodium (Amobarbital Sodium Injection)
Anakinra
Anti-Abeta
Anti-Beta7
Anti-Beta20
Anti-CD4
Anti-CD20
Anti-CD40
Anti-IFNalpha
Anti-IL13
Anti-OX40L
Anti-oxLDS
Anti-NGF
Anti-NRP1
Arixtra
Amphadase (Hyaluronidase Inj)
Ammonul (Sodium Phenylacetate and Sodium Benzoate Injection)
Anaprox
Anzemet Injection (Dolasetron Mesylate Injection)
Apidra (Insulin Glulisine [rDNA origin] Inj)
Apomab
Aranesp (darbepoetin alfa)
Argatroban (Argatroban Injection)
Arginine Hydrochloride Injection (R-Gene 10)
Aristocort
Aristospan
Arsenic Trioxide Injection (Trisenox)
Articane HCl and Epinephrine Injection (Septocaine)
Arzerra (Ofatumumab Injection)
Asclera (Polidocanol Injection)
Ataluren
Ataluren-DMD
Atenolol Inj (Tenormin I.V. Injection)
Atracurium Besylate Injection (Atracurium Besylate Injection)
Avastin
Azactam Injection (Aztreonam Injection)
Azithromycin (Zithromax Injection)
Aztreonam Injection (Azactam Injection)
Baclofen Injection (Lioresal Intrathecal)
Bacteriostatic Water (Bacteriostatic Water for Injection)
Baclofen Injection (Lioresal Intrathecal)
Bal in Oil Ampules (Dimercarprol Injection)
BayHepB
BayTet
Benadryl
Bendamustine Hydrochloride Injection (Treanda)
Benztropine Mesylate Injection (Cogentin)
Betamethasone Injectable Suspension (Celestone Soluspan)
Bexxar
Bicillin C-R 900/300 (Penicillin G Benzathine and Penicillin G Procaine Injection)
Blenoxane (Bleomycin Sulfate Injection)
Bleomycin Sulfate Injection (Blenoxane)
Boniva Injection (Ibandronate Sodium Injection)
Botox Cosmetic (OnabotulinumtoxinA for Injection)
BR3-FC
Bravelle (Urofollitropin Injection)
Bretylium (Bretylium Tosylate Injection)
Brevital Sodium (Methohexital Sodium for Injection)
Brethine
Briobacept
BTT-1023
Bupivacaine HCl
Byetta
Ca-DTPA (Pentetate Calcium Trisodium Inj)
Cabazitaxel Injection (Jevtana)
Caffeine Alkaloid (Caffeine and Sodium Benzoate Injection)
Calcijex Injection (Calcitrol)
Calcitrol (Calcijex Injection)
Calcium Chloride (Calcium Chloride Injection 10%)
Calcium Disodium Versenate (Edetate Calcium Disodium Injection)
Campath (Altemtuzumab)
Camptosar Injection (Irinotecan Hydrochloride)
Canakinumab Injection (Ilaris)
Capastat Sulfate (Capreomycin for Injection)
Capreomycin for Injection (Capastat Sulfate)
Cardiolite (Prep kit for Technetium Tc99 Sestamibi for Injection)
Carticel
Cathflo
Cefazolin and Dextrose for Injection (Cefazolin Injection)
Cefepime Hydrochloride
Cefotaxime
Ceftriaxone
Cerezyme
Carnitor Injection
Caverject
Celestone Soluspan
Celsior
Cerebyx (Fosphenytoin Sodium Injection)
Ceredase (Alglucerase Injection)
Ceretec (Technetium Tc99m Exametazime Injection)
Certolizumab
CF-101
Chloramphenicol Sodium Succinate (Chloramphenicol Sodium Succinate Injection)
Chloramphenicol Sodium Succinate Injection (Chloramphenicol Sodium Succinate)
Cholestagel (Colesevelam HCL)
Choriogonadotropin Alfa Injection (Ovidrel)
Cimzia
Cisplatin (Cisplatin Injection)
Clolar (Clofarabine Injection)
Clomiphine Citrate
Clonidine Injection (Duraclon)
Cogentin (Benztropine Mesylate Injection)
Colistimethate Injection (Coly-Mycin M)
Coly-Mycin M (Colistimethate Injection)
Compath
Conivaptan Hcl Injection (Vaprisol)
Conjugated Estrogens for Injection (Premarin Injection)
Copaxone
Corticorelin Ovine Triflutate for Injection (Acthrel)
Corvert (Ibutilide Fumarate Injection)
Cubicin (Daptomycin Injection)
CF-101
Cyanokit (Hydroxocobalamin for Injection)
Cytarabine Liposome Injection (DepoCyt)
Cyanocobalamin
Cytovene (ganciclovir)
D.H.E. 45
Dacetuzumab
Dacogen (Decitabine Injection)
Dalteparin
Dantrium IV (Dantrolene Sodium for Injection)
Dantrolene Sodium for Injection (Dantrium IV)
Daptomycin Injection (Cubicin)
Darbepoietin Alfa
DDAVP Injection (Desmopressin Acetate Injection)
Decavax
Decitabine Injection (Dacogen)
Dehydrated Alcohol (Dehydrated Alcohol Injection)
Denosumab Injection (Prolia)
Delatestryl
Delestrogen
Delteparin Sodium
Depacon (Valproate Sodium Injection)
Depo Medrol (Methylprednisolone Acetate Injectable Suspension)
DepoCyt (Cytarabine Liposome Injection)
DepoDur (Morphine Sulfate XR Liposome Injection)
Desmopressin Acetate Injection (DDAVP Injection)
Depo-Estradiol
Depo-Provera 104 mg/ml
Depo-Provera 150 mg/ml
Depo-Testosterone
Dexrazoxane for Injection, Intravenous Infusion Only (Totect)
Dextrose/Electrolytes
Dextrose and Sodium Chloride Inj (Dextrose 5% in 0.9% Sodium Chloride)
Dextrose
Diazepam Injection (Diazepam Injection)
Digoxin Injection (Lanoxin Injection)
Dilaudid-HP (Hydromorphone Hydrochloride Injection)
Dimercarprol Injection (Bal in Oil Ampules)
Diphenhydramine Injection (Benadryl Injection)
Dipyridamole Injection (Dipyridamole Injection)
DMOAD
Docetaxel for Injection (Taxotere)
Dolasetron Mesylate Injection (Anzemet Injection)
Doribax (Doripenem for Injection)
Doripenem for Injection (Doribax)
Doxercalciferol Injection (Hectorol Injection)
Doxil (Doxorubicin Hcl Liposome Injection)
Doxorubicin Hcl Liposome Injection (Doxil)
Duraclon (Clonidine Injection)
Duramorph (Morphine Injection)
Dysport (Abobotulinumtoxin A Injection)
Ecallantide Injection (Kalbitor)
EC-Naprosyn (naproxen)
Edetate Calcium Disodium Injection (Calcium Disodium Versenate)
Edex (Alprostadil for Injection)
Engerix
Edrophonium Injection (Enlon)
Eliglustat Tartate
Eloxatin (Oxaliplatin Injection)
Emend Injection (Fosaprepitant Dimeglumine Injection)
Enalaprilat Injection (Enalaprilat Injection)
Enlon (Edrophonium Injection)
Enoxaparin Sodium Injection (Lovenox)
Eovist (Gadoxetate Disodium Injection)
Enbrel (etanercept)
Enoxaparin
Epicel
Epinepherine
Epipen
Epipen Jr.
Epratuzumab
Erbitux
Ertapenem Injection (Invanz)
Erythropoieten
Essential Amino Acid Injection (Nephramine)
Estradiol Cypionate
Estradiol Valerate
Etanercept
Exenatide Injection (Byetta)
Evlotra
Fabrazyme (Adalsidase beta)
Famotidine Injection
FDG (Fludeoxyglucose F 18 Injection)
Feraheme (Ferumoxytol Injection)
Feridex I.V. (Ferumoxides Injectable Solution)
Fertinex
Ferumoxides Injectable Solution (Feridex I.V.)
Ferumoxytol Injection (Feraheme)
Flagyl Injection (Metronidazole Injection)
Fluarix
Fludara (Fludarabine Phosphate)
Fludeoxyglucose F 18 Injection (FDG)
Fluorescein Injection (Ak-Fluor)
Follistim AQ Cartridge (Follitropin Beta Injection)
Follitropin Alfa Injection (Gonal-f RFF)
Follitropin Beta Injection (Follistim AQ Cartridge)
Folotyn (Pralatrexate Solution for Intravenous Injection)
Fondaparinux
Forteo (Teriparatide (rDNA origin) Injection)
Fostamatinib
Fosaprepitant Dimeglumine Injection (Emend Injection)
Foscarnet Sodium Injection (Foscavir)
Foscavir (Foscarnet Sodium Injection)
Fosphenytoin Sodium Injection (Cerebyx)
Fospropofol Disodium Injection (Lusedra)
Fragmin
Fuzeon (enfuvirtide)
GA101
Gadobenate Dimeglumine Injection (Multihance)
Gadofosveset Trisodium Injection (Ablavar)
Gadoteridol Injection Solution (ProHance)
Gadoversetamide Injection (OptiMARK)
Gadoxetate Disodium Injection (Eovist)
Ganirelix (Ganirelix Acetate Injection)
Gardasil
GC1008
GDFD
Gemtuzumab Ozogamicin for Injection (Mylotarg)
Genotropin
Gentamicin Injection
GENZ-112638
Golimumab Injection (Simponi Injection)
Gonal-f RFF (Follitropin Alfa Injection)
Granisetron Hydrochloride (Kytril Injection)
Gentamicin Sulfate
Glatiramer Acetate
Glucagen
Glucagon
HAE1
Haldol (Haloperidol Injection)
Havrix
Hectorol Injection (Doxercalciferol Injection)
Hedgehog Pathway Inhibitor
Heparin
Herceptin
hG-CSF
Humalog
Human Growth Hormone
Humatrope
HuMax
Humegon
Humira
Humulin
Ibandronate Sodium Injection (Boniva Injection)
Ibuprofen Lysine Injection (NeoProfen)
Ibutilide Fumarate Injection (Corvert)
Idamycin PFS (Idarubicin Hydrochloride Injection)
Idarubicin Hydrochloride Injection (Idamycin PFS)
Ilaris (Canakinumab Injection)
Imipenem and Cilastatin for Injection (Primaxin I.V.)
Imitrex
Incobotulinumtoxin A for Injection (Xeomin)
Increlex (Mecasermin [rDNA origin] Injection)
Indocin IV (Indomethacin Inj)
Indomethacin Inj (Indocin IV)
Infanrix
Innohep
Insulin
Insulin Aspart [rDNA origin] Inj (NovoLog)
Insulin Glargine [rDNA origin] Injection (Lantus)
Insulin Glulisine [rDNA origin] Inj (Apidra)
Interferon alfa-2b, Recombinant for Injection (Intron A)
Intron A (Interferon alfa-2b, Recombinant for Injection)
Invanz (Ertapenem Injection)
Invega Sustenna (Paliperidone Palmitate Extended-Release Injectable Suspension)
Invirase (saquinavir mesylate)
Iobenguane I 123 Injection for Intravenous Use (AdreView)
Iopromide Injection (Ultravist)
Ioversol Injection (Optiray Injection)
Iplex (Mecasermin Rinfabate [rDNA origin] Injection)
Iprivask
Irinotecan Hydrochloride (Camptosar Injection)
Iron Sucrose Injection (Venofer)
Istodax (Romidepsin for Injection)
Itraconazole Injection (Sporanox Injection)
Jevtana (Cabazitaxel Injection)
Jonexa
Kalbitor (Ecallantide Injection)
KCL in DSNS (Potassium Chloride in 5% Dextrose and Sodium Chloride Injection)
KCL in D5 W
KCL in NS
Kenalog 10 Injection (Triamcinolone Acetonide Injectable Suspension)
Kepivance (Palifermin)
Keppra Injection (Levetiracetam)
Keratinocyte
KFG
Kinase Inhibitor
Kineret (Anakinra)
Kinlytic (Urokinase Injection)
Kinrix
Klonopin (clonazepam)
Kytril Injection (Granisetron Hydrochloride)
lacosamide Tablet and Injection (Vimpat)
Lactated Ringer's
Lanoxin Injection (Digoxin Injection)
Lansoprazole for Injection (Prevacid I.V.)
Lantus
Leucovorin Calcium (Leucovorin Calcium Injection)
Lente (L)
Leptin
Levemir
Leukine Sargramostim
Leuprolide Acetate
Levothyroxine
Levetiracetam (Keppra Injection)
Lovenox
Levocarnitine Injection (Carnitor Injection)
Lexiscan (Regadenoson Injection)
Lioresal Intrathecal (Baclofen Injection)
Liraglutide [rDNA] Injection (Victoza)
Lovenox (Enoxaparin Sodium Injection)
Lucentis (Ranibizumab Injection)
Lumizyme
Lupron (Leuprolide Acetate Injection)
Lusedra (Fospropofol Disodium Injection)
Maci
Magnesium Sulfate (Magnesium Sulfate Injection)
Mannitol Injection (Mannitol IV)
Marcaine (Bupivacaine Hydrochloride and Epinephrine Injection)
Maxipime (Cefepime Hydrochloride for Injection)
MDP Multidose Kit of Technetium Injection (Technetium Tc99m Medronate Injection)
Mecasermin [rDNA origin] Injection (Increlex)
Mecasermin Rinfabate [rDNA origin] Injection (Iplex)
Melphalan Hcl Injection (Alkeran Injection)
Methotrexate
Menactra
Menopur (Menotropins Injection)
Menotropins for Injection (Repronex)
Methohexital Sodium for Injection (Brevital Sodium)
Methyldopate Hydrochloride Injection, Solution (Methyldopate Hcl)
Methylene Blue (Methylene Blue Injection)
Methylprednisolone Acetate Injectable Suspension (Depo Medrol)
MetMab
Metoclopramide Injection (Reglan Injection)
Metrodin (Urofollitropin for Injection)
Metronidazole Injection (Flagyl Injection)
Miacalcin
Midazolam (Midazolam Injection)
Mimpara (Cinacalet)
Minocin Injection (Minocycline Inj)
Minocycline Inj (Minocin Injection)
Mipomersen
Mitoxantrone for Injection Concentrate (Novantrone)
Morphine Injection (Duramorph)
Morphine Sulfate XR Liposome Injection (DepoDur)
Morrhuate Sodium (Morrhuate Sodium Injection)
Motesanib
Mozobil (Plerixafor Injection)
Multihance (Gadobenate Dimeglumine Injection)
Multiple Electrolytes and Dextrose Injection
Multiple Electrolytes Injection
Mylotarg (Gemtuzumab Ozogamicin for Injection)
Myozyme (Alglucosidase alfa)
Nafcillin Injection (Nafcillin Sodium)
Nafcillin Sodium (Nafcillin Injection)
Naltrexone XR Inj (Vivitrol)
Naprosyn (naproxen)
NeoProfen (Ibuprofen Lysine Injection)
Nandrol Decanoate
Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection)
NEO-GAA
NeoTect (Technetium Tc 99m Depreotide Injection)
Nephramine (Essential Amino Acid Injection)
Neulasta (pegfilgrastim)
Neupogen (Filgrastim)
Novolin
Novolog
NeoRecormon
Neutrexin (Trimetrexate Glucuronate Inj)
NPH (N)
Nexterone (Amiodarone HCl Injection)
Norditropin (Somatropin Injection)
Normal Saline (Sodium Chloride Injection)
Novantrone (Mitoxantrone for Injection Concentrate)
Novolin 70/30 Innolet (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection)
NovoLog (Insulin Aspart [rDNA origin] Inj)
Nplate (romiplostim)
Nutropin (Somatropin (rDNA origin) for Inj)
Nutropin AQ
Nutropin Depot (Somatropin (rDNA origin) for Inj)
Octreotide Acetate Injection (Sandostatin LAR)
Ocrelizumab
Ofatumumab Injection (Arzerra)
Olanzapine Extended Release Injectable Suspension (Zyprexa Relprevv)
Omnitarg
Omnitrope (Somatropin [rDNA origin] Injection)
Ondansetron Hydrochloride Injection (Zofran Injection)
OptiMARK (Gadoversetamide Injection)
Optiray Injection (Ioversol Injection)
Orencia
Osmitrol Injection in Aviva (Mannitol Injection in Aviva Plastic Vessel)
Osmitrol Injection in Viaflex (Mannitol Injection in Viaflex Plastic Vessel)
Osteoprotegrin
Ovidrel (Choriogonadotropin Alfa Injection)
Oxacillin (Oxacillin for Injection)
Oxaliplatin Injection (Eloxatin)
Oxytocin Injection (Pitocin)
Paliperidone Palmitate Extended-Release Injectable Suspension (Invega Sustenna)
Pamidronate Disodium Injection (Pamidronate Disodium Injection)
Panitumumab Injection for Intravenous Use (Vectibix)
Papaverine Hydrochloride Injection (Papaverine Injection)
Papaverine Injection (Papaverine Hydrochloride Injection)
Parathyroid Hormone
Paricalcitol Injection Fliptop Vial (Zemplar Injection)
PARP Inhibitor
Pediarix
PEGIntron
Peginterferon
Pegfilgrastim
Penicillin G Benzathine and Penicillin G Procaine
Pentetate Calcium Trisodium Inj (Ca-DTPA)
Pentetate Zinc Trisodium Injection (Zn-DTPA)
Pepcid Injection (Famotidine Injection)
Pergonal
Pertuzumab
Phentolamine Mesylate (Phentolamine Mesylate for Injection)
Physostigmine Salicylate (Physostigmine Salicylate (injection))
Physostigmine Salicylate (injection) (Physostigmine Salicylate)
Piperacillin and Tazobactam Injection (Zosyn)
Pitocin (Oxytocin Injection)
Plasma-Lyte 148 (Multiple Electrolytes Inj)
Plasma-Lyte 56 and Dextrose (Multiple Electrolytes and Dextrose Injection in Viaflex
Plastic Vessel)
PlasmaLyte
Plerixafor Injection (Mozobil)
Polidocanol Injection (Asclera)
Potassium Chloride
Pralatrexate Solution for Intravenous Injection (Folotyn)
Pramlintide Acetate Injection (Symlin)
Premarin Injection (Conjugated Estrogens for Injection)
Prep kit for Technetium Tc99 Sestamibi for Injection (Cardiolite)
Prevacid I.V. (Lansoprazole for Injection)
Primaxin I.V. (Imipenem and Cilastatin for Injection)
Prochymal
Procrit
Progesterone
ProHance (Gadoteridol Injection Solution)
Prolia (Denosumab Injection)
Promethazine HCl Injection (Promethazine Hydrochloride Injection)
Propranolol Hydrochloride Injection (Propranolol Hydrochloride Injection)
Quinidine Gluconate Injection (Quinidine Injection)
Quinidine Injection (Quinidine Gluconate Injection)
R-Gene 10 (Arginine Hydrochloride Injection)
Ranibizumab Injection (Lucentis)
Ranitidine Hydrochloride Injection (Zantac Injection)
Raptiva
Reclast (Zoledronic Acid Injection)
Recombivarix HB
Regadenoson Injection (Lexiscan)
Reglan Injection (Metoclopramide Injection)
Remicade
Renagel
Renvela (Sevelamer Carbonate)
Repronex (Menotropins for Injection)
Retrovir IV (Zidovudine Injection)
rhApo2L/TRAIL
Ringer's and 5% Dextrose Injection (Ringers in Dextrose)
Ringer's Injection (Ringers Injection)
Rituxan
Rituximab
Rocephin (ceftriaxone)
Rocuronium Bromide Injection (Zemuron)
Roferon-A (interferon alfa-2a)
Romazicon (flumazenil)
Romidepsin for Injection (Istodax)
Saizen (Somatropin Injection)
Sandostatin LAR (Octreotide Acetate Injection)
Sclerostin Ab
Sensipar (cinacalcet)
Sensorcaine (Bupivacaine HCl Injections)
Septocaine (Articane HCl and Epinephrine Injection)
Serostim LQ (Somatropin (rDNA origin) Injection)
Simponi Injection (Golimumab Injection)
Sodium Acetate (Sodium Acetate Injection)
Sodium Bicarbonate (Sodium Bicarbonate 5% Injection)
Sodium Lactate (Sodium Lactate Injection in AVIVA)
Sodium Phenylacetate and Sodium Benzoate Injection (Ammonul)
Somatropin (rDNA origin) for Inj (Nutropin)
Sporanox Injection (Itraconazole Injection)
Stelara Injection (Ustekinumab)
Stemgen
Sufenta (Sufentanil Citrate Injection)
Sufentanil Citrate Injection (Sufenta)
Sumavel
Sumatriptan Injection (Alsuma)
Symlin
Symlin Pen
Systemic Hedgehog Antagonist
Synvisc-One (Hylan G-F 20 Single Intra-articular Injection)
Tarceva
Taxotere (Docetaxel for Injection)
Technetium Tc 99m
Telavancin for Injection (Vibativ)
Temsirolimus Injection (Torisel)
Tenormin I.V. Injection (Atenolol Inj)
Teriparatide (rDNA origin) Injection (Forteo)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Propionate
Tev-Tropin (Somatropin, rDNA Origin, for Injection)
tgAAC94
Thallous Chloride
Theophylline
Thiotepa (Thiotepa Injection)
Thymoglobulin (Anti-Thymocyte Globulin (Rabbit)
Thyrogen (Thyrotropin Alfa for Injection)
Ticarcillin Disodium and Clavulanate Potassium Galaxy (Timentin Injection)
Tigan Injection (Trimethobenzamide Hydrochloride Injectable)
Timentin Injection (Ticarcillin Disodium and Clavulanate Potassium Galaxy)
TNKase
Tobramycin Injection (Tobramycin Injection)
Tocilizumab Injection (Actemra)
Torisel (Temsirolimus Injection)
Totect (Dexrazoxane for Injection, Intravenous Infusion Only)
Trastuzumab-DM1
Travasol (Amino Acids (Injection))
Treanda (Bendamustine Hydrochloride Injection)
Trelstar (Triptorelin Pamoate for Injectable Suspension)
Triamcinolone Acetonide
Triamcinolone Diacetate
Triamcinolone Hexacetonide Injectable Suspension (Aristospan Injection 20 mg)
Triesence (Triamcinolone Acetonide Injectable Suspension)
Trimethobenzamide Hydrochloride Injectable (Tigan Injection)
Trimetrexate Glucuronate Inj (Neutrexin)
Triptorelin Pamoate for Injectable Suspension (Trelstar)
Twinject
Trivaris (Triamcinolone Acetonide Injectable Suspension)
Trisenox (Arsenic Trioxide Injection)
Twinrix
Typhoid Vi
Ultravist (Iopromide Injection)
Urofollitropin for Injection (Metrodin)
Urokinase Injection (Kinlytic)
Ustekinumab (Stelara Injection)
Ultralente (U)
Valium (diazepam)
Valproate Sodium Injection (Depacon)
Valtropin (Somatropin Injection)
Vancomycin Hydrochloride (Vancomycin Hydrochloride Injection)
Vancomycin Hydrochloride Injection (Vancomycin Hydrochloride)
Vaprisol (Conivaptan Hcl Injection)
VAQTA
Vasovist (Gadofosveset Trisodium Injection for Intravenous Use)
Vectibix (Panitumumab Injection for Intravenous Use)
Venofer (Iron Sucrose Injection)
Verteporfin Inj (Visudyne)
Vibativ (Telavancin for Injection)
Victoza (Liraglutide [rDNA] Injection)
Vimpat (lacosamide Tablet and Injection)
Vinblastine Sulfate (Vinblastine Sulfate Injection)
Vincasar PFS (Vincristine Sulfate Injection)
Victoza
Vincristine Sulfate (Vincristine Sulfate Injection)
Visudyne (Verteporfin Inj)
Vitamin B-12
Vivitrol (Naltrexone XR Inj)
Voluven (Hydroxyethyl Starch in Sodium Chloride Injection)
Xeloda
Xenical (orlistat)
Xeomin (Incobotulinumtoxin A for Injection)
Xolair
Zantac Injection (Ranitidine Hydrochloride Injection)
Zemplar Injection (Paricalcitol Injection Fliptop Vial)
Zemuron (Rocuronium Bromide Injection)
Zenapax (daclizumab)
Zevalin
Zidovudine Injection (Retrovir IV)
Zithromax Injection (Azithromycin)
Zn-DTPA (Pentetate Zinc Trisodium Injection)
Zofran Injection (Ondansetron Hydrochloride Injection)
Zingo
Zoledronic Acid for Inj (Zometa)
Zoledronic Acid Injection (Reclast)
Zometa (Zoledronic Acid for Inj)
Zosyn (Piperacillin and Tazobactam Injection)
Zyprexa Relprevv (Olanzapine Extended Release Injectable Suspension)
Liquid Drugs (Non-Injectable)
Abilify
AccuNeb (Albuterol Sulfate Inhalation Solution)
Actidose Aqua (Activated Charcoal Suspension)
Activated Charcoal Suspension (Actidose Aqua)
Advair
Agenerase Oral Solution (Amprenavir Oral Solution)
Akten (Lidocaine Hydrochloride Ophthalmic Gel)
Alamast (Pemirolast Potassium Ophthalmic Solution)
Albumin (Human) 5% Solution (Buminate 5%)
Albuterol Sulfate Inhalation Solution
Alinia
Alocril
Alphagan
Alrex
Alvesco
Amprenavir Oral Solution
Analpram-HC
Arformoterol Tartrate Inhalation Solution (Brovana)
Aristospan Injection 20 mg (Triamcinolone Hexacetonide Injectable Suspension)
Asacol
Asmanex
Astepro
Astepro (Azelastine Hydrochloride Nasal Spray)
Atrovent Nasal Spray (Ipratropium Bromide Nasal Spray)
Atrovent Nasal Spray 0.06
Augmentin ES-600
Azasite (Azithromycin Ophthalmic Solution)
Azelaic Acid (Finacea Gel)
Azelastine Hydrochloride Nasal Spray (Astepro)
Azelex (Azelaic Acid Cream)
Azopt (Brinzolamide Ophthalmic Suspension)
Bacteriostatic Saline
Balanced Salt
Bepotastine
Bactroban Nasal
Bactroban
Beclovent
Benzac W
Betimol
Betoptic S
Bepreve
Bimatoprost Ophthalmic Solution
Bleph 10 (Sulfacetamide Sodium Ophthalmic Solution 10%)
Brinzolamide Ophthalmic Suspension (Azopt)
Bromfenac Ophthalmic Solution (Xibrom)
Bromhist
Brovana (Arformoterol Tartrate Inhalation Solution)
Budesonide Inhalation Suspension (Pulmicort Respules)
Cambia (Diclofenac Potassium for Oral Solution)
Capex
Carac
Carboxine-PSE
Carnitor
Cayston (Aztreonam for Inhalation Solution)
Cellcept
Centany
Cerumenex
Ciloxan Ophthalmic Solution (Ciprofloxacin HCL Ophthalmic Solution)
Ciprodex
Ciprofloxacin HCL Ophthalmic Solution (Ciloxan Ophthalmic Solution)
Clemastine Fumarate Syrup (Clemastine Fumarate Syrup)
CoLyte (PEG Electrolytes Solution)
Combiven
Comtan
Condylox
Cordran
Cortisporin Ophthalmic Suspension
Cortisporin Otic Suspension
Cromolyn Sodium Inhalation Solution (Intal Nebulizer Solution)
Cromolyn Sodium Ophthalmic Solution (Opticrom)
Crystalline Amino Acid Solution with Electrolytes (Aminosyn Electrolytes)
Cutivate
Cuvposa (Glycopyrrolate Oral Solution)
Cyanocobalamin (CaloMist Nasal Spray)
Cyclosporine Oral Solution (Gengraf Oral Solution)
Cyclogyl
Cysview (Hexaminolevulinate Hydrochloride Intravesical Solution)
DermOtic Oil (Fluocinolone Acetonide Oil Ear Drops)
Desmopressin Acetate Nasal Spray
DDAVP
Derma-Smoothe/FS
Dexamethasone Intensol
Dianeal Low Calcium
Dianeal PD
Diclofenac Potassium for Oral Solution (Cambia)
Didanosine Pediatric Powder for Oral Solution (Videx)
Differin
Dilantin 125 (Phenytoin Oral Suspension)
Ditropan
Dorzolamide Hydrochloride Ophthalmic Solution (Trusopt)
Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution (Cosopt)
Dovonex Scalp (Calcipotriene Solution)
Doxycycline Calcium Oral Suspension (Vibramycin Oral)
Efudex
Elaprase (Idursulfase Solution)
Elestat (Epinastine HCl Ophthalmic Solution)
Elocon
Epinastine HCl Ophthalmic Solution (Elestat)
Epivir HBV
Epogen (Epoetin alfa)
Erythromycin Topical Solution 1.5% (Staticin)
Ethiodol (Ethiodized Oil)
Ethosuximide Oral Solution (Zarontin Oral Solution)
Eurax
Extraneal (Icodextrin Peritoneal Dialysis Solution)
Felbatol
Feridex I.V. (Ferumoxides Injectable Solution)
Flovent
Floxin Otic (Ofloxacin Otic Solution)
Flo-Pred (Prednisolone Acetate Oral Suspension)
Fluoroplex
Flunisolide Nasal Solution (Flunisolide Nasal Spray 0.025%)
Fluorometholone Ophthalmic Suspension (FML)
Flurbiprofen Sodium Ophthalmic Solution (Ocufen)
FML
Foradil
Formoterol Fumarate Inhalation Solution (Perforomist)
Fosamax
Furadantin (Nitrofurantoin Oral Suspension)
Furoxone
Gammagard Liquid (Immune Globulin Intravenous (Human) 10%)
Gantrisin (Acetyl Sulfisoxazole Pediatric Suspension)
Gatifloxacin Ophthalmic Solution (Zymar)
Gengraf Oral Solution (Cyclosporine Oral Solution)
Glycopyrrolate Oral Solution (Cuvposa)
Halcinonide Topical Solution (Halog Solution)
Halog Solution (Halcinonide Topical Solution)
HEP-LOCK U/P (Preservative-Free Heparin Lock Flush Solution)
Heparin Lock Flush Solution (Hepflush 10)
Hexaminolevulinate Hydrochloride Intravesical Solution (Cysview)
Hydrocodone Bitartrate and Acetaminophen Oral Solution (Lortab Elixir)
Hydroquinone 3% Topical Solution (Melquin-3 Topical Solution)
IAP Antagonist
Isopto
Ipratropium Bromide Nasal Spray (Atrovent Nasal Spray)
Itraconazole Oral Solution (Sporanox Oral Solution)
Ketorolac Tromethamine Ophthalmic Solution (Acular LS)
Kaletra
Lanoxin
Lexiva
Leuprolide Acetate for Depot Suspension (Lupron Depot 11.25 mg)
Levobetaxolol Hydrochloride Ophthalmic Suspension (Betaxon)
Levocarnitine Tablets, Oral Solution, Sugar-Free (Carnitor)
Levofloxacin Ophthalmic Solution 0.5% (Quixin)
Lidocaine HCl Sterile Solution (Xylocaine MPF Sterile Solution)
Lok Pak (Heparin Lock Flush Solution)
Lorazepam Intensol
Lortab Elixir (Hydrocodone Bitartrate and Acetaminophen Oral Solution)
Lotemax (Loteprednol Etabonate Ophthalmic Suspension)
Loteprednol Etabonate Ophthalmic Suspension (Alrex)
Low Calcium Peritoneal Dialysis Solutions (Dianeal Low Calcium)
Lumigan (Bimatoprost Ophthalmic Solution 0.03% for Glaucoma)
Lupron Depot 11.25 mg (Leuprolide Acetate for Depot Suspension)
Megestrol Acetate Oral Suspension (Megestrol Acetate Oral Suspension)
MEK Inhibitor
Mepron
Mesnex
Mestinon
Mesalamine Rectal Suspension Enema (Rowasa)
Melquin-3 Topical Solution (Hydroquinone 3% Topical Solution)
MetMab
Methyldopate Hcl (Methyldopate Hydrochloride Injection, Solution)
Methylin Oral Solution (Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL)
Methylprednisolone Acetate Injectable Suspension (Depo Medrol)
Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL (Methylin Oral Solution)
Methylprednisolone sodium succinate (Solu Medrol)
Metipranolol Ophthalmic Solution (Optipranolol)
Migranal
Miochol-E (Acetylcholine Chloride Intraocular Solution)
Micro-K for Liquid Suspension (Potassium Chloride Extended Release Formulation for Liquid Suspension)
Minocin (Minocycline Hydrochloride Oral Suspension)
Nasacort
Neomycin and Polymyxin B Sulfates and Hydrocortisone
Nepafenac Ophthalmic Suspension (Nevanac)
Nevanac (Nepafenac Ophthalmic Suspension)
Nitrofurantoin Oral Suspension (Furadantin)
Noxafil (Posaconazole Oral Suspension)
Nystatin (oral) (Nystatin Oral Suspension)
Nystatin Oral Suspension (Nystatin (oral))
Ocufen (Flurbiprofen Sodium Ophthalmic Solution)
Ofloxacin Ophthalmic Solution (Ofloxacin Ophthalmic Solution)
Ofloxacin Otic Solution (Floxin Otic)
Olopatadine Hydrochloride Ophthalmic Solution (Pataday)
Opticrom (Cromolyn Sodium Ophthalmic Solution)
Optipranolol (Metipranolol Ophthalmic Solution)
Patanol
Pediapred
PerioGard
Phenytoin Oral Suspension (Dilantin 125)
Phisohex
Posaconazole Oral Suspension (Noxafil)
Potassium Chloride Extended Release Formulation for Liquid Suspension (Micro-K for
Liquid Suspension)
Pataday (Olopatadine Hydrochloride Ophthalmic Solution)
Patanase Nasal Spray (Olopatadine Hydrochloride Nasal Spray)
PEG Electrolytes Solution (CoLyte)
Pemirolast Potassium Ophthalmic Solution (Alamast)
Penlac (Ciclopirox Topical Solution)
PENNSAID (Diclofenac Sodium Topical Solution)
Perforomist (Formoterol Fumarate Inhalation Solution)
Peritoneal Dialysis Solution
Phenylephrine Hydrochloride Ophthalmic Solution (Neo-Synephrine)
Phospholine Iodide (Echothiophate Iodide for Ophthalmic Solution)
Podofilox (Podofilox Topical Solution)
Pred Forte (Prednisolone Acetate Ophthalmic Suspension)
Pralatrexate Solution for Intravenous Injection (Folotyn)
Pred Mild
Prednisone Intensol
Prednisolone Acetate Ophthalmic Suspension (Pred Forte)
Prevacid
PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution)
ProAir
Proglycem
ProHance (Gadoteridol Injection Solution)
Proparacaine Hydrochloride Ophthalmic Solution (Alcaine)
Propine
Pulmicort
Pulmozyme
Quixin (Levofloxacin Ophthalmic Solution 0.5%)
QVAR
Rapamune
Rebetol
Relacon-HC
Rotarix (Rotavirus Vaccine, Live, Oral Suspension)
Rotavirus Vaccine, Live, Oral Suspension (Rotarix)
Rowasa (Mesalamine Rectal Suspension Enema)
Sabril (Vigabatrin Oral Solution)
Sacrosidase Oral Solution (Sucraid)
Sandimmune
Sepra
Serevent Diskus
Solu Cortef (Hydrocortisone Sodium Succinate)
Solu Medrol (Methylprednisolone sodium succinate)
Spiriva
Sporanox Oral Solution (Itraconazole Oral Solution)
Staticin (Erythromycin Topical Solution 1.5%)
Stalevo
Starlix
Sterile Hemofiltration Hemodiafiltration Solution (PrismaSol Solution)
Stimate
Sucralfate (Carafate Suspension)
Sulfacetamide Sodium Ophthalmic Solution 10% (Bleph 10)
Synarel Nasal Solution (Nafarelin Acetate Nasal Solution for Endometriosis)
Taclonex Scalp (Calcipotriene and Betamethasone Dipropionate Topical Suspension)
Tamiflu
Tobi
TobraDex
Tobradex ST (Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05%)
Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05% (Tobradex ST)
Timolol
Timoptic
Travatan Z
Treprostinil Inhalation Solution (Tyvaso)
Trusopt (Dorzolamide Hydrochloride Ophthalmic Solution)
Tyvaso (Treprostinil Inhalation Solution)
Ventolin
Vfend
Vibramycin Oral (Doxycycline Calcium Oral Suspension)
Videx (Didanosine Pediatric Powder for Oral Solution)
Vigabatrin Oral Solution (Sabril)
Viokase
Viracept
Viramune
Vitamin K1 (Fluid Colloidal Solution of Vitamin K1)
Voltaren Ophthalmic (Diclofenac Sodium Ophthalmic Solution)
Zarontin Oral Solution (Ethosuximide Oral Solution)
Ziagen
Zyvox
Zymar (Gatifloxacin Ophthalmic Solution)
Zymaxid (Gatifloxacin Ophthalmic Solution)
Drug Classes
5-alpha-reductase inhibitors
5-aminosalicylates
5HT3 receptor antagonists
adamantane antivirals
adrenal cortical steroids
adrenal corticosteroid inhibitors
adrenergic bronchodilators
agents for hypertensive emergencies
agents for pulmonary hypertension
aldosterone receptor antagonists
alkylating agents
alpha-adrenoreceptor antagonists
alpha-glucosidase inhibitors
alternative medicines
amebicides
aminoglycosides
aminopenicillins
aminosalicylates
amylin analogs
Analgesic Combinations
Analgesics
androgens and anabolic steroids
angiotensin converting enzyme inhibitors
angiotensin II inhibitors
anorectal preparations
anorexiants
antacids
anthelmintics
anti-angiogenic ophthalmic agents
anti-CTLA-4 monoclonal antibodies
anti-infectives
antiadrenergic agents, centrally acting
antiadrenergic agents, peripherally acting
antiandrogens
antianginal agents
antiarrhythmic agents
antiasthmatic combinations
antibiotics/antineoplastics
anticholinergic antiemetics
anticholinergic antiparkinson agents
anticholinergic bronchodilators
anticholinergic chronotropic agents
anticholinergics/antispasmodics
anticoagulants
anticonvulsants
antidepressants
antidiabetic agents
antidiabetic combinations
antidiarrheals
antidiuretic hormones
antidotes
antiemetic/antivertigo agents
antifungals
antigonadotropic agents
antigout agents
antihistamines
antihyperlipidemic agents
antihyperlipidemic combinations
antihypertensive combinations
antihyperuricemic agents
antimalarial agents
antimalarial combinations
antimalarial quinolines
antimetabolites
antimigraine agents
antineoplastic detoxifying agents
antineoplastic interferons
antineoplastic monoclonal antibodies
antineoplastics
antiparkinson agents
antiplatelet agents
antipseudomonal penicillins
antipsoriatics
antipsychotics
antirheumatics
antiseptic and germicides
antithyroid agents
antitoxins and antivenins
antituberculosis agents
antituberculosis combinations
antitussives
antiviral agents
antiviral combinations
antiviral interferons
anxiolytics, sedatives, and hypnotics
aromatase inhibitors
atypical antipsychotics
azole antifungals
bacterial vaccines
barbiturate anticonvulsants
barbiturates
BCR-ABL tyrosine kinase inhibitors
benzodiazepine anticonvulsants
benzodiazepines
beta-adrenergic blocking agents
beta-lactamase inhibitors
bile acid sequestrants
biologicals
bisphosphonates
bone resorption inhibitors
bronchodilator combinations
bronchodilators
calcitonin
calcium channel blocking agents
carbamate anticonvulsants
carbapenems
carbonic anhydrase inhibitor anticonvulsants
carbonic anhydrase inhibitors
cardiac stressing agents
cardioselective beta blockers
cardiovascular agents
catecholamines
CD20 monoclonal antibodies
CD33 monoclonal antibodies
CD52 monoclonal antibodies
central nervous system agents
cephalosporins
cerumenolytics
chelating agents
chemokine receptor antagonist
chloride channel activators
cholesterol absorption inhibitors
cholinergic agonists
cholinergic muscle stimulants
cholinesterase inhibitors
CNS stimulants
coagulation modifiers
colony stimulating factors
contraceptives
corticotropin
coumarins and indandiones
cox-2 inhibitors
decongestants
dermatological agents
diagnostic radiopharmaceuticals
dibenzazepine anticonvulsants
digestive enzymes
dipeptidyl peptidase 4 inhibitors
diuretics
dopaminergic antiparkinsonism agents
drugs used in alcohol dependence
echinocandins
EGFR inhibitors
estrogen receptor antagonists
estrogens
expectorants
factor Xa inhibitors
fatty acid derivative anticonvulsants
fibric acid derivatives
first generation cephalosporins
fourth generation cephalosporins
functional bowel disorder agents
gallstone solubilizing agents
gamma-aminobutyric acid analogs
gamma-aminobutyric acid reuptake inhibitors
gamma-aminobutyric acid transaminase inhibitors
gastrointestinal agents
general anesthetics
genitourinary tract agents
GI stimulants
glucocorticoids
glucose elevating agents
glycopeptide antibiotics
glycoprotein platelet inhibitors
glycylcyclines
gonadotropin releasing hormones
gonadotropin-releasing hormone antagonists
gonadotropins
group I antiarrhythmics
group II antiarrhythmics
group III antiarrhythmics
group IV antiarrhythmics
group V antiarrhythmics
growth hormone receptor blockers
growth hormones
H. pylori eradication agents
H2 antagonists
hematopoietic stem cell mobilizer
heparin antagonists
heparins
HER2 inhibitors
herbal products
histone deacetylase inhibitors
hormone replacement therapy
hormones
hormones/antineoplastics
hydantoin anticonvulsants
illicit (street) drugs
immune globulins
immunologic agents
immunosuppressive agents
impotence agents
in vivo diagnostic biologicals
incretin mimetics
inhaled anti-infectives
inhaled corticosteroids
inotropic agents
insulin
insulin-like growth factor
integrase strand transfer inhibitor
interferons
intravenous nutritional products
iodinated contrast media
ionic iodinated contrast media
iron products
ketolides
laxatives
leprostatics
leukotriene modifiers
lincomycin derivatives
lipoglycopeptides
local injectable anesthetics
loop diuretics
lung surfactants
lymphatic staining agents
lysosomal enzymes
macrolide derivatives
macrolides
magnetic resonance imaging contrast media
mast cell stabilizers
medical gas
meglitinides
metabolic agents
methylxanthines
mineralocorticoids
minerals and electrolytes
miscellaneous agents
miscellaneous analgesics
miscellaneous antibiotics
miscellaneous anticonvulsants
miscellaneous antidepressants
miscellaneous antidiabetic agents
miscellaneous antiemetics
miscellaneous antifungals
miscellaneous antihyperlipidemic agents
miscellaneous antimalarials
miscellaneous antineoplastics
miscellaneous antiparkinson agents
miscellaneous antipsychotic agents
miscellaneous antituberculosis agents
miscellaneous antivirals
miscellaneous anxiolytics, sedatives and hypnotics
miscellaneous biologicals
miscellaneous bone resorption inhibitors
miscellaneous cardiovascular agents
miscellaneous central nervous system agents
miscellaneous coagulation modifiers
miscellaneous diuretics
miscellaneous genitourinary tract agents
miscellaneous GI agents
miscellaneous hormones
miscellaneous metabolic agents
miscellaneous ophthalmic agents
miscellaneous otic agents
miscellaneous respiratory agents
miscellaneous sex hormones
miscellaneous topical agents
miscellaneous uncategorized agents
miscellaneous vaginal agents
mitotic inhibitors
monoamine oxidase inhibitors
monoclonal antibodies
mouth and throat products
mTOR inhibitors
mTOR kinase inhibitors
mucolytics
multikinase inhibitors
muscle relaxants
mydriatics
narcotic analgesic combinations
narcotic analgesics
nasal anti-infectives
nasal antihistamines and decongestants
nasal lubricants and irrigations
nasal preparations
nasal steroids
natural penicillins
neuraminidase inhibitors
neuromuscular blocking agents
next generation cephalosporins
nicotinic acid derivatives
nitrates
NNRTIs
non-cardioselective beta blockers
non-iodinated contrast media
non-ionic iodinated contrast media
non-sulfonylureas
nonsteroidal anti-inflammatory agents
norepinephrine reuptake inhibitors
norepinephrine-dopamine reuptake inhibitors
nucleoside reverse transcriptase inhibitors (NRTIs)
nutraceutical products
nutritional products
ophthalmic anesthetics
ophthalmic anti-infectives
ophthalmic anti-inflammatory agents
ophthalmic antihistamines and decongestants
ophthalmic diagnostic agents
ophthalmic glaucoma agents
ophthalmic lubricants and irrigations
ophthalmic preparations
ophthalmic steroids
ophthalmic steroids with anti-infectives
ophthalmic surgical agents
oral nutritional supplements
otic anesthetics
otic anti-infectives
otic preparations
otic steroids
otic steroids with anti-infectives
oxazolidinedione anticonvulsants
parathyroid hormone and analogs
penicillinase resistant penicillins
penicillins
peripheral opioid receptor antagonists
peripheral vasodilators
peripherally acting antiobesity agents
phenothiazine antiemetics
phenothiazine antipsychotics
phenylpiperazine antidepressants
plasma expanders
platelet aggregation inhibitors
platelet-stimulating agents
polyenes
potassium-sparing diuretics
probiotics
progesterone receptor modulators
progestins
prolactin inhibitors
prostaglandin D2 antagonists
protease inhibitors
proton pump inhibitors
psoralens
psychotherapeutic agents
psychotherapeutic combinations
purine nucleosides
pyrrolidine anticonvulsants
quinolones
radiocontrast agents
radiologic adjuncts
radiologic agents
radiologic conjugating agents
radiopharmaceuticals
RANK ligand inhibitors
recombinant human erythropoietins
renin inhibitors
respiratory agents
respiratory inhalant products
rifamycin derivatives
salicylates
sclerosing agents
second generation cephalosporins
selective estrogen receptor modulators
selective serotonin reuptake inhibitors
serotonin-norepinephrine reuptake inhibitors
serotoninergic neuroenteric modulators
sex hormone combinations
sex hormones
skeletal muscle relaxant combinations
skeletal muscle relaxants
smoking cessation agents
somatostatin and somatostatin analogs
spermicides
statins
sterile irrigating solutions
streptomyces derivatives
succinimide anticonvulsants
sulfonamides
sulfonylureas
synthetic ovulation stimulants
tetracyclic antidepressants
tetracyclines
therapeutic radiopharmaceuticals
thiazide diuretics
thiazolidinediones
thioxanthenes
third generation cephalosporins
thrombin inhibitors
thrombolytics
thyroid drugs
tocolytic agents
topical acne agents
topical agents
topical anesthetics
topical anti-infectives
topical antibiotics
topical antifungals
topical antihistamines
topical antipsoriatics
topical antivirals
topical astringents
topical debriding agents
topical depigmenting agents
topical emollients
topical keratolytics
topical steroids
topical steroids with anti-infectives
toxoids
triazine anticonvulsants
tricyclic antidepressants
trifunctional monoclonal antibodies
tumor necrosis factor (TNF) inhibitors
tyrosine kinase inhibitors
ultrasound contrast media
upper respiratory combinations
urea anticonvulsants
urinary anti-infectives
urinary antispasmodics
urinary pH modifiers
uterotonic agents
vaccine
vaccine combinations
vaginal anti-infectives
vaginal preparations
vasodilators
vasopressin antagonists
vasopressors
VEGF/VEGFR inhibitors
viral vaccines
viscosupplementation agents
vitamin and mineral combinations
vitamins
Diagnostic Tests
17-Hydroxyprogesterone
ACE (Angiotensin I converting enzyme)
Acetaminophen
Acid phosphatase
ACTH
Activated clotting time
Activated protein C resistance
Adrenocorticotropic hormone (ACTH)
Alanine aminotransferase (ALT)
Albumin
Aldolase
Aldosterone
Alkaline phosphatase
Alkaline phosphatase (ALP)
Alpha1-antitrypsin
Alpha-fetoprotein
Alpha-fetoprotien
Ammonia levels
Amylase
ANA (antinuclear antbodies)
ANA (antinuclear antibodies)
Angiotensin-converting enzyme (ACE)
Anion gap
Anticardiolipin antibody
Anticardiolipin antivbodies (ACA)
Anti-centromere antibody
Antidiuretic hormone
Anti-DNA
Anti-Dnase-B
Anti-Gliadin antibody
Anti-glomerular basement membrane antibody
Anti-HBc (Hepatitis B core antibodies
Anti-HBs (Hepatitis B surface antibody
Antiphospholipid antibody
Anti-RNA polymerase
Anti-Smith (Sm) antibodies
Anti-Smooth Muscle antibody
Antistreptolysin O (ASO)
Antithrombin III
Anti-Xa activity
Anti-Xa assay
Apolipoproteins
Arsenic
Aspartate aminotransferase (AST)
B12
Basophil
Beta-2-Microglobulin
Beta-hydroxybutyrate
B-HCG
Bilirubin
Bilirubin, direct
Bilirubin, indirect
Bilirubin, total
Bleeding time
Blood gases (arterial)
Blood urea nitrogen (BUN)
BUN
BUN (blood urea nitrogen)
CA 125
CA 15-3
CA 19-9
Calcitonin
Calcium
Calcium (ionized)
Carbon monoxide (CO)
Carcinoembryonic antigen (CEA)
CBC
CEA
CEA (carcinoembryonic antigen)
Ceruloplasmin
CH50Chloride
Cholesterol
Cholesterol, HDL
Clot lysis time
Clot retraction time
CMP
CO2
Cold agglutinins
Complement C3
Copper
Corticotrophin releasing hormone (CRH) stimulation test
Cortisol
Cortrosyn stimulation test
C-peptide
CPK (Total)
CPK-MB
C-reactive protein
Creatinine
Creatinine kinase (CK)
Cryoglobulins
DAT (Direct antiglobulin test)
D-Dimer
Dexamethasone suppression test
DHEA-S
Dilute Russell viper venom
Elliptocytes
Eosinophil
Erythrocyte sedimentation rate (ESR)
Estradiol
Estriol
Ethanol
Ethylene glycol
Euglobulin lysis
Factor V Leiden
Factor VIII inhibitor
Factor VIII level
Ferritin
Fibrin split products
Fibrinogen
Folate
Folate (serum
Fractional excretion of sodium (FENA)
FSH (follicle stimulating factor)
FTA-ABS
Gamma glutamyl transferase (GGT)
Gastrin
GGTP (Gamma glutamyl transferase)
Glucose
Growth hormone
Haptoglobin
HBeAg (Hepatitis Be antigen)
HBs-Ag (Hepatitis B surface antigen)
Helicobacter pylori
Hematocrit
Hematocrit (HCT)
Hemoglobin
Hemoglobin A1C
Hemoglobin electrophoresis
Hepatitis A antibodies
Hepatitis C antibodies
IAT (Indirect antiglobulin test)
Immunofixation (IFE)
Iron
Lactate dehydrogenase (LDH)
Lactic acid (lactate)
LDH
LH (Leutinizing hormone
Lipase
Lupus anticoagulant
Lymphocyte
Magnesium
MCH (mean corpuscular hemoglobin
MCHC (mean corpuscular hemoglobin concentration)
MCV (mean corpuscular volume)
Methylmalonate
Monocyte
MPV (mean platelet volume)
Myoglobin
Neutrophil
Parathyroid hormone (PTH)
Phosphorus
Platelets (plt)
Potassium
Prealbumin
Prolactin
Prostate specific antigen (PSA)
Protein C
Protein S
PSA (prostate specific antigen)
PT (Prothrombin time)
PTT (Partial thromboplastin time)
RDW (red cell distribution width)
Renin
Rennin
Reticulocyte count
reticulocytes
Rheumatoid factor (RF)
Sed Rate
Serum glutamic-pyruvic transaminase (SGPT
Serum protein electrophoresis (SPEP)
Sodium
T3-resin uptake (T3RU)
T4, Free
Thrombin time
Thyroid stimulating hormone (TSH)
Thyroxine (T4)
Total iron binding capacity (TIBC)
Total protein
Transferrin
Transferrin saturation
Triglyceride (TG)
Troponin
Uric acid
Vitamin B12
White blood cells (WBC)
Widal test

### Claim 329 (depends on 328)

The invention of claim 328, wherein said fluid composition comprises an inhalation anesthetic.

### Claim 330 (depends on 329)

The invention of claim 329, wherein said inhalation anesthetic comprises a fluoroether inhalation anesthetic agent.

### Claim 331 (depends on 329)

The invention of claim 329, wherein said inhalation anesthetic comprises sevoflurane, enflurane, isoflurane, methoxyflurane, desflurane, or a combination of any two or more of these.

### Claim 332 (depends on 328)

The invention of claim 328, wherein said fluid composition comprises a drug.

### Claim 333 (depends on 332)

The invention of claim 332, wherein said drug comprises Ablavar (Gadofosveset Trisodium Injection).

### Claim 334 (depends on 332)

The invention of claim 332, wherein said drug comprises Abobotulinumtoxin A Injection (Dysport).

### Claim 335 (depends on 332)

The invention of claim 332, wherein said drug comprises Accretropin (Somatropin Injection).

### Claim 336 (depends on 332)

The invention of claim 332, wherein said drug comprises Acetadote (Acetylcysteine Injection).

### Claim 337 (depends on 332)

The invention of claim 332, wherein said drug comprises Acetazolamide Injection (Acetazolamide Injection).

### Claim 338 (depends on 332)

The invention of claim 332, wherein said drug comprises Acetylcysteine Injection (Acetadote).

### Claim 339 (depends on 332)

The invention of claim 332, wherein said drug comprises Actemra (Tocilizumab Injection).

### Claim 340 (depends on 332)

The invention of claim 332, wherein said drug comprises Acthrel (Corticorelin Ovine Triflutate for Injection).

### Claim 341 (depends on 332)

The invention of claim 332, wherein said drug comprises Acyclovir for Injection (Zovirax Injection).

### Claim 342 (depends on 332)

The invention of claim 332, wherein said drug comprises Adacel.

### Claim 343 (depends on 332)

The invention of claim 332, wherein said drug comprises Adalimumab.

### Claim 344 (depends on 332)

The invention of claim 332, wherein said drug comprises Adenoscan (Adenosine Injection).

### Claim 345 (depends on 332)

The invention of claim 332, wherein said drug comprises Adenosine Injection (Adenoscan).

### Claim 346 (depends on 332)

The invention of claim 332, wherein said drug comprises Adrenaclick.

### Claim 347 (depends on 332)

The invention of claim 332, wherein said drug comprises AdreView (Iobenguane 1123 Injection for Intravenous Use).

### Claim 348 (depends on 332)

The invention of claim 332, wherein said drug comprises Afluria.

### Claim 349 (depends on 332)

The invention of claim 332, wherein said drug comprises Ak-Fluor (Fluorescein Injection).

### Claim 350 (depends on 332)

The invention of claim 332, wherein said drug comprises Alglucerase Injection (Ceredase).

### Claim 351 (depends on 332)

The invention of claim 332, wherein said drug comprises Alkeran Injection (Melphalan Hcl Injection).

### Claim 352 (depends on 332)

The invention of claim 332, wherein said drug comprises Allopurinol Sodium for Injection (Aloprim).

### Claim 353 (depends on 332)

The invention of claim 332, wherein said drug comprises Aloprim (Allopurinol Sodium for Injection).

### Claim 354 (depends on 332)

The invention of claim 332, wherein said drug comprises Alprostadil.

### Claim 355 (depends on 332)

The invention of claim 332, wherein said drug comprises Alsuma (Sumatriptan Injection).

### Claim 356 (depends on 332)

The invention of claim 332, wherein said drug comprises Amino Acid Injections.

### Claim 357 (depends on 332)

The invention of claim 332, wherein said drug comprises Aminosyn.

### Claim 358 (depends on 332)

The invention of claim 332, wherein said drug comprises Apidra.

### Claim 359 (depends on 332)

The invention of claim 332, wherein said drug comprises Apremilast.

### Claim 360 (depends on 332)

The invention of claim 332, wherein said drug comprises Alprostadil Dual Chamber System for Injection (Caverject Impulse).

### Claim 361 (depends on 332)

The invention of claim 332, wherein said drug comprises AMG 108.

### Claim 362 (depends on 332)

The invention of claim 332, wherein said drug comprises AMG 714.

### Claim 363 (depends on 332)

The invention of claim 332, wherein said drug comprises Amiodarone HCl Injection (Amiodarone HCl Injection).

### Claim 364 (depends on 332)

The invention of claim 332, wherein said drug comprises Amobarbital Sodium Injection (Amytal Sodium).

### Claim 365 (depends on 332)

The invention of claim 332, wherein said drug comprises Amytal Sodium (Amobarbital Sodium Injection).

### Claim 366 (depends on 332)

The invention of claim 332, wherein said drug comprises Anakinra.

### Claim 367 (depends on 332)

The invention of claim 332, wherein said drug comprises Arixtra.

### Claim 368 (depends on 332)

The invention of claim 332, wherein said drug comprises Amphadase (Hyaluronidase Inj).

### Claim 369 (depends on 332)

The invention of claim 332, wherein said drug comprises Ammonul (Sodium Phenylacetate and Sodium Benzoate Injection).

### Claim 370 (depends on 332)

The invention of claim 332, wherein said drug comprises Anzemet Injection (Dolasetron Mesylate Injection).

### Claim 371 (depends on 332)

The invention of claim 332, wherein said drug comprises Apidra (Insulin Glulisine [rDNA origin] Inj).

### Claim 372 (depends on 332)

The invention of claim 332, wherein said drug comprises Argatroban (Argatroban Injection).

### Claim 373 (depends on 332)

The invention of claim 332, wherein said drug comprises Arginine Hydrochloride Injection (R-Gene 10).

### Claim 374 (depends on 332)

The invention of claim 332, wherein said drug comprises Aristocort.

### Claim 375 (depends on 332)

The invention of claim 332, wherein said drug comprises Aristospan.

### Claim 376 (depends on 332)

The invention of claim 332, wherein said drug comprises Arsenic Trioxide Injection (Trisenox).

### Claim 377 (depends on 332)

The invention of claim 332, wherein said drug comprises Articane HCl and Epinephrine Injection (Septocaine).

### Claim 378 (depends on 332)

The invention of claim 332, wherein said drug comprises Arzerra (Ofatumumab Injection).

### Claim 379 (depends on 332)

The invention of claim 332, wherein said drug comprises Asclera (Polidocanol Injection).

### Claim 380 (depends on 332)

The invention of claim 332, wherein said drug comprises Atenolol Inj (Tenormin I.V. Injection).

### Claim 381 (depends on 332)

The invention of claim 332, wherein said drug comprises Atracurium Besylate Injection (Atracurium Besylate Injection).

### Claim 382 (depends on 332)

The invention of claim 332, wherein said drug comprises Avastin.

### Claim 383 (depends on 332)

The invention of claim 332, wherein said drug comprises Azactam Injection (Aztreonam Injection).

### Claim 384 (depends on 332)

The invention of claim 332, wherein said drug comprises Azithromycin (Zithromax Injection).

### Claim 385 (depends on 332)

The invention of claim 332, wherein said drug comprises Aztreonam Injection (Azactam Injection).

### Claim 386 (depends on 332)

The invention of claim 332, wherein said drug comprises Baclofen Injection (Lioresal Intrathecal).

### Claim 387 (depends on 332)

The invention of claim 332, wherein said drug comprises Bacteriostatic Water (Bacteriostatic Water for Injection).

### Claim 388 (depends on 332)

The invention of claim 332, wherein said drug comprises Baclofen Injection (Lioresal Intrathecal).

### Claim 389 (depends on 332)

The invention of claim 332, wherein said drug comprises Bal in Oil Ampules (Dimercarprol Injection).

### Claim 390 (depends on 332)

The invention of claim 332, wherein said drug comprises BayHepB.

### Claim 391 (depends on 332)

The invention of claim 332, wherein said drug comprises BayTet.

### Claim 392 (depends on 332)

The invention of claim 332, wherein said drug comprises Benadryl.

### Claim 393 (depends on 332)

The invention of claim 332, wherein said drug comprises Bendamustine Hydrochloride Injection (Treanda).

### Claim 394 (depends on 332)

The invention of claim 332, wherein said drug comprises Benztropine Mesylate Injection (Cogentin).

### Claim 395 (depends on 332)

The invention of claim 332, wherein said drug comprises Betamethasone Injectable Suspension (Celestone Soluspan).

### Claim 396 (depends on 332)

The invention of claim 332, wherein said drug comprises Bexxar.

### Claim 397 (depends on 332)

The invention of claim 332, wherein said drug comprises Bicillin C-R 900/300 (Penicillin G Benzathine and Penicillin G Procaine Injection).

### Claim 398 (depends on 332)

The invention of claim 332, wherein said drug comprises Blenoxane (Bleomycin Sulfate Injection).

### Claim 399 (depends on 332)

The invention of claim 332, wherein said drug comprises Bleomycin Sulfate Injection (Blenoxane).

### Claim 400 (depends on 332)

The invention of claim 332, wherein said drug comprises Boniva Injection (Ibandronate Sodium Injection).

### Claim 401 (depends on 332)

The invention of claim 332, wherein said drug comprises Botox Cosmetic (OnabotulinumtoxinA for Injection).

### Claim 402 (depends on 332)

The invention of claim 332, wherein said drug comprises Bravelle (Urofollitropin Injection).

### Claim 403 (depends on 332)

The invention of claim 332, wherein said drug comprises Bretylium (Bretylium Tosylate Injection).

### Claim 404 (depends on 332)

The invention of claim 332, wherein said drug comprises Brevital Sodium (Methohexital Sodium for Injection).

### Claim 405 (depends on 332)

The invention of claim 332, wherein said drug comprises Brethine.

### Claim 406 (depends on 332)

The invention of claim 332, wherein said drug comprises Briobacept.

### Claim 407 (depends on 332)

The invention of claim 332, wherein said drug comprises BTT-1023.

### Claim 408 (depends on 332)

The invention of claim 332, wherein said drug comprises Bupivacaine HCl.

### Claim 409 (depends on 332)

The invention of claim 332, wherein said drug comprises Byetta.

### Claim 410 (depends on 332)

The invention of claim 332, wherein said drug comprises Ca-DTPA (Pentetate Calcium Trisodium Inj).

### Claim 411 (depends on 332)

The invention of claim 332, wherein said drug comprises Cabazitaxel Injection (Jevtana).

### Claim 412 (depends on 332)

The invention of claim 332, wherein said drug comprises Caffeine Alkaloid (Caffeine and Sodium Benzoate Injection).

### Claim 413 (depends on 332)

The invention of claim 332, wherein said drug comprises Calcijex Injection (Calcitrol).

### Claim 414 (depends on 332)

The invention of claim 332, wherein said drug comprises Calcitrol (Calcijex Injection).

### Claim 415 (depends on 332)

The invention of claim 332, wherein said drug comprises Calcium Chloride (Calcium Chloride Injection 10%).

### Claim 416 (depends on 332)

The invention of claim 332, wherein said drug comprises Calcium Disodium Versenate (Edetate Calcium Disodium Injection).

### Claim 417 (depends on 332)

The invention of claim 332, wherein said drug comprises Camptosar Injection (Irinotecan Hydrochloride).

### Claim 418 (depends on 332)

The invention of claim 332, wherein said drug comprises Canakinumab Injection (Ilaris).

### Claim 419 (depends on 332)

The invention of claim 332, wherein said drug comprises Capastat Sulfate (Capreomycin for Injection).

### Claim 420 (depends on 332)

The invention of claim 332, wherein said drug comprises Capreomycin for Injection (Capastat Sulfate).

### Claim 421 (depends on 332)

The invention of claim 332, wherein said drug comprises Cardiolite (Prep kit for Technetium Tc99 Sestamibi for Injection).

### Claim 422 (depends on 332)

The invention of claim 332, wherein said drug comprises Cefazolin and Dextrose for Injection (Cefazolin Injection).

### Claim 423 (depends on 332)

The invention of claim 332, wherein said drug comprises Cefepime Hydrochloride.

### Claim 424 (depends on 332)

The invention of claim 332, wherein said drug comprises Cefotaxime.

### Claim 425 (depends on 332)

The invention of claim 332, wherein said drug comprises Ceftriaxone.

### Claim 426 (depends on 332)

The invention of claim 332, wherein said drug comprises Carnitor Injection.

### Claim 427 (depends on 332)

The invention of claim 332, wherein said drug comprises Caverject.

### Claim 428 (depends on 332)

The invention of claim 332, wherein said drug comprises Celestone Soluspan.

### Claim 429 (depends on 332)

The invention of claim 332, wherein said drug comprises Cerebyx (Fosphenytoin Sodium Injection).

### Claim 430 (depends on 332)

The invention of claim 332, wherein said drug comprises Ceredase (Alglucerase Injection).

### Claim 431 (depends on 332)

The invention of claim 332, wherein said drug comprises Ceretec (Technetium Tc99m Exametazime Injection).

### Claim 432 (depends on 332)

The invention of claim 332, wherein said drug comprises Certolizumab.

### Claim 433 (depends on 332)

The invention of claim 332, wherein said drug comprises CF-101.

### Claim 434 (depends on 332)

The invention of claim 332, wherein said drug comprises Chloramphenicol Sodium Succinate (Chloramphenicol Sodium Succinate Injection).

### Claim 435 (depends on 332)

The invention of claim 332, wherein said drug comprises Chloramphenicol Sodium Succinate Injection (Chloramphenicol Sodium Succinate).

### Claim 436 (depends on 332)

The invention of claim 332, wherein said drug comprises Choriogonadotropin Alfa Injection (Ovidrel).

### Claim 437 (depends on 332)

The invention of claim 332, wherein said drug comprises Cimzia.

### Claim 438 (depends on 332)

The invention of claim 332, wherein said drug comprises Cisplatin (Cisplatin Injection).

### Claim 439 (depends on 332)

The invention of claim 332, wherein said drug comprises Clomiphine Citrate.

### Claim 440 (depends on 332)

The invention of claim 332, wherein said drug comprises Clonidine Injection (Duraclon).

### Claim 441 (depends on 332)

The invention of claim 332, wherein said drug comprises Cogentin (Benztropine Mesylate Injection).

### Claim 442 (depends on 332)

The invention of claim 332, wherein said drug comprises Colistimethate Injection (Coly-Mycin M).

### Claim 443 (depends on 332)

The invention of claim 332, wherein said drug comprises Coly-Mycin M (Colistimethate Injection).

### Claim 444 (depends on 332)

The invention of claim 332, wherein said drug comprises Compath.

### Claim 445 (depends on 332)

The invention of claim 332, wherein said drug comprises Conivaptan Hcl Injection (Vaprisol).

### Claim 446 (depends on 332)

The invention of claim 332, wherein said drug comprises Conjugated Estrogens for Injection (Premarin Injection).

### Claim 447 (depends on 332)

The invention of claim 332, wherein said drug comprises Copaxone.

### Claim 448 (depends on 332)

The invention of claim 332, wherein said drug comprises Corticorelin Ovine Triflutate for Injection (Acthrel).

### Claim 449 (depends on 332)

The invention of claim 332, wherein said drug comprises Corvert (Ibutilide Fumarate Injection).

### Claim 450 (depends on 332)

The invention of claim 332, wherein said drug comprises Cubicin (Daptomycin Injection).

### Claim 451 (depends on 332)

The invention of claim 332, wherein said drug comprises CF-101.

### Claim 452 (depends on 332)

The invention of claim 332, wherein said drug comprises Cyanokit (Hydroxocobalamin for Injection).

### Claim 453 (depends on 332)

The invention of claim 332, wherein said drug comprises Cytarabine Liposome Injection (DepoCyt).

### Claim 454 (depends on 332)

The invention of claim 332, wherein said drug comprises Cyanocobalamin.

### Claim 455 (depends on 332)

The invention of claim 332, wherein said drug comprises D.H.E. 45.

### Claim 456 (depends on 332)

The invention of claim 332, wherein said drug comprises Dacogen (Decitabine Injection).

### Claim 457 (depends on 332)

The invention of claim 332, wherein said drug comprises Dalteparin.

### Claim 458 (depends on 332)

The invention of claim 332, wherein said drug comprises Dantrium IV (Dantrolene Sodium for Injection).

### Claim 459 (depends on 332)

The invention of claim 332, wherein said drug comprises Dantrolene Sodium for Injection (Dantrium IV).

### Claim 460 (depends on 332)

The invention of claim 332, wherein said drug comprises Daptomycin Injection (Cubicin).

### Claim 461 (depends on 332)

The invention of claim 332, wherein said drug comprises Darbepoietin Alfa.

### Claim 462 (depends on 332)

The invention of claim 332, wherein said drug comprises DDAVP Injection (Desmopressin Acetate Injection).

### Claim 463 (depends on 332)

The invention of claim 332, wherein said drug comprises Decavax.

### Claim 464 (depends on 332)

The invention of claim 332, wherein said drug comprises Decitabine Injection (Dacogen).

### Claim 466 (depends on 332)

The invention of claim 332, wherein said drug comprises Denosumab Injection (Prolia).

### Claim 467 (depends on 332)

The invention of claim 332, wherein said drug comprises Delatestryl.

### Claim 468 (depends on 332)

The invention of claim 332, wherein said drug comprises Delestrogen.

### Claim 469 (depends on 332)

The invention of claim 332, wherein said drug comprises Delteparin Sodium.

### Claim 470 (depends on 332)

The invention of claim 332, wherein said drug comprises Depacon (Valproate Sodium Injection).

### Claim 471 (depends on 332)

The invention of claim 332, wherein said drug comprises Depo Medrol (Methylprednisolone Acetate Injectable Suspension).

### Claim 472 (depends on 332)

The invention of claim 332, wherein said drug comprises DepoCyt (Cytarabine Liposome Injection).

### Claim 473 (depends on 332)

The invention of claim 332, wherein said drug comprises DepoDur (Morphine Sulfate XR Liposome Injection).

### Claim 474 (depends on 332)

The invention of claim 332, wherein said drug comprises Desmopressin Acetate Injection (DDAVP Injection).

### Claim 475 (depends on 332)

The invention of claim 332, wherein said drug comprises Depo-Estradiol.

### Claim 476 (depends on 332)

The invention of claim 332, wherein said drug comprises Depo-Provera 104 mg/ml.

### Claim 477 (depends on 332)

The invention of claim 332, wherein said drug comprises Depo-Provera 150 mg/ml.

### Claim 478 (depends on 332)

The invention of claim 332, wherein said drug comprises Depo-Testosterone.

### Claim 479 (depends on 332)

The invention of claim 332, wherein said drug comprises Dexrazoxane for Injection, Intravenous Infusion Only (Totect).

### Claim 480 (depends on 332)

The invention of claim 332, wherein said drug comprises Dextrose/Electrolytes.

### Claim 481 (depends on 332)

The invention of claim 332, wherein said drug comprises Dextrose and Sodium Chloride Inj (Dextrose 5% in 0.9% Sodium Chloride).

### Claim 482 (depends on 332)

The invention of claim 332, wherein said drug comprises Dextrose.

### Claim 483 (depends on 332)

The invention of claim 332, wherein said drug comprises Diazepam Injection (Diazepam Injection).

### Claim 484 (depends on 332)

The invention of claim 332, wherein said drug comprises Digoxin Injection (Lanoxin Injection).

### Claim 485 (depends on 332)

The invention of claim 332, wherein said drug comprises Dilaudid-HP (Hydromorphone Hydrochloride Injection).

### Claim 486 (depends on 332)

The invention of claim 332, wherein said drug comprises Dimercarprol Injection (Bal in Oil Ampules).

### Claim 487 (depends on 332)

The invention of claim 332, wherein said drug comprises Diphenhydramine Injection (Benadryl Injection).

### Claim 488 (depends on 332)

The invention of claim 332, wherein said drug comprises Dipyridamole Injection (Dipyridamole Injection).

### Claim 489 (depends on 332)

The invention of claim 332, wherein said drug comprises Docetaxel for Injection (Taxotere).

### Claim 490 (depends on 332)

The invention of claim 332, wherein said drug comprises Dolasetron Mesylate Injection (Anzemet Injection).

### Claim 491 (depends on 332)

The invention of claim 332, wherein said drug comprises Doribax (Doripenem for Injection).

### Claim 492 (depends on 332)

The invention of claim 332, wherein said drug comprises Doripenem for Injection (Doribax).

### Claim 493 (depends on 332)

The invention of claim 332, wherein said drug comprises Doxercalciferol Injection (Hectorol Injection).

### Claim 494 (depends on 332)

The invention of claim 332, wherein said drug comprises Doxil (Doxorubicin Hcl Liposome Injection).

### Claim 495 (depends on 332)

The invention of claim 332, wherein said drug comprises Doxorubicin Hcl Liposome Injection (Doxil).

### Claim 496 (depends on 332)

The invention of claim 332, wherein said drug comprises Duraclon (Clonidine Injection).

### Claim 497 (depends on 332)

The invention of claim 332, wherein said drug comprises Duramorph (Morphine Injection).

### Claim 498 (depends on 332)

The invention of claim 332, wherein said drug comprises Dysport (Abobotulinumtoxin A Injection).

### Claim 499 (depends on 332)

The invention of claim 332, wherein said drug comprises Ecallantide Injection (Kalbitor).

### Claim 500 (depends on 332)

The invention of claim 332, wherein said drug comprises Edetate Calcium Disodium Injection (Calcium Disodium Versenate).

### Claim 501 (depends on 332)

The invention of claim 332, wherein said drug comprises Edex (Alprostadil for Injection).

### Claim 502 (depends on 332)

The invention of claim 332, wherein said drug comprises Engerix.

### Claim 503 (depends on 332)

The invention of claim 332, wherein said drug comprises Edrophonium Injection (Enlon).

### Claim 504 (depends on 332)

The invention of claim 332, wherein said drug comprises Eloxatin (Oxaliplatin Injection).

### Claim 505 (depends on 332)

The invention of claim 332, wherein said drug comprises Emend Injection (Fosaprepitant Dimeglumine Injection).

### Claim 506 (depends on 332)

The invention of claim 332, wherein said drug comprises Enalaprilat Injection (Enalaprilat Injection).

### Claim 507 (depends on 332)

The invention of claim 332, wherein said drug comprises Enlon (Edrophonium Injection).

### Claim 508 (depends on 332)

The invention of claim 332, wherein said drug comprises Enoxaparin Sodium Injection (Lovenox).

### Claim 509 (depends on 332)

The invention of claim 332, wherein said drug comprises Eovist (Gadoxetate Disodium Injection).

### Claim 510 (depends on 332)

The invention of claim 332, wherein said drug comprises Enbrel.

### Claim 511 (depends on 332)

The invention of claim 332, wherein said drug comprises Enoxaparin.

### Claim 512 (depends on 332)

The invention of claim 332, wherein said drug comprises Epinepherine.

### Claim 513 (depends on 332)

The invention of claim 332, wherein said drug comprises Epipen.

### Claim 514 (depends on 332)

The invention of claim 332, wherein said drug comprises Epipen Jr.

### Claim 515 (depends on 332)

The invention of claim 332, wherein said drug comprises Erbitux.

### Claim 516 (depends on 332)

The invention of claim 332, wherein said drug comprises Ertapenem Injection (Invanz).

### Claim 517 (depends on 332)

The invention of claim 332, wherein said drug comprises Erythropoieten.

### Claim 518 (depends on 332)

The invention of claim 332, wherein said drug comprises Essential Amino Acid Injection (Nephramine).

### Claim 519 (depends on 332)

The invention of claim 332, wherein said drug comprises Estradiol Cypionate.

### Claim 520 (depends on 332)

The invention of claim 332, wherein said drug comprises Estradiol Valerate.

### Claim 521 (depends on 332)

The invention of claim 332, wherein said drug comprises Etanercept.

### Claim 522 (depends on 332)

The invention of claim 332, wherein said drug comprises Exenatide Injection (Byetta).

### Claim 523 (depends on 332)

The invention of claim 332, wherein said drug comprises Famotidine Injection.

### Claim 524 (depends on 332)

The invention of claim 332, wherein said drug comprises FDG (Fludeoxyglucose F 18 Injection).

### Claim 525 (depends on 332)

The invention of claim 332, wherein said drug comprises Feraheme (Ferumoxytol Injection).

### Claim 526 (depends on 332)

The invention of claim 332, wherein said drug comprises Feridex I.V. (Ferumoxides Injectable Solution).

### Claim 527 (depends on 332)

The invention of claim 332, wherein said drug comprises Fertinex.

### Claim 528 (depends on 332)

The invention of claim 332, wherein said drug comprises Ferumoxides Injectable Solution (Feridex I.V.).

### Claim 529 (depends on 332)

The invention of claim 332, wherein said drug comprises Ferumoxytol Injection (Feraheme).

### Claim 530 (depends on 332)

The invention of claim 332, wherein said drug comprises Flagyl Injection (Metronidazole Injection).

### Claim 531 (depends on 332)

The invention of claim 332, wherein said drug comprises Fluarix.

### Claim 532 (depends on 332)

The invention of claim 332, wherein said drug comprises Fludeoxyglucose F 18 Injection (FDG).

### Claim 533 (depends on 332)

The invention of claim 332, wherein said drug comprises Fluorescein Injection (Ak-Fluor).

### Claim 534 (depends on 332)

The invention of claim 332, wherein said drug comprises Follistim AQ Cartridge (Follitropin Beta Injection).

### Claim 535 (depends on 332)

The invention of claim 332, wherein said drug comprises Follitropin Alfa Injection (Gonal-f RFF).

### Claim 536 (depends on 332)

The invention of claim 332, wherein said drug comprises Follitropin Beta Injection (Follistim AQ Cartridge).

### Claim 537 (depends on 332)

The invention of claim 332, wherein said drug comprises Folotyn (Pralatrexate Solution for Intravenous Injection).

### Claim 538 (depends on 332)

The invention of claim 332, wherein said drug comprises Fondaparinux.

### Claim 539 (depends on 332)

The invention of claim 332, wherein said drug comprises Forteo (Teriparatide (rDNA origin) Injection).

### Claim 540 (depends on 332)

The invention of claim 332, wherein said drug comprises Fostamatinib.

### Claim 541 (depends on 332)

The invention of claim 332, wherein said drug comprises Fosaprepitant Dimeglumine Injection (Emend Injection).

### Claim 542 (depends on 332)

The invention of claim 332, wherein said drug comprises Foscarnet Sodium Injection (Foscavir).

### Claim 543 (depends on 332)

The invention of claim 332, wherein said drug comprises Foscavir (Foscarnet Sodium Injection).

### Claim 544 (depends on 332)

The invention of claim 332, wherein said drug comprises Fosphenytoin Sodium Injection (Cerebyx).

### Claim 545 (depends on 332)

The invention of claim 332, wherein said drug comprises Fospropofol Disodium Injection (Lusedra).

### Claim 546 (depends on 332)

The invention of claim 332, wherein said drug comprises Fragmin.

### Claim 547 (depends on 332)

The invention of claim 332, wherein said drug comprises Gadobenate Dimeglumine Injection (Multihance).

### Claim 548 (depends on 332)

The invention of claim 332, wherein said drug comprises Gadofosveset Trisodium Injection (Ablavar).

### Claim 549 (depends on 332)

The invention of claim 332, wherein said drug comprises Gadoteridol Injection Solution (ProHance).

### Claim 550 (depends on 332)

The invention of claim 332, wherein said drug comprises Gadoversetamide Injection (OptiMARK).

### Claim 551 (depends on 332)

The invention of claim 332, wherein said drug comprises Gadoxetate Disodium Injection (Eovist).

### Claim 552 (depends on 332)

The invention of claim 332, wherein said drug comprises Ganirelix (Ganirelix Acetate Injection).

### Claim 553 (depends on 332)

The invention of claim 332, wherein said drug comprises Gardasil.

### Claim 554 (depends on 332)

The invention of claim 332, wherein said drug comprises Gemtuzumab Ozogamicin for Injection (Mylotarg).

### Claim 555 (depends on 332)

The invention of claim 332, wherein said drug comprises Genotropin.

### Claim 556 (depends on 332)

The invention of claim 332, wherein said drug comprises Gentamicin Injection.

### Claim 557 (depends on 332)

The invention of claim 332, wherein said drug comprises Golimumab Injection (Simponi Injection).

### Claim 558 (depends on 332)

The invention of claim 332, wherein said drug comprises Gonal-f RFF (Follitropin Alfa Injection).

### Claim 559 (depends on 332)

The invention of claim 332, wherein said drug comprises Granisetron Hydrochloride (Kytril Injection).

### Claim 560 (depends on 332)

The invention of claim 332, wherein said drug comprises Gentamicin Sulfate.

### Claim 561 (depends on 332)

The invention of claim 332, wherein said drug comprises Glatiramer Acetate.

### Claim 562 (depends on 332)

The invention of claim 332, wherein said drug comprises Glucagen.

### Claim 563 (depends on 332)

The invention of claim 332, wherein said drug comprises Glucagon.

### Claim 564 (depends on 332)

The invention of claim 332, wherein said drug comprises Haldol (Haloperidol Injection).

### Claim 565 (depends on 332)

The invention of claim 332, wherein said drug comprises Havrix.

### Claim 566 (depends on 332)

The invention of claim 332, wherein said drug comprises Hectorol InjectiZn (Doxercalciferol Injection).

### Claim 567 (depends on 332)

The invention of claim 332, wherein said drug comprises Heparin.

### Claim 568 (depends on 332)

The invention of claim 332, wherein said drug comprises Herceptin.

### Claim 569 (depends on 332)

The invention of claim 332, wherein said drug comprises hG-CSF.

### Claim 570 (depends on 332)

The invention of claim 332, wherein said drug comprises Humalog.

### Claim 571 (depends on 332)

The invention of claim 332, wherein said drug comprises Human Growth Hormone.

### Claim 572 (depends on 332)

The invention of claim 332, wherein said drug comprises Humatrope.

### Claim 573 (depends on 332)

The invention of claim 332, wherein said drug comprises HuMax.

### Claim 574 (depends on 332)

The invention of claim 332, wherein said drug comprises Humegon.

### Claim 575 (depends on 332)

The invention of claim 332, wherein said drug comprises Humira.

### Claim 576 (depends on 332)

The invention of claim 332, wherein said drug comprises Humulin.

### Claim 577 (depends on 332)

The invention of claim 332, wherein said drug comprises Ibandr8nate Sodium Injection (Boniva Injection).

### Claim 578 (depends on 332)

The invention of claim 332, wherein said drug comprises Ibuprofen Lysine Injection (NeoProfen).

### Claim 579 (depends on 332)

The invention of claim 332, wherein said drug comprises Ibutilide Fumarate Injection (Corvert).

### Claim 580 (depends on 332)

The invention of claim 332, wherein said drug comprises Idamycin PFS (Idarubicin Hydrochloride Injection).

### Claim 581 (depends on 332)

The invention of claim 332, wherein said drug comprises Idarubicin Hydrochloride Injection (Idamycin PFS).

### Claim 582 (depends on 332)

The invention of claim 332, wherein said drug comprises Ilaris (Canakinumab Injection).

### Claim 583 (depends on 332)

The invention of claim 332, wherein said drug comprises Imipenem and Cilastatin for Injection (Primaxin I.V.).

### Claim 584 (depends on 332)

The invention of claim 332, wherein said drug comprises Imitrex.

### Claim 585 (depends on 332)

The invention of claim 332, wherein said drug comprises Incobotulinumtoxin A for Injection (Xeomin).

### Claim 586 (depends on 332)

The invention of claim 332, wherein said drug comprises Increlex (Mecasermin [rDNA origin] Injection).

### Claim 587 (depends on 332)

The invention of claim 332, wherein said drug comprises Indocin IV (Indomethacin Inj).

### Claim 588 (depends on 332)

The invention of claim 332, wherein said drug comprises Indomethacin Inj (Indocin IV).

### Claim 589 (depends on 332)

The invention of claim 332, wherein said drug comprises Infanrix.

### Claim 590 (depends on 332)

The invention of claim 332, wherein said drug comprises Innohep.

### Claim 591 (depends on 332)

The invention of claim 332, wherein said drug comprises Insulin/

### Claim 592 (depends on 332)

The invention of claim 332, wherein said drug comprises Insulin Aspart [rDNA origin] Inj (NovoLog).

### Claim 593 (depends on 332)

The invention of claim 332, wherein said drug comprises Insulin Glargine [rDNA origin] Injection (Lantus).

### Claim 594 (depends on 332)

The invention of claim 332, wherein said drug comprises Insulin Glulisine [rDNA origin] Inj (Apidra).

### Claim 595 (depends on 332)

The invention of claim 332, wherein said drug comprises Interferon alfa-2b, Recombinant for Injection (Intron A).

### Claim 596 (depends on 332)

The invention of claim 332, wherein said drug comprises Intron A (Interferon alfa-2b, Recombinant for Injection).

### Claim 597 (depends on 332)

The invention of claim 332, wherein said drug comprises Invanz (Ertapenem Injection).

### Claim 598 (depends on 332)

The invention of claim 332, wherein said drug comprises Invega Sustenna (Paliperidone Palmitate Extended-Release Injectable Suspension).

### Claim 599 (depends on 332)

The invention of claim 332, wherein said drug comprises Iobenguane I 123 Injection for Intravenous Use (AdreView).

### Claim 600 (depends on 332)

The invention of claim 332, wherein said drug comprises Iopromide Injection (Ultravist).

### Claim 601 (depends on 332)

The invention of claim 332, wherein said drug comprises Ioversol Injection (Optiray Injection).

### Claim 602 (depends on 332)

The invention of claim 332, wherein said drug comprises Iplex (Mecasermin Rinfabate [rDNA origin] Injection).

### Claim 603 (depends on 332)

The invention of claim 332, wherein said drug comprises Iprivask.

### Claim 604 (depends on 332)

The invention of claim 332, wherein said drug comprises Irinotecan Hydrochloride (Camptosar Injection).

### Claim 605 (depends on 332)

The invention of claim 332, wherein said drug comprises Iron Sucrose Injection (Venofer).

### Claim 606 (depends on 332)

The invention of claim 332, wherein said drug comprises Istodax (Romidepsin for Injection).

### Claim 607 (depends on 332)

The invention of claim 332, wherein said drug comprises Itraconazole Injection (Sporanox Injection).

### Claim 608 (depends on 332)

The invention of claim 332, wherein said drug comprises Jevtana (Cabazitaxel Injection).

### Claim 609 (depends on 332)

The invention of claim 332, wherein said drug comprises Kalbitor (Ecallantide Injection).

### Claim 610 (depends on 332)

The invention of claim 332, wherein said drug comprises KCL in DSNS (Potassium Chloride in 5% Dextrose and Sodium Chloride Injection).

### Claim 611 (depends on 332)

The invention of claim 332, wherein said drug comprises KCL in D5 W.

### Claim 612 (depends on 332)

The invention of claim 332, wherein said drug comprises KCL in NS.

### Claim 613 (depends on 332)

The invention of claim 332, wherein said drug comprises Kenalog 10 Injection (Triamcinolone Acetonide Injectable Suspension).

### Claim 614 (depends on 332)

The invention of claim 332, wherein said drug comprises Keppra Injection (Levetiracetam).

### Claim 615 (depends on 332)

The invention of claim 332, wherein said drug comprises Kineret.

### Claim 616 (depends on 332)

The invention of claim 332, wherein said drug comprises Kinlytic (Urokinase Injection).

### Claim 617 (depends on 332)

The invention of claim 332, wherein said drug comprises Kinrix.

### Claim 618 (depends on 332)

The invention of claim 332, wherein said drug comprises Kytril Injection (Granisetron Hydrochloride).

### Claim 619 (depends on 332)

The invention of claim 332, wherein said drug comprises lacosamide Tablet and Injection (Vimpat).

### Claim 620 (depends on 332)

The invention of claim 332, wherein said drug comprises Lactated Ringer's.

### Claim 621 (depends on 332)

The invention of claim 332, wherein said drug comprises Lanoxin Injection (Digoxin Injection).

### Claim 622 (depends on 332)

The invention of claim 332, wherein said drug comprises Lansoprazole for Injection (Prevacid I.V.).

### Claim 623 (depends on 332)

The invention of claim 332, wherein said drug comprises Lantus.

### Claim 624 (depends on 332)

The invention of claim 332, wherein said drug comprises Leucovorin Calcium (Leucovorin Calcium Injection).

### Claim 625 (depends on 332)

The invention of claim 332, wherein said drug comprises Lente (L).

### Claim 626 (depends on 332)

The invention of claim 332, wherein said drug comprises Levemir.

### Claim 627 (depends on 332)

The invention of claim 332, wherein said drug comprises Leuproide Acetate.

### Claim 628 (depends on 332)

The invention of claim 332, wherein said drug comprises Levothyroxine.

### Claim 629 (depends on 332)

The invention of claim 332, wherein said drug comprises Levetiracetam (Keppra Injection).

### Claim 630 (depends on 332)

The invention of claim 332, wherein said drug comprises Lovenox.

### Claim 631 (depends on 332)

The invention of claim 332, wherein said drug comprises Levocarnitine Injection (Carnitor Injection).

### Claim 632 (depends on 332)

The invention of claim 332, wherein said drug comprises Lexiscan (Regadenoson Injection).

### Claim 633 (depends on 332)

The invention of claim 332, wherein said drug comprises Lioresal Intrathecal (Baclofen Injection).

### Claim 634 (depends on 332)

The invention of claim 332, wherein said drug comprises Liraglutide [rDNA] Injection (Victoza).

### Claim 635 (depends on 332)

The invention of claim 332, wherein said drug comprises Lovenox (Enoxaparin Sodium Injection).

### Claim 636 (depends on 332)

The invention of claim 332, wherein said drug comprises Lucentis (Ranibizumab Injection).

### Claim 637 (depends on 332)

The invention of claim 332, wherein said drug comprises Lupron (Leuprolide Acetate Injection).

### Claim 638 (depends on 332)

The invention of claim 332, wherein said drug comprises Lusedra (Fospropofol Disodium Injection).

### Claim 639 (depends on 332)

The invention of claim 332, wherein said drug comprises Magnesium Sulfate (Magnesium Sulfate Injection).

### Claim 640 (depends on 332)

The invention of claim 332, wherein said drug comprises Mannitol Injection (Mannitol IV).

### Claim 641 (depends on 332)

The invention of claim 332, wherein said drug comprises Marcaine (Bupivacaine Hydrochloride and Epinephrine Injection).

### Claim 642 (depends on 332)

The invention of claim 332, wherein said drug comprises Maxipime (Cefepime Hydrochloride for Injection).

### Claim 643 (depends on 332)

The invention of claim 332, wherein said drug comprises MDP Multidose Kit of Technetium Injection (Technetium Tc99m Medronate Injection).

### Claim 644 (depends on 332)

The invention of claim 332, wherein said drug comprises Mecasermin [rDNA origin] Injection (Increlex).

### Claim 645 (depends on 332)

The invention of claim 332, wherein said drug comprises Dehydrated Alcohol (Dehydrated Alcohol Injection).

### Claim 645 (depends on 332)

The invention of claim 332, wherein said drug comprises Mecasermin Rinfabate [rDNA origin] Injection (Iplex).

### Claim 646 (depends on 332)

The invention of claim 332, wherein said drug comprises Melphalan Hcl Injection (Alkeran Injection).

### Claim 647 (depends on 332)

The invention of claim 332, wherein said drug comprises Methotrexate.

### Claim 648 (depends on 332)

The invention of claim 332, wherein said drug comprises Menactra.

### Claim 649 (depends on 332)

The invention of claim 332, wherein said drug comprises Menopur (Menotropins Injection).

### Claim 650 (depends on 332)

The invention of claim 332, wherein said drug comprises Menotropins for Injection (Repronex).

### Claim 651 (depends on 332)

The invention of claim 332, wherein said drug comprises Methohexital Sodium for Injection (Brevital Sodium).

### Claim 652 (depends on 332)

The invention of claim 332, wherein said drug comprises Methyldopate Hydrochloride Injection, Solution (Methyldopate Hcl).

### Claim 653 (depends on 332)

The invention of claim 332, wherein said drug comprises Methylene Blue (Methylene Blue Injection).

### Claim 654 (depends on 332)

The invention of claim 332, wherein said drug comprises Methylprednisolone Acetate Injectable Suspension (Depo Medrol).

### Claim 655 (depends on 332)

The invention of claim 332, wherein said drug comprises Metoclopramide Injection (Reglan Injection).

### Claim 656 (depends on 332)

The invention of claim 332, wherein said drug comprises Metrodin (Urofollitropin for Injection).

### Claim 657 (depends on 332)

The invention of claim 332, wherein said drug comprises Metronidazole Injection (Flagyl Injection).

### Claim 658 (depends on 332)

The invention of claim 332, wherein said drug comprises Miacalcin.

### Claim 659 (depends on 332)

The invention of claim 332, wherein said drug comprises Midazolam (Midazolam Injection).

### Claim 660 (depends on 332)

The invention of claim 332, wherein said drug comprises Minocin Injection (Minocycline Inj).

### Claim 661 (depends on 332)

The invention of claim 332, wherein said drug comprises Minocycline Inj (Minocin Injection).

### Claim 662 (depends on 332)

The invention of claim 332, wherein said drug comprises Mitoxantrone for Injection Concentrate (Novantrone).

### Claim 663 (depends on 332)

The invention of claim 332, wherein said drug comprises Morphine Injection (Duramorph).

### Claim 664 (depends on 332)

The invention of claim 332, wherein said drug comprises Morphine Sulfate XR Liposome Injection (DepoDur).

### Claim 665 (depends on 332)

The invention of claim 332, wherein said drug comprises Morrhuate Sodium (Morrhuate Sodium Injection).

### Claim 666 (depends on 332)

The invention of claim 332, wherein said drug comprises Mozobil (Plerixafor Injection).

### Claim 667 (depends on 332)

The invention of claim 332, wherein said drug comprises Multihance (Gadobenate Dimeglumine Injection).

### Claim 668 (depends on 332)

The invention of claim 332, wherein said drug comprises Multiple Electrolytes and Dextrose Injection.

### Claim 669 (depends on 332)

The invention of claim 332, wherein said drug comprises Multiple Electrolytes Injection.

### Claim 670 (depends on 332)

The invention of claim 332, wherein said drug comprises Mylotarg (Gemtuzumab Ozogamicin for Injection).

### Claim 671 (depends on 332)

The invention of claim 332, wherein said drug comprises Nafcillin Injection (Nafcillin Sodium).

### Claim 672 (depends on 332)

The invention of claim 332, wherein said drug comprises Nafcillin Sodium (Nafcillin Injection).

### Claim 673 (depends on 332)

The invention of claim 332, wherein said drug comprises Naltrexone XR Inj (Vivitrol).

### Claim 674 (depends on 332)

The invention of claim 332, wherein said drug comprises NeoProfen (Ibuprofen Lysine Injection).

### Claim 675 (depends on 332)

The invention of claim 332, wherein said drug comprises Nandrol Decanoate.

### Claim 676 (depends on 332)

The invention of claim 332, wherein said drug comprises Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection).

### Claim 677 (depends on 332)

The invention of claim 332, wherein said drug comprises NeoTect (Technetium Tc 99m Depreotide Injection).

### Claim 678 (depends on 332)

The invention of claim 332, wherein said drug comprises Nephramine (Essential Amino Acid Injection).

### Claim 679 (depends on 332)

The invention of claim 332, wherein said drug comprises Neulasta.

### Claim 680 (depends on 332)

The invention of claim 332, wherein said drug comprises Neupogen.

### Claim 681 (depends on 332)

The invention of claim 332, wherein said drug comprises Novolin.

### Claim 682 (depends on 332)

The invention of claim 332, wherein said drug comprises Novolog.

### Claim 683 (depends on 332)

The invention of claim 332, wherein said drug comprises NeoRecormon.

### Claim 684 (depends on 332)

The invention of claim 332, wherein said drug comprises Neutrexin (Trimetrexate Glucuronate Inj).

### Claim 685 (depends on 332)

The invention of claim 332, wherein said drug comprises NPH (N).

### Claim 686 (depends on 332)

The invention of claim 332, wherein said drug comprises Nexterone (Amiodarone HCl Injection).

### Claim 687 (depends on 332)

The invention of claim 332, wherein said drug comprises Norditropin (Somatropin Injection).

### Claim 688 (depends on 332)

The invention of claim 332, wherein said drug comprises Normal Saline (Sodium Chloride Injection).

### Claim 689 (depends on 332)

The invention of claim 332, wherein said drug comprises Novantrone (Mitoxantrone for Injection Concentrate).

### Claim 690 (depends on 332)

The invention of claim 332, wherein said drug comprises Novolin 70/30 Innolet (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection).

### Claim 691 (depends on 332)

The invention of claim 332, wherein said drug comprises NovoLog (Insulin Aspart [rDNA origin] Inj).

### Claim 692 (depends on 332)

The invention of claim 332, wherein said drug comprises Nutropin (Somatropin (rDNA origin) for Inj).

### Claim 693 (depends on 332)

The invention of claim 332, wherein said drug comprises Nutropin Depot (Somatropin (rDNA origin) for Inj).

### Claim 694 (depends on 332)

The invention of claim 332, wherein said drug comprises Octreotide Acetate Injection (Sandostatin LAR).

### Claim 695 (depends on 332)

The invention of claim 332, wherein said drug comprises Ocrelizumab.

### Claim 696 (depends on 332)

The invention of claim 332, wherein said drug comprises Ofatumumab Injection (Arzerra).

### Claim 697 (depends on 332)

The invention of claim 332, wherein said drug comprises Olanzapine Extended Release Injectable Suspension (Zyprexa Relprevv).

### Claim 698 (depends on 332)

The invention of claim 332, wherein said drug comprises Omnitrope (Somatropin [rDNA origin] Injection).

### Claim 699 (depends on 332)

The invention of claim 332, wherein said drug comprises Ondansetron Hydrochloride Injection (Zofran Injection).

### Claim 700 (depends on 332)

The invention of claim 332, wherein said drug comprises OptiMARK (Gadoversetamide Injection).

### Claim 701 (depends on 332)

The invention of claim 332, wherein said drug comprises Optiray Injection (Ioversol Injection).

### Claim 702 (depends on 332)

The invention of claim 332, wherein said drug comprises Orencia.

### Claim 703 (depends on 332)

The invention of claim 332, wherein said drug comprises Osmitrol Injection in Aviva (Mannitol Injection in Aviva Plastic Vessel).

### Claim 704 (depends on 332)

The invention of claim 332, wherein said drug comprises Osmitrol Injection in Viaflex (Mannitol Injection in Viaflex Plastic Vessel).

### Claim 705 (depends on 332)

The invention of claim 332, wherein said drug comprises Ovidrel (Choriogonadotropin Alfa Injection).

### Claim 706 (depends on 332)

The invention of claim 332, wherein said drug comprises Oxacillin (Oxacillin for Injection).

### Claim 707 (depends on 332)

The invention of claim 332, wherein said drug comprises Oxaliplatin Injection (Eloxatin).

### Claim 708 (depends on 332)

The invention of claim 332, wherein said drug comprises Oxytocin Injection (Pitocin).

### Claim 709 (depends on 332)

The invention of claim 332, wherein said drug comprises Paliperidone Palmitate Extended-Release Injectable Suspension (Invega Sustenna).

### Claim 710 (depends on 332)

The invention of claim 332, wherein said drug comprises Pamidronate Disodium Injection (Pamidronate Disodium Injection).

### Claim 711 (depends on 332)

The invention of claim 332, wherein said drug comprises Panitumumab Injection for Intravenous Use (Vectibix).

### Claim 712 (depends on 332)

The invention of claim 332, wherein said drug comprises Papaverine Hydrochloride Injection (Papaverine Injection).

### Claim 713 (depends on 332)

The invention of claim 332, wherein said drug comprises Papaverine Injection (Papaverine Hydrochloride Injection).

### Claim 714 (depends on 332)

The invention of claim 332, wherein said drug comprises Parathyroid Hormone.

### Claim 715 (depends on 332)

The invention of claim 332, wherein said drug comprises Paricalcitol Injection Fliptop Vial (Zemplar Injection).

### Claim 716 (depends on 332)

The invention of claim 332, wherein said drug comprises Pediarix.

### Claim 717 (depends on 332)

The invention of claim 332, wherein said drug comprises PEGIntron.

### Claim 718 (depends on 332)

The invention of claim 332, wherein said drug comprises Peginterferon.

### Claim 719 (depends on 332)

The invention of claim 332, wherein said drug comprises Pegfilgrastim.

### Claim 720 (depends on 332)

The invention of claim 332, wherein said drug comprises Penicillin G Benzathine and Penicillin G Procaine.

### Claim 721 (depends on 332)

The invention of claim 332, wherein said drug comprises Pentetate Calcium Trisodium Inj (Ca-DTPA).

### Claim 722 (depends on 332)

The invention of claim 332, wherein said drug comprises Pentetate Zinc Trisodium Injection (Zn-DTPA).

### Claim 723 (depends on 332)

The invention of claim 332, wherein said drug comprises Pepcid Injection (Famotidine Injection).

### Claim 724 (depends on 332)

The invention of claim 332, wherein said drug comprises Pergonal.

### Claim 725 (depends on 332)

The invention of claim 332, wherein said drug comprises Phentolamine Mesylate (Phentolamine Mesylate for Injection).

### Claim 726 (depends on 332)

The invention of claim 332, wherein said drug comprises Physostigmine Salicylate (Physostigmine Salicylate (injection)).

### Claim 727 (depends on 332)

The invention of claim 332, wherein said drug comprises Physostigmine Salicylate (injection) (Physostigmine Salicylate).

### Claim 728 (depends on 332)

The invention of claim 332, wherein said drug comprises Piperacillin and Tazobactam Injection (Zosyn).

### Claim 729 (depends on 332)

The invention of claim 332, wherein said drug comprises Pitocin (Oxytocin Injection).

### Claim 730 (depends on 332)

The invention of claim 332, wherein said drug comprises Plasma-Lyte 148 (Multiple Electrolytes Inj).

### Claim 731 (depends on 332)

The invention of claim 332, wherein said drug comprises Plasma-Lyte 56 and Dextrose (Multiple Electrolytes and Dextrose Injection in Viaflex Plastic Vessel).

### Claim 732 (depends on 332)

The invention of claim 332, wherein said drug comprises PlasmaLyte.

### Claim 733 (depends on 332)

The invention of claim 332, wherein said drug comprises Plerixafor Injection (Mozobil).

### Claim 734 (depends on 332)

The invention of claim 332, wherein said drug comprises Polidocanol Injection (Asclera).

### Claim 735 (depends on 332)

The invention of claim 332, wherein said drug comprises Potassium Chloride.

### Claim 736 (depends on 332)

The invention of claim 332, wherein said drug comprises Pralatrexate Solution for Intravenous Injection (Folotyn).

### Claim 737 (depends on 332)

The invention of claim 332, wherein said drug comprises Pramlintide Acetate Injection (Symlin).

### Claim 738 (depends on 332)

The invention of claim 332, wherein said drug comprises Premarin Injection (Conjugated Estrogens for Injection).

### Claim 739 (depends on 332)

The invention of claim 332, wherein said drug comprises Prep kit for Technetium Tc99 Sestamibi for Injection (Cardiolite).

### Claim 740 (depends on 332)

The invention of claim 332, wherein said drug comprises Prevacid I.V. (Lansoprazole for Injection).

### Claim 741 (depends on 332)

The invention of claim 332, wherein said drug comprises Primaxin I.V. (Imipenem and Cilastatin for Injection).

### Claim 742 (depends on 332)

The invention of claim 332, wherein said drug comprises Progesterone.

### Claim 743 (depends on 332)

The invention of claim 332, wherein said drug comprises ProHance (Gadoteridol Injection Solution).

### Claim 744 (depends on 332)

The invention of claim 332, wherein said drug comprises Prolia (Denosumab Injection).

### Claim 745 (depends on 332)

The invention of claim 332, wherein said drug comprises Promethazine HCl Injection (Promethazine Hydrochloride Injection).

### Claim 746 (depends on 332)

The invention of claim 332, wherein said drug comprises Propranolol Hydrochloride Injection (Propranolol Hydrochloride Injection).

### Claim 747 (depends on 332)

The invention of claim 332, wherein said drug comprises Quinidine Gluconate Injection (Quinidine Injection).

### Claim 748 (depends on 332)

The invention of claim 332, wherein said drug comprises Quinidine Injection (Quinidine Gluconate Injection).

### Claim 749 (depends on 332)

The invention of claim 332, wherein said drug comprises R-Gene 10 (Arginine Hydrochloride Injection).

### Claim 750 (depends on 332)

The invention of claim 332, wherein said drug comprises Ranibizumab Injection (Lucentis).

### Claim 751 (depends on 332)

The invention of claim 332, wherein said drug comprises Ranitidine Hydrochloride Injection (Zantac Injection).

### Claim 752 (depends on 332)

The invention of claim 332, wherein said drug comprises Reclast (Zoledronic Acid Injection).

### Claim 753 (depends on 332)

The invention of claim 332, wherein said drug comprises Recombivarix HB.

### Claim 754 (depends on 332)

The invention of claim 332, wherein said drug comprises Regadenoson Injection (Lexiscan).

### Claim 755 (depends on 332)

The invention of claim 332, wherein said drug comprises Reglan Injection (Metoclopramide Injection).

### Claim 756 (depends on 332)

The invention of claim 332, wherein said drug comprises Remicade.

### Claim 757 (depends on 332)

The invention of claim 332, wherein said drug comprises Repronex (Menotropins for Injection).

### Claim 758 (depends on 332)

The invention of claim 332, wherein said drug comprises Retrovir IV (Zidovudine Injection).

### Claim 759 (depends on 332)

The invention of claim 332, wherein said drug comprises Ringer's and 5% Dextrose Injection (Ringers in Dextrose).

### Claim 760 (depends on 332)

The invention of claim 332, wherein said drug comprises Ringer's Injection (Ringers Injection).

### Claim 761 (depends on 332)

The invention of claim 332, wherein said drug comprises Rituxan.

### Claim 762 (depends on 332)

The invention of claim 332, wherein said drug comprises Rituximab.

### Claim 763 (depends on 332)

The invention of claim 332, wherein said drug comprises Rocuronium Bromide Injection (Zemuron).

### Claim 764 (depends on 332)

The invention of claim 332, wherein said drug comprises Romidepsin for Injection (Istodax).

### Claim 765 (depends on 332)

The invention of claim 332, wherein said drug comprises Saizen (Somatropin Injection).

### Claim 766 (depends on 332)

The invention of claim 332, wherein said drug comprises Sandostatin LAR (Octreotide Acetate Injection).

### Claim 767 (depends on 332)

The invention of claim 332, wherein said drug comprises Sensorcaine (Bupivacaine HCl Injections).

### Claim 768 (depends on 332)

The invention of claim 332, wherein said drug comprises Septocaine (Articane HCl and Epinephrine Injection).

### Claim 769 (depends on 332)

The invention of claim 332, wherein said drug comprises Serostim LQ (Somatropin (rDNA origin) Injection).

### Claim 770 (depends on 332)

The invention of claim 332, wherein said drug comprises Simponi Injection (Golimumab Injection).

### Claim 771 (depends on 332)

The invention of claim 332, wherein said drug comprises Sodium Acetate (Sodium Acetate Injection).

### Claim 772 (depends on 332)

The invention of claim 332, wherein said drug comprises Sodium Bicarbonate (Sodium Bicarbonate 5% Injection).

### Claim 773 (depends on 332)

The invention of claim 332, wherein said drug comprises Sodium Lactate (Sodium Lactate Injection in AVIVA).

### Claim 774 (depends on 332)

The invention of claim 332, wherein said drug comprises Sodium Phenylacetate and Sodium Benzoate Injection (Ammonul).

### Claim 775 (depends on 332)

The invention of claim 332, wherein said drug comprises Somatropin (rDNA origin) for Inj (Nutropin).

### Claim 776 (depends on 332)

The invention of claim 332, wherein said drug comprises Sporanox Injection (Itraconazole Injection).

### Claim 777 (depends on 332)

The invention of claim 332, wherein said drug comprises Stelara Injection (Ustekinumab).

### Claim 778 (depends on 332)

The invention of claim 332, wherein said drug comprises Sufenta (Sufentanil Citrate Injection).

### Claim 779 (depends on 332)

The invention of claim 332, wherein said drug comprises Sufentanil Citrate Injection (Sufenta).

### Claim 780 (depends on 332)

The invention of claim 332, wherein said drug comprises Sumavel.

### Claim 782 (depends on 332)

The invention of claim 332, wherein said drug comprises Symlin.

### Claim 783 (depends on 332)

The invention of claim 332, wherein said drug comprises Symlin Pen.

### Claim 784 (depends on 332)

The invention of claim 332, wherein said drug comprises Synvisc-One (Hylan G-F 20 Single Intra-articular Injection).

### Claim 785 (depends on 332)

The invention of claim 332, wherein said drug comprises Taxotere (Docetaxel for Injection).

### Claim 786 (depends on 332)

The invention of claim 332, wherein said drug comprises vvTechnetium Tc 99m.

### Claim 787 (depends on 332)

The invention of claim 332, wherein said drug comprises Telavancin for Injection (Vibativ).

### Claim 788 (depends on 332)

The invention of claim 332, wherein said drug comprises Temsirolimus Injection (Torisel).

### Claim 789 (depends on 332)

The invention of claim 332, wherein said drug comprises Tenormin I.V. Injection (Atenolol Inj).

### Claim 790 (depends on 332)

The invention of claim 332, wherein said drug comprises Teriparatide (rDNA origin) Injection (Forteo).

### Claim 791 (depends on 332)

The invention of claim 332, wherein said drug comprises Testosterone Cypionate.

### Claim 792 (depends on 332)

The invention of claim 332, wherein said drug comprises Testosterone Enanthate.

### Claim 793 (depends on 332)

The invention of claim 332, wherein said drug comprises Testosterone Propionate.

### Claim 794 (depends on 332)

The invention of claim 332, wherein said drug comprises Tev-Tropin (Somatropin, rDNA Origin, for Injection).

### Claim 795 (depends on 332)

The invention of claim 332, wherein said drug comprises tgAAC94.

### Claim 796 (depends on 332)

The invention of claim 332, wherein said drug comprises Thallous Chloride.

### Claim 797 (depends on 332)

The invention of claim 332, wherein said drug comprises Theophylline.

### Claim 798 (depends on 332)

The invention of claim 332, wherein said drug comprises Thiotepa (Thiotepa Injection).

### Claim 799 (depends on 332)

The invention of claim 332, wherein said drug comprises Thyrogen (Thyrotropin Alfa for Injection).

### Claim 800 (depends on 332)

The invention of claim 332, wherein said drug comprises Ticarcillin Disodium and Clavulanate Potassium Galaxy (Timentin Injection).

### Claim 801 (depends on 332)

The invention of claim 332, wherein said drug comprises Tigan Injection (Trimethobenzamide Hydrochloride Injectable).

### Claim 802 (depends on 332)

The invention of claim 332, wherein said drug comprises Timentin Injection (Ticarcillin Disodium and Clavulanate Potassium Galaxy).

### Claim 803 (depends on 332)

The invention of claim 332, wherein said drug comprises Tobramycin Injection (Tobramycin Injection).

### Claim 804 (depends on 332)

The invention of claim 332, wherein said drug comprises Tocilizumab Injection (Actemra).

### Claim 805 (depends on 332)

The invention of claim 332, wherein said drug comprises Torisel (Temsirolimus Injection).

### Claim 806 (depends on 332)

The invention of claim 332, wherein said drug comprises Totect (Dexrazoxane for Injection, Intravenous Infusion Only).

### Claim 807 (depends on 332)

The invention of claim 332, wherein said drug comprises Travasol (Amino Acids (Injection)).

### Claim 808 (depends on 332)

The invention of claim 332, wherein said drug comprises Treanda (Bendamustine Hydrochloride Injection).

### Claim 809 (depends on 332)

The invention of claim 332, wherein said drug comprises Trelstar (Triptorelin Pamoate for Injectable Suspension).

### Claim 810 (depends on 332)

The invention of claim 332, wherein said drug comprises Triamcinolone Acetonide.

### Claim 811 (depends on 332)

The invention of claim 332, wherein said drug comprises Triamcinolone Diacetate.

### Claim 812 (depends on 332)

The invention of claim 332, wherein said drug comprises Triamcinolone Hexacetonide Injectable Suspension (Aristospan Injection 20 mg).

### Claim 813 (depends on 332)

The invention of claim 332, wherein said drug comprises Triesence (Triamcinolone Acetonide Injectable Suspension).

### Claim 814 (depends on 332)

The invention of claim 332, wherein said drug comprises Trimethobenzamide Hydrochloride Injectable (Tigan Injection).

### Claim 815 (depends on 332)

The invention of claim 332, wherein said drug comprises Trimetrexate Glucuronate Inj (Neutrexin).

### Claim 816 (depends on 332)

The invention of claim 332, wherein said drug comprises Triptorelin Pamoate for Injectable Suspension (Trelstar).

### Claim 817 (depends on 332)

The invention of claim 332, wherein said drug comprises Twinject.

### Claim 818 (depends on 332)

The invention of claim 332, wherein said drug comprises Trivaris (Triamcinolone Acetonide Injectable Suspension).

### Claim 819 (depends on 332)

The invention of claim 332, wherein said drug comprises Trisenox (Arsenic Trioxide Injection).

### Claim 820 (depends on 332)

The invention of claim 332, wherein said drug comprises Twinrix.

### Claim 822 (depends on 332)

The invention of claim 332, wherein said drug comprises Ultravist (Iopromide Injection).

### Claim 823 (depends on 332)

The invention of claim 332, wherein said drug comprises Urofollitropin for Injection (Metrodin).

### Claim 824 (depends on 332)

The invention of claim 332, wherein said drug comprises Urokinase Injection (Kinlytic).

### Claim 825 (depends on 332)

The invention of claim 332, wherein said drug comprises Ustekinumab (Stelara Injection).

### Claim 826 (depends on 332)

The invention of claim 332, wherein said drug comprises Ultralente (U).

### Claim 827 (depends on 332)

The invention of claim 332, wherein said drug comprises Valproate Sodium Injection (Depacon).

### Claim 828 (depends on 332)

The invention of claim 332, wherein said drug comprises Valtropin (Somatropin Injection).

### Claim 829 (depends on 332)

The invention of claim 332, wherein said drug comprises Vancomycin Hydrochloride (Vancomycin Hydrochloride Injection).

### Claim 830 (depends on 332)

The invention of claim 332, wherein said drug comprises Vancomycin Hydrochloride Injection (Vancomycin Hydrochloride).

### Claim 831 (depends on 332)

The invention of claim 332, wherein said drug comprises Vaprisol (Conivaptan Hcl Injection).

### Claim 832 (depends on 332)

The invention of claim 332, wherein said drug comprises VAQTA.

### Claim 833 (depends on 332)

The invention of claim 332, wherein said drug comprises Vasovist (Gadofosveset Trisodium Injection for Intravenous Use).

### Claim 834 (depends on 332)

The invention of claim 332, wherein said drug comprises Vectibix (Panitumumab Injection for Intravenous Use).

### Claim 835 (depends on 332)

The invention of claim 332, wherein said drug comprises Venofer (Iron Sucrose Injection).

### Claim 836 (depends on 332)

The invention of claim 332, wherein said drug comprises Verteporfin Inj (Visudyne).

### Claim 837 (depends on 332)

The invention of claim 332, wherein said drug comprises Vibativ (Telavancin for Injection).

### Claim 838 (depends on 332)

The invention of claim 332, wherein said drug comprises Victoza (Liraglutide [rDNA] Injection).

### Claim 839 (depends on 332)

The invention of claim 332, wherein said drug comprises Vimpat (lacosamide Tablet and Injection).

### Claim 840 (depends on 332)

The invention of claim 332, wherein said drug comprises Vinblastine Sulfate (Vinblastine Sulfate Injection).

### Claim 841 (depends on 332)

The invention of claim 332, wherein said drug comprises Vincasar PFS (Vincristine Sulfate Injection).

### Claim 842 (depends on 332)

The invention of claim 332, wherein said drug comprises Victoza.

### Claim 843 (depends on 332)

The invention of claim 332, wherein said drug comprises Vincristine Sulfate (Vincristine Sulfate Injection).

### Claim 844 (depends on 332)

The invention of claim 332, wherein said drug comprises Visudyne (Verteporfin Inj).

### Claim 845 (depends on 332)

The invention of claim 332, wherein said drug comprises Vitamin B-12.

### Claim 846 (depends on 332)

The invention of claim 332, wherein said drug comprises Vivitrol (Naltrexone XR Inj).

### Claim 847 (depends on 332)

The invention of claim 332, wherein said drug comprises Voluven (Hydroxyethyl Starch in Sodium Chloride Injection).

### Claim 848 (depends on 332)

The invention of claim 332, wherein said drug comprises Xeomin (Incobotulinumtoxin A for Injection).

### Claim 849 (depends on 332)

The invention of claim 332, wherein said drug comprises Zantac Injection (Ranitidine Hydrochloride Injection).

### Claim 850 (depends on 332)

The invention of claim 332, wherein said drug comprises Zemplar Injection (Paricalcitol Injection Fliptop Vial).

### Claim 851 (depends on 332)

The invention of claim 332, wherein said drug comprises Zemuron (Rocuronium Bromide Injection).

### Claim 852 (depends on 332)

The invention of claim 332, wherein said drug comprises Zevalin.

### Claim 853 (depends on 332)

The invention of claim 332, wherein said drug comprises Zidovudine Injection (Retrovir IV).

### Claim 854 (depends on 332)

The invention of claim 332, wherein said drug comprises Zithromax Injection (Azithromycin).

### Claim 855 (depends on 332)

The invention of claim 332, wherein said drug comprises Zn-DTPA (Pentetate Zinc Trisodium Injection).

### Claim 856 (depends on 332)

The invention of claim 332, wherein said drug comprises Zofran Injection (Ondansetron Hydrochloride Injection).

### Claim 857 (depends on 332)

The invention of claim 332, wherein said drug comprises Zingo.

### Claim 858 (depends on 332)

The invention of claim 332, wherein said drug comprises Zoledronic Acid for Inj (Zometa).

### Claim 859 (depends on 332)

The invention of claim 332, wherein said drug comprises Zoledronic Acid Injection (Reclast).

### Claim 860 (depends on 332)

The invention of claim 332, wherein said drug comprises Zometa (Zoledronic Acid for Inj).

### Claim 861 (depends on 332)

The invention of claim 332, wherein said drug comprises Zosyn (Piperacillin and Tazobactam Injection).

### Claim 862 (depends on 332)

The invention of claim 332, wherein said drug comprises Zyprexa Relprevv (Olanzapine Extended Release Injectable Suspension).

### Claim 863 (depends on 332)

The invention of claim 332, wherein said drug comprises Abilify.

### Claim 864 (depends on 332)

The invention of claim 332, wherein said drug comprises AccuNeb (Albuterol Sulfate Inhalation Solution).

### Claim 865 (depends on 332)

The invention of claim 332, wherein said drug comprises Actidose Aqua (Activated Charcoal Suspension).

### Claim 866 (depends on 332)

The invention of claim 332, wherein said drug comprises Activated Charcoal Suspension (Actidose Aqua).

### Claim 867 (depends on 332)

The invention of claim 332, wherein said drug comprises Advair.

### Claim 868 (depends on 332)

The invention of claim 332, wherein said drug comprises Agenerase Oral Solution (Amprenavir Oral Solution).

### Claim 869 (depends on 332)

The invention of claim 332, wherein said drug comprises Akten (Lidocaine Hydrochloride Ophthalmic Gel).

### Claim 870 (depends on 332)

The invention of claim 332, wherein said drug comprises Alamast (Pemirolast Potassium Ophthalmic Solution).

### Claim 871 (depends on 332)

The invention of claim 332, wherein said drug comprises Albumin (Human) 5% Solution (Buminate 5%).

### Claim 872 (depends on 332)

The invention of claim 332, wherein said drug comprises Albuterol Sulfate Inhalation Solution.

### Claim 873 (depends on 332)

The invention of claim 332, wherein said drug comprises Alinia.

### Claim 874 (depends on 332)

The invention of claim 332, wherein said drug comprises Alocril.

### Claim 875 (depends on 332)

The invention of claim 332, wherein said drug comprises Alphagan.

### Claim 876 (depends on 332)

The invention of claim 332, wherein said drug comprises Alrex.

### Claim 877 (depends on 332)

The invention of claim 332, wherein said drug comprises Alvesco.

### Claim 878 (depends on 332)

The invention of claim 332, wherein said drug comprises Amprenavir Oral Solution.

### Claim 879 (depends on 332)

The invention of claim 332, wherein said drug comprises Analpram-HC.

### Claim 880 (depends on 332)

The invention of claim 332, wherein said drug comprises Arformoterol Tartrate Inhalation Solution (Brovana).

### Claim 881 (depends on 332)

The invention of claim 332, wherein said drug comprises Aristospan Injection 20 mg (Triamcinolone Hexacetonide Injectable Suspension).

### Claim 882 (depends on 332)

The invention of claim 332, wherein said drug comprises Asacol.

### Claim 883 (depends on 332)

The invention of claim 332, wherein said drug comprises Asmanex Astepro.

### Claim 884 (depends on 332)

The invention of claim 332, wherein said drug comprises Astepro (Azelastine Hydrochloride Nasal Spray).

### Claim 885 (depends on 332)

The invention of claim 332, wherein said drug comprises Atrovent Nasal Spray (Ipratropium Bromide Nasal Spray).

### Claim 886 (depends on 332)

The invention of claim 332, wherein said drug comprises Atrovent Nasal Spray 0.06.

### Claim 887 (depends on 332)

The invention of claim 332, wherein said drug comprises Augmentin ES-600.

### Claim 888 (depends on 332)

The invention of claim 332, wherein said drug comprises Azasite (Azithromycin Ophthalmic Solution).

### Claim 889 (depends on 332)

The invention of claim 332, wherein said drug comprises Azelaic Acid (Finacea Gel).

### Claim 890 (depends on 332)

The invention of claim 332, wherein said drug comprises Azelastine Hydrochloride Nasal Spray (Astepro).

### Claim 891 (depends on 332)

The invention of claim 332, wherein said drug comprises Azelex (Azelaic Acid Cream).

### Claim 892 (depends on 332)

The invention of claim 332, wherein said drug comprises Azopt (Brinzolamide Ophthalmic Suspension).

### Claim 893 (depends on 332)

The invention of claim 332, wherein said drug comprises Bacteriostatic Saline.

### Claim 894 (depends on 332)

The invention of claim 332, wherein said drug comprises Balanced Salt.

### Claim 895 (depends on 332)

The invention of claim 332, wherein said drug comprises Bepotastine.

### Claim 896 (depends on 332)

The invention of claim 332, wherein said drug comprises Bactroban Nasal.

### Claim 897 (depends on 332)

The invention of claim 332, wherein said drug comprises Bactroban.

### Claim 898 (depends on 332)

The invention of claim 332, wherein said drug comprises Beclovent.

### Claim 899 (depends on 332)

The invention of claim 332, wherein said drug comprises Benzac W.

### Claim 900 (depends on 332)

The invention of claim 332, wherein said drug comprises Betimol.

### Claim 901 (depends on 332)

The invention of claim 332, wherein said drug comprises Betoptic S.

### Claim 902 (depends on 332)

The invention of claim 332, wherein said drug comprises Bepreve.

### Claim 903 (depends on 332)

The invention of claim 332, wherein said drug comprises Bimatoprost Ophthalmic Solution.

### Claim 904 (depends on 332)

The invention of claim 332, wherein said drug comprises Bleph 10 (Sulfacetamide Sodium Ophthalmic Solution 10%).

### Claim 905 (depends on 332)

The invention of claim 332, wherein said drug comprises Brinzolamide Ophthalmic Suspension (Azopt).

### Claim 906 (depends on 332)

The invention of claim 332, wherein said drug comprises Bromfenac Ophthalmic Solution (Xibrom).

### Claim 907 (depends on 332)

The invention of claim 332, wherein said drug comprises Bromhist.

### Claim 908 (depends on 332)

The invention of claim 332, wherein said drug comprises Brovana (Arformoterol Tartrate Inhalation Solution).

### Claim 909 (depends on 332)

The invention of claim 332, wherein said drug comprises Budesonide Inhalation Suspension (Pulmicort Respules).

### Claim 910 (depends on 332)

The invention of claim 332, wherein said drug comprises Cambia (Diclofenac Potassium for Oral Solution).

### Claim 911 (depends on 332)

The invention of claim 332, wherein said drug comprises Capex.

### Claim 912 (depends on 332)

The invention of claim 332, wherein said drug comprises Carac.

### Claim 913 (depends on 332)

The invention of claim 332, wherein said drug comprises Carboxine-PSE.

### Claim 914 (depends on 332)

The invention of claim 332, wherein said drug comprises Carnitor.

### Claim 915 (depends on 332)

The invention of claim 332, wherein said drug comprises Cayston (Aztreonam for Inhalation Solution).

### Claim 916 (depends on 332)

The invention of claim 332, wherein said drug comprises Cellcept.

### Claim 917 (depends on 332)

The invention of claim 332, wherein said drug comprises Centany.

### Claim 918 (depends on 332)

The invention of claim 332, wherein said drug comprises Cerumenex.

### Claim 919 (depends on 332)

The invention of claim 332, wherein said drug comprises Ciloxan Ophthalmic Solution (Ciprofloxacin HCL Ophthalmic Solution).

### Claim 920 (depends on 332)

The invention of claim 332, wherein said drug comprises Ciprodex.

### Claim 921 (depends on 332)

The invention of claim 332, wherein said drug comprises Ciprofloxacin HCL Ophthalmic Solution (Ciloxan Ophthalmic Solution).

### Claim 922 (depends on 332)

The invention of claim 332, wherein said drug comprises Clemastine Fumarate Syrup (Clemastine Fumarate Syrup).

### Claim 923 (depends on 332)

The invention of claim 332, wherein said drug comprises CoLyte (PEG Electrolytes Solution).

### Claim 924 (depends on 332)

The invention of claim 332, wherein said drug comprises Combiven.

### Claim 925 (depends on 332)

The invention of claim 332, wherein said drug comprises Comtan.

### Claim 926 (depends on 332)

The invention of claim 332, wherein said drug comprises Condylox.

### Claim 927 (depends on 332)

The invention of claim 332, wherein said drug comprises Cordran.

### Claim 928 (depends on 332)

The invention of claim 332, wherein said drug comprises Cortisporin Ophthalmic Suspension.

### Claim 929 (depends on 332)

The invention of claim 332, wherein said drug comprises Cortisporin Otic Suspension.

### Claim 930 (depends on 332)

The invention of claim 332, wherein said drug comprises Cromolyn Sodium Inhalation Solution (Intal Nebulizer Solution).

### Claim 931 (depends on 332)

The invention of claim 332, wherein said drug comprises Cromolyn Sodium Ophthalmic Solution (Opticrom).

### Claim 932 (depends on 332)

The invention of claim 332, wherein said drug comprises Crystalline Amino Acid Solution with Electrolytes (Aminosyn Electrolytes).

### Claim 933 (depends on 332)

The invention of claim 332, wherein said drug comprises Cutivate.

### Claim 934 (depends on 332)

The invention of claim 332, wherein said drug comprises Cuvposa (Glycopyrrolate Oral Solution).

### Claim 935 (depends on 332)

The invention of claim 332, wherein said drug comprises Cyanocobalamin (CaloMist Nasal Spray).

### Claim 936 (depends on 332)

The invention of claim 332, wherein said drug comprises Cyclosporine Oral Solution (Gengraf Oral Solution).

### Claim 937 (depends on 332)

The invention of claim 332, wherein said drug comprises Cyclogyl.

### Claim 938 (depends on 332)

The invention of claim 332, wherein said drug comprises Cysview (Hexaminolevulinate Hydrochloride Intravesical Solution).

### Claim 939 (depends on 332)

The invention of claim 332, wherein said drug comprises DermOtic Oil (Fluocinolone Acetonide Oil Ear Drops).

### Claim 940 (depends on 332)

The invention of claim 332, wherein said drug comprises Desmopressin Acetate Nasal Spray.

### Claim 941 (depends on 332)

The invention of claim 332, wherein said drug comprises DDAVP.

### Claim 942 (depends on 332)

The invention of claim 332, wherein said drug comprises Derma-Smoothe/FS.

### Claim 943 (depends on 332)

The invention of claim 332, wherein said drug comprises Dexamethasone Intensol.

### Claim 944 (depends on 332)

The invention of claim 332, wherein said drug comprises Dianeal Low Calcium.

### Claim 945 (depends on 332)

The invention of claim 332, wherein said drug comprises Dianeal PD.

### Claim 946 (depends on 332)

The invention of claim 332, wherein said drug comprises Diclofenac Potassium for Oral Solution (Cambia).

### Claim 947 (depends on 332)

The invention of claim 332, wherein said drug comprises Didanosine Pediatric Powder for Oral Solution (Videx).

### Claim 948 (depends on 332)

The invention of claim 332, wherein said drug comprises Differin.

### Claim 949 (depends on 332)

The invention of claim 332, wherein said drug comprises Dilantin 125 (Phenytoin Oral Suspension).

### Claim 950 (depends on 332)

The invention of claim 332, wherein said drug comprises Ditropan.

### Claim 951 (depends on 332)

The invention of claim 332, wherein said drug comprises Dorzolamide Hydrochloride Ophthalmic Solution (Trusopt).

### Claim 952 (depends on 332)

The invention of claim 332, wherein said drug comprises Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution (Cosopt).

### Claim 953 (depends on 332)

The invention of claim 332, wherein said drug comprises Dovonex Scalp (Calcipotriene Solution).

### Claim 954 (depends on 332)

The invention of claim 332, wherein said drug comprises Doxycycline Calcium Oral Suspension (Vibramycin Oral).

### Claim 955 (depends on 332)

The invention of claim 332, wherein said drug comprises Efudex.

### Claim 956 (depends on 332)

The invention of claim 332, wherein said drug comprises Elaprase (Idursulfase Solution).

### Claim 957 (depends on 332)

The invention of claim 332, wherein said drug comprises Elestat (Epinastine HCl Ophthalmic Solution).

### Claim 958 (depends on 332)

The invention of claim 332, wherein said drug comprises Elocon.

### Claim 959 (depends on 332)

The invention of claim 332, wherein said drug comprises Epinastine HCl Ophthalmic Solution (Elestat).

### Claim 960 (depends on 332)

The invention of claim 332, wherein said drug comprises Epivir HBV.

### Claim 961 (depends on 332)

The invention of claim 332, wherein said drug comprises Epogen.

### Claim 962 (depends on 332)

The invention of claim 332, wherein said drug comprises Erythromycin Topical Solution 1.5% (Staticin).

### Claim 963 (depends on 332)

The invention of claim 332, wherein said drug comprises Ethiodol (Ethiodized Oil).

### Claim 964 (depends on 332)

The invention of claim 332, wherein said drug comprises Ethosuximide Oral Solution (Zarontin Oral Solution).

### Claim 965 (depends on 332)

The invention of claim 332, wherein said drug comprises Eurax.

### Claim 966 (depends on 332)

The invention of claim 332, wherein said drug comprises Extraneal (Icodextrin Peritoneal Dialysis Solution).

### Claim 967 (depends on 332)

The invention of claim 332, wherein said drug comprises Felbatol.

### Claim 968 (depends on 332)

The invention of claim 332, wherein said drug comprises Feridex I.V. (Ferumoxides Injectable Solution).

### Claim 969 (depends on 332)

The invention of claim 332, wherein said drug comprises Flovent.

### Claim 970 (depends on 332)

The invention of claim 332, wherein said drug comprises Floxin Otic (Ofloxacin Otic Solution).

### Claim 971 (depends on 332)

The invention of claim 332, wherein said drug comprises Flo-Pred (Prednisolone Acetate Oral Suspension).

### Claim 972 (depends on 332)

The invention of claim 332, wherein said drug comprises Fluoroplex.

### Claim 973 (depends on 332)

The invention of claim 332, wherein said drug comprises Flunisolide Nasal Solution (Flunisolide Nasal Spray 0.025%).

### Claim 974 (depends on 332)

The invention of claim 332, wherein said drug comprises Fluorometholone Ophthalmic Suspension (FML).

### Claim 975 (depends on 332)

The invention of claim 332, wherein said drug comprises Flurbiprofen Sodium Ophthalmic Solution (Ocufen).

### Claim 976 (depends on 332)

The invention of claim 332, wherein said drug comprises FML.

### Claim 977 (depends on 332)

The invention of claim 332, wherein said drug comprises Foradil.

### Claim 978 (depends on 332)

The invention of claim 332, wherein said drug comprises Formoterol Fumarate Inhalation Solution (Perforomist).

### Claim 979 (depends on 332)

The invention of claim 332, wherein said drug comprises Fosamax.

### Claim 980 (depends on 332)

The invention of claim 332, wherein said drug comprises Furadantin (Nitrofurantoin Oral Suspension).

### Claim 981 (depends on 332)

The invention of claim 332, wherein said drug comprises Furoxone.

### Claim 982 (depends on 332)

The invention of claim 332, wherein said drug comprises Gammagard Liquid (Immune Globulin Intravenous (Human) 10%).

### Claim 983 (depends on 332)

The invention of claim 332, wherein said drug comprises Gantrisin (Acetyl Sulfisoxazole Pediatric Suspension).

### Claim 984 (depends on 332)

The invention of claim 332, wherein said drug comprises Gatifloxacin Ophthalmic Solution (Zymar).

### Claim 985 (depends on 332)

The invention of claim 332, wherein said drug comprises Gengraf Oral Solution (Cyclosporine Oral Solution).

### Claim 986 (depends on 332)

The invention of claim 332, wherein said drug comprises Glycopyrrolate Oral Solution (Cuvposa).

### Claim 987 (depends on 332)

The invention of claim 332, wherein said drug comprises Halcinonide Topical Solution (Halog Solution).

### Claim 988 (depends on 332)

The invention of claim 332, wherein said drug comprises Halog Solution (Halcinonide Topical Solution).

### Claim 989 (depends on 332)

The invention of claim 332, wherein said drug comprises HEP-LOCK U/P (Preservative-Free Heparin Lock Flush Solution).

### Claim 990 (depends on 332)

The invention of claim 332, wherein said drug comprises Heparin Lock Flush Solution (Hepflush 10).

### Claim 991 (depends on 332)

The invention of claim 332, wherein said drug comprises Hexaminolevulinate Hydrochloride Intravesical Solution (Cysview).

### Claim 992 (depends on 332)

The invention of claim 332, wherein said drug comprises Hydrocodone Bitartrate and Acetaminophen Oral Solution (Lortab Elixir).

### Claim 993 (depends on 332)

The invention of claim 332, wherein said drug comprises Hydroquinone 3% Topical Solution (Melquin-3 Topical Solution).

### Claim 994 (depends on 332)

The invention of claim 332, wherein said drug comprises Isopto.

### Claim 995 (depends on 332)

The invention of claim 332, wherein said drug comprises Ipratropium Bromide Nasal Spray (Atrovent Nasal Spray).

### Claim 996 (depends on 332)

The invention of claim 332, wherein said drug comprises Itraconazole Oral Solution (Sporanox Oral Solution).

### Claim 997 (depends on 332)

The invention of claim 332, wherein said drug comprises Ketorolac Tromethamine Ophthalmic Solution (Acular LS).

### Claim 998 (depends on 332)

The invention of claim 332, wherein said drug comprises Kaletra.

### Claim 999 (depends on 332)

The invention of claim 332, wherein said drug comprises Lanoxin.

### Claim 1000 (depends on 332)

The invention of claim 332, wherein said drug comprises Lexiva.

### Claim 1001 (depends on 332)

The invention of claim 332, wherein said drug comprises Leuprolide Acetate for Depot Suspension (Lupron Depot 11.25 mg).

### Claim 1002 (depends on 332)

The invention of claim 332, wherein said drug comprises Levobetaxolol Hydrochloride Ophthalmic Suspension (Betaxon).

### Claim 1003 (depends on 332)

The invention of claim 332, wherein said drug comprises Levocarnitine Tablets, Oral Solution, Sugar-Free (Carnitor).

### Claim 1004 (depends on 332)

The invention of claim 332, wherein said drug comprises Levofloxacin Ophthalmic Solution 0.5% (Quixin).

### Claim 1005 (depends on 332)

The invention of claim 332, wherein said drug comprises Lidocaine HCl Sterile Solution (Xylocaine MPF Sterile Solution).

### Claim 1006 (depends on 332)

The invention of claim 332, wherein said drug comprises Lok Pak (Heparin Lock Flush Solution).

### Claim 1007 (depends on 332)

The invention of claim 332, wherein said drug comprises Lorazepam Intensol.

### Claim 1008 (depends on 332)

The invention of claim 332, wherein said drug comprises Lortab Elixir (Hydrocodone Bitartrate and Acetaminophen Oral Solution).

### Claim 1009 (depends on 332)

The invention of claim 332, wherein said drug comprises Lotemax (Loteprednol Etabonate Ophthalmic Suspension).

### Claim 1010 (depends on 332)

The invention of claim 332, wherein said drug comprises Loteprednol Etabonate Ophthalmic Suspension (Alrex).

### Claim 1011 (depends on 332)

The invention of claim 332, wherein said drug comprises Low Calcium Peritoneal Dialysis Solutions (Dianeal Low Calcium).

### Claim 1012 (depends on 332)

The invention of claim 332, wherein said drug comprises Lumigan (Bimatoprost Ophthalmic Solution 0.03% for Glaucoma).

### Claim 1013 (depends on 332)

The invention of claim 332, wherein said drug comprises Lupron Depot 11.25 mg (Leuprolide Acetate for Depot Suspension).

### Claim 1014 (depends on 332)

The invention of claim 332, wherein said drug comprises Megestrol Acetate Oral Suspension (Megestrol Acetate Oral Suspension).

### Claim 1015 (depends on 332)

The invention of claim 332, wherein said drug comprises Mepron.

### Claim 1016 (depends on 332)

The invention of claim 332, wherein said drug comprises Mesnex.

### Claim 1017 (depends on 332)

The invention of claim 332, wherein said drug comprises Mestinon.

### Claim 1018 (depends on 332)

The invention of claim 332, wherein said drug comprises Mesalamine Rectal Suspension Enema (Rowasa).

### Claim 1019 (depends on 332)

The invention of claim 332, wherein said drug comprises Melquin-3 Topical Solution (Hydroquinone 3% Topical Solution).

### Claim 1020 (depends on 332)

The invention of claim 332, wherein said drug comprises Methyldopate Hcl (Methyldopate Hydrochloride Injection, Solution).

### Claim 1021 (depends on 332)

The invention of claim 332, wherein said drug comprises Methylin Oral Solution (Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL).

### Claim 1022 (depends on 332)

The invention of claim 332, wherein said drug comprises Methylprednisolone Acetate Injectable Suspension (Depo Medrol).

### Claim 1023 (depends on 332)

The invention of claim 332, wherein said drug comprises Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL (Methylin Oral Solution).

### Claim 1024 (depends on 332)

The invention of claim 332, wherein said drug comprises Methylprednisolone sodium succinate (Solu Medrol).

### Claim 1025 (depends on 332)

The invention of claim 332, wherein said drug comprises Metipranolol Ophthalmic Solution (Optipranolol).

### Claim 1026 (depends on 332)

The invention of claim 332, wherein said drug comprises Migranal.

### Claim 1027 (depends on 332)

The invention of claim 332, wherein said drug comprises Miochol-E (Acetylcholine Chloride Intraocular Solution).

### Claim 1028 (depends on 332)

The invention of claim 332, wherein said drug comprises Micro-K for Liquid Suspension (Potassium Chloride Extended Release Formulation for Liquid Suspension).

### Claim 1029 (depends on 332)

The invention of claim 332, wherein said drug comprises Minocin (Minocycline Hydrochloride Oral Suspension).

### Claim 1030 (depends on 332)

The invention of claim 332, wherein said drug comprises Nasacort.

### Claim 1031 (depends on 332)

The invention of claim 332, wherein said drug comprises Neomycin and Polymyxin B Sulfates and Hydrocortisone.

### Claim 1032 (depends on 332)

The invention of claim 332, wherein said drug comprises Nepafenac Ophthalmic Suspension (Nevanac).

### Claim 1033 (depends on 332)

The invention of claim 332, wherein said drug comprises Nevanac (Nepafenac Ophthalmic Suspension).

### Claim 1034 (depends on 332)

The invention of claim 332, wherein said drug comprises Nitrofurantoin Oral Suspension (Furadantin).

### Claim 1035 (depends on 332)

The invention of claim 332, wherein said drug comprises Noxafil (Posaconazole Oral Suspension).

### Claim 1036 (depends on 332)

The invention of claim 332, wherein said drug comprises Nystatin (oral) (Nystatin Oral Suspension).

### Claim 1037 (depends on 332)

The invention of claim 332, wherein said drug comprises Nystatin Oral Suspension (Nystatin (oral)).

### Claim 1038 (depends on 332)

The invention of claim 332, wherein said drug comprises Ocufen (Flurbiprofen Sodium Ophthalmic Solution).

### Claim 1039 (depends on 332)

The invention of claim 332, wherein said drug comprises Ofloxacin Ophthalmic Solution (Ofloxacin Ophthalmic Solution).

### Claim 1040 (depends on 332)

The invention of claim 332, wherein said drug comprises Ofloxacin Otic Solution (Floxin Otic).

### Claim 1041 (depends on 332)

The invention of claim 332, wherein said drug comprises Olopatadine Hydrochloride Ophthalmic Solution (Pataday).

### Claim 1042 (depends on 332)

The invention of claim 332, wherein said drug comprises Opticrom (Cromolyn Sodium Ophthalmic Solution).

### Claim 1043 (depends on 332)

The invention of claim 332, wherein said drug comprises Optipranolol (Metipranolol Ophthalmic Solution).

### Claim 1044 (depends on 332)

The invention of claim 332, wherein said drug comprises Patanol.

### Claim 1045 (depends on 332)

The invention of claim 332, wherein said drug comprises Pediapred.

### Claim 1046 (depends on 332)

The invention of claim 332, wherein said drug comprises PerioGard.

### Claim 1047 (depends on 332)

The invention of claim 332, wherein said drug comprises Phenytoin Oral Suspension (Dilantin 125).

### Claim 1048 (depends on 332)

The invention of claim 332, wherein said drug comprises Phisohex.

### Claim 1049 (depends on 332)

The invention of claim 332, wherein said drug comprises Posaconazole Oral Suspension (Noxafil).

### Claim 1050 (depends on 332)

The invention of claim 332, wherein said drug comprises Potassium Chloride Extended Release Formulation for Liquid Suspension (Micro-K for Liquid Suspension).

### Claim 1051 (depends on 332)

The invention of claim 332, wherein said drug comprises Pataday (Olopatadine Hydrochloride Ophthalmic Solution).

### Claim 1052 (depends on 332)

The invention of claim 332, wherein said drug comprises Patanase Nasal Spray (Olopatadine Hydrochloride Nasal Spray).

### Claim 1053 (depends on 332)

The invention of claim 332, wherein said drug comprises PEG Electrolytes Solution (CoLyte).

### Claim 1054 (depends on 332)

The invention of claim 332, wherein said drug comprises Pemirolast Potassium Ophthalmic Solution (Alamast).

### Claim 1055 (depends on 332)

The invention of claim 332, wherein said drug comprises Penlac (Ciclopirox Topical Solution).

### Claim 1056 (depends on 332)

The invention of claim 332, wherein said drug comprises PENNSAID (Diclofenac Sodium Topical Solution).

### Claim 1057 (depends on 332)

The invention of claim 332, wherein said drug comprises Perforomist (Formoterol Fumarate Inhalation Solution).

### Claim 1058 (depends on 332)

The invention of claim 332, wherein said drug comprises Peritoneal Dialysis Solution.

### Claim 1059 (depends on 332)

The invention of claim 332, wherein said drug comprises Phenylephrine Hydrochloride Ophthalmic Solution (Neo-Synephrine).

### Claim 1060 (depends on 332)

The invention of claim 332, wherein said drug comprises Phospholine Iodide (Echothiophate Iodide for Ophthalmic Solution).

### Claim 1061 (depends on 332)

The invention of claim 332, wherein said drug comprises Podofilox (Podofilox Topical Solution).

### Claim 1062 (depends on 332)

The invention of claim 332, wherein said drug comprises Pred Forte (Prednisolone Acetate Ophthalmic Suspension).

### Claim 1063 (depends on 332)

The invention of claim 332, wherein said drug comprises Pralatrexate Solution for Intravenous Injection (Folotyn).

### Claim 1064 (depends on 332)

The invention of claim 332, wherein said drug comprises Pred Mild.

### Claim 1065 (depends on 332)

The invention of claim 332, wherein said drug comprises Prednisone Intensol.

### Claim 1066 (depends on 332)

The invention of claim 332, wherein said drug comprises Prednisolone Acetate Ophthalmic Suspension (Pred Forte).

### Claim 1067 (depends on 332)

The invention of claim 332, wherein said drug comprises Prevacid.

### Claim 1068 (depends on 332)

The invention of claim 332, wherein said drug comprises PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution).

### Claim 1069 (depends on 332)

The invention of claim 332, wherein said drug comprises ProAir.

### Claim 1070 (depends on 332)

The invention of claim 332, wherein said drug comprises Proglycem.

### Claim 1071 (depends on 332)

The invention of claim 332, wherein said drug comprises ProHance (Gadoteridol Injection Solution).

### Claim 1072 (depends on 332)

The invention of claim 332, wherein said drug comprises Proparacaine Hydrochloride Ophthalmic Solution (Alcaine).

### Claim 1073 (depends on 332)

The invention of claim 332, wherein said drug comprises Propine.

### Claim 1074 (depends on 332)

The invention of claim 332, wherein said drug comprises Pulmicort.

### Claim 1075 (depends on 332)

The invention of claim 332, wherein said drug comprises Pulmozyme.

### Claim 1076 (depends on 332)

The invention of claim 332, wherein said drug comprises Quixin (Levofloxacin Ophthalmic Solution 0.5%).

### Claim 1077 (depends on 332)

The invention of claim 332, wherein said drug comprises QVAR.

### Claim 1078 (depends on 332)

The invention of claim 332, wherein said drug comprises Rapamune.

### Claim 1079 (depends on 332)

The invention of claim 332, wherein said drug comprises Rebetol.

### Claim 1080 (depends on 332)

The invention of claim 332, wherein said drug comprises Relacon-HC.

### Claim 1081 (depends on 332)

The invention of claim 332, wherein said drug comprises Rotarix (Rotavirus Vaccine, Live, Oral Suspension).

### Claim 1082 (depends on 332)

The invention of claim 332, wherein said drug comprises Rotavirus Vaccine, Live, Oral Suspension (Rotarix).

### Claim 1083 (depends on 332)

The invention of claim 332, wherein said drug comprises Rowasa (Mesalamine Rectal Suspension Enema).

### Claim 1084 (depends on 332)

The invention of claim 332, wherein said drug comprises Sabril (Vigabatrin Oral Solution).

### Claim 1085 (depends on 332)

The invention of claim 332, wherein said drug comprises Sacrosidase Oral Solution (Sucraid).

### Claim 1086 (depends on 332)

The invention of claim 332, wherein said drug comprises Sandimmune.

### Claim 1087 (depends on 332)

The invention of claim 332, wherein said drug comprises Serevent Diskus.

### Claim 1088 (depends on 332)

The invention of claim 332, wherein said drug comprises Solu Cortef (Hydrocortisone Sodium Succinate).

### Claim 1089 (depends on 332)

The invention of claim 332, wherein said drug comprises Solu Medrol (Methylprednisolone sodium succinate).

### Claim 1090 (depends on 332)

The invention of claim 332, wherein said drug comprises Spiriva.

### Claim 1091 (depends on 332)

The invention of claim 332, wherein said drug comprises Sporanox Oral Solution (Itraconazole Oral Solution).

### Claim 1092 (depends on 332)

The invention of claim 332, wherein said drug comprises Staticin (Erythromycin Topical Solution 1.5%).

### Claim 1093 (depends on 332)

The invention of claim 332, wherein said drug comprises Stalevo.

### Claim 1094 (depends on 332)

The invention of claim 332, wherein said drug comprises Starlix.

### Claim 1095 (depends on 332)

The invention of claim 332, wherein said drug comprises Sterile Hemofiltration Hemodiafiltration Solution (PrismaSol Solution).

### Claim 1096 (depends on 332)

The invention of claim 332, wherein said drug comprises Stimate.

### Claim 1097 (depends on 332)

The invention of claim 332, wherein said drug comprises Sucralfate (Carafate Suspension).

### Claim 1098 (depends on 332)

The invention of claim 332, wherein said drug comprises Sulfacetamide Sodium Ophthalmic Solution 10% (Bleph 10).

### Claim 1099 (depends on 332)

The invention of claim 332, wherein said drug comprises Synarel Nasal Solution (Nafarelin Acetate Nasal Solution for Endometriosis).

### Claim 1100 (depends on 332)

The invention of claim 332, wherein said drug comprises Taclonex Scalp (Calcipotriene and Betamethasone Dipropionate Topical Suspension).

### Claim 1101 (depends on 332)

The invention of claim 332, wherein said drug comprises Tamiflu.

### Claim 1102 (depends on 332)

The invention of claim 332, wherein said drug comprises Tobi.

### Claim 1103 (depends on 332)

The invention of claim 332, wherein said drug comprises TobraDex.

### Claim 1104 (depends on 332)

The invention of claim 332, wherein said drug comprises Tobradex ST (Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05%).

### Claim 1105 (depends on 332)

The invention of claim 332, wherein said drug comprises Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05% (Tobradex ST).

### Claim 1106 (depends on 332)

The invention of claim 332, wherein said drug comprises Timolol.

### Claim 1107 (depends on 332)

The invention of claim 332, wherein said drug comprises Timoptic.

### Claim 1108 (depends on 332)

The invention of claim 332, wherein said drug comprises Travatan Z.

### Claim 1109 (depends on 332)

The invention of claim 332, wherein said drug comprises Treprostinil Inhalation Solution (Tyvaso).

### Claim 1110 (depends on 332)

The invention of claim 332, wherein said drug comprises Trusopt (Dorzolamide Hydrochloride Ophthalmic Solution).

### Claim 1111 (depends on 332)

The invention of claim 332, wherein said drug comprises Tyvaso (Treprostinil Inhalation Solution).

### Claim 1112 (depends on 332)

The invention of claim 332, wherein said drug comprises Ventolin.

### Claim 1113 (depends on 332)

The invention of claim 332, wherein said drug comprises Vfend.

### Claim 1114 (depends on 332)

The invention of claim 332, wherein said drug comprises Vibramycin Oral (Doxycycline Calcium Oral Suspension).

### Claim 1115 (depends on 332)

The invention of claim 332, wherein said drug comprises Videx (Didanosine Pediatric Powder for Oral Solution).

### Claim 1116 (depends on 332)

The invention of claim 332, wherein said drug comprises Vigabatrin Oral Solution (Sabril).

### Claim 1117 (depends on 332)

The invention of claim 332, wherein said drug comprises Viokase.

### Claim 1118 (depends on 332)

The invention of claim 332, wherein said drug comprises Viracept.

### Claim 1119 (depends on 332)

The invention of claim 332, wherein said drug comprises Viramune.

### Claim 1120 (depends on 332)

The invention of claim 332, wherein said drug comprises Vitamin K1 (Aqueous Colloidal Solution of Vitamin K1).

### Claim 1121 (depends on 332)

The invention of claim 332, wherein said drug comprises Voltaren Ophthalmic (Diclofenac Sodium Ophthalmic Solution).

### Claim 1122 (depends on 332)

The invention of claim 332, wherein said drug comprises Zarontin Oral Solution (Ethosuximide Oral Solution).

### Claim 1123 (depends on 332)

The invention of claim 332, wherein said drug comprises Ziagen.

### Claim 1124 (depends on 332)

The invention of claim 332, wherein said drug comprises Zyvox.

### Claim 1125 (depends on 332)

The invention of claim 332, wherein said drug comprises Zymar (Gatifloxacin Ophthalmic Solution).

### Claim 1126 (depends on 332)

The invention of claim 332, wherein said drug comprises Zymaxid (Gatifloxacin Ophthalmic Solution)

### Claim 1127 (depends on 328)

The invention of claim 328, wherein said fluid composition comprises a diagnostic test material.

### Claim 1128 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises 17-Hydroxyprogesterone.

### Claim 1129 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises ACE (Angiotensin I converting enzyme)

### Claim 1130 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Acetaminophen.

### Claim 1131 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Acid phosphatase.

### Claim 1132 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises ACTH.

### Claim 1133 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Activated clotting time.

### Claim 1134 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Activated protein C resistance.

### Claim 1135 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Adrenocorticotropic hormone (ACTH).

### Claim 1136 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Alanine aminotransferase (ALT).

### Claim 1137 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Albumin.

### Claim 1138 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Aldolase.

### Claim 1139 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Aldosterone.

### Claim 1140 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Alkaline phosphatase.

### Claim 1141 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Alkaline phosphatase (ALP).

### Claim 1142 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Alpha1-antitrypsin.

### Claim 1143 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Alpha-fetoprotein.

### Claim 1144 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Alpha-fetoprotien.

### Claim 1145 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Ammonia levels.

### Claim 1146 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Amylase.

### Claim 1147 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises ANA (antinuclear antbodies).

### Claim 1148 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises ANA (antinuclear antibodies).

### Claim 1149 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Angiotensin-converting enzyme (ACE).

### Claim 1150 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anion gap.

### Claim 1151 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anticardiolipin antibody.

### Claim 1152 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anticardiolipin antivbodies (ACA).

### Claim 1153 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-centromere antibody.

### Claim 1154 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Antidiuretic hormone.

### Claim 1155 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-DNA.

### Claim 1156 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-Dnase-B.

### Claim 1157 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-Gliadin antibody.

### Claim 1158 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-glomerular basement membrane antibody.

### Claim 1159 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-HBc (Hepatitis B core antibodies.

### Claim 1160 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-HBs (Hepatitis B surface antibody.

### Claim 1161 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Antiphospholipid antibody.

### Claim 1162 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-RNA polymerase.

### Claim 1163 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-Smith (Sm) antibodies.

### Claim 1164 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-Smooth Muscle antibody.

### Claim 1165 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Antistreptolysin O (ASO).

### Claim 1166 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Antithrombin III.

### Claim 1167 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-Xa activity.

### Claim 1168 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Anti-Xa assay.

### Claim 1169 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Apolipoproteins.

### Claim 1170 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Arsenic.

### Claim 1171 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Aspartate aminotransferase (AST).

### Claim 1172 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises B12.

### Claim 1173 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Basophil.

### Claim 1174 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Beta-2-Microglobulin.

### Claim 1175 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Beta-hydroxybutyrate.

### Claim 1176 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises B-HCG.

### Claim 1177 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Bilirubin.

### Claim 1179 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Bilirubin, indirect.

### Claim 1180 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Bilirubin, total.

### Claim 1181 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Bleeding time.

### Claim 1182 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Blood gases (arterial).

### Claim 1183 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Blood urea nitrogen (BUN).

### Claim 1184 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises BUN.

### Claim 1185 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises BUN (blood urea nitrogen).

### Claim 1186 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CA 125.

### Claim 1187 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CA 15-3.

### Claim 1188 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CA 19-9.

### Claim 1189 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Calcitonin.

### Claim 1190 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Calcium.

### Claim 1191 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Calcium (ionized).

### Claim 1192 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Carbon monoxide (CO).

### Claim 1193 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Carcinoembryonic antigen (CEA).

### Claim 1194 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CBC.

### Claim 1195 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CEA.

### Claim 1196 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CEA (carcinoembryonic antigen).

### Claim 1197 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Ceruloplasmin.

### Claim 1198 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CH50Chloride.

### Claim 1199 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Cholesterol.

### Claim 1200 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Cholesterol, HDL.

### Claim 1201 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Clot lysis time.

### Claim 1202 (depends on 1127)

Clot The invention of claim 1127, wherein said diagnostic test material comprises retraction time.

### Claim 1203 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CMP.

### Claim 1204 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CO2.

### Claim 1205 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Cold agglutinins.

### Claim 1206 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Complement C3.

### Claim 1207 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Copper.

### Claim 1208 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Corticotrophin releasing hormone (CRH) stimulation test.

### Claim 1209 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Cortisol.

### Claim 1210 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Cortrosyn stimulation test.

### Claim 1211 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises C-peptide.

### Claim 1212 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CPK (Total).

### Claim 1213 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises CPK-MB.

### Claim 1214 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises C-reactive protein.

### Claim 1215 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Creatinine.

### Claim 1216 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Creatinine kinase (CK).

### Claim 1217 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Cryoglobulins.

### Claim 1218 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises DAT (Direct antiglobulin test).

### Claim 1219 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises D-Dimer.

### Claim 1220 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Dexamethasone suppression test/

### Claim 1221 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises DHEA-S.

### Claim 1222 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Dilute Russell viper venom.

### Claim 1223 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Elliptocytes.

### Claim 1224 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Eosinophil.

### Claim 1225 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Erythrocyte sedimentation rate (ESR).

### Claim 1226 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Estradiol.

### Claim 1227 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Estriol.

### Claim 1228 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Ethanol.

### Claim 1229 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Ethylene glycol.

### Claim 1230 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Euglobulin lysis.

### Claim 1231 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Factor V Leiden.

### Claim 1232 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Factor VIII inhibitor.

### Claim 1233 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Factor VIII level.

### Claim 1234 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Ferritin.

### Claim 1235 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Fibrin split products.

### Claim 1236 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Fibrinogen.

### Claim 1237 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Folate.

### Claim 1238 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Folate (serum).

### Claim 1239 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Fractional excretion of sodium (FENA).

### Claim 1240 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises FSH (follicle stimulating factor).

### Claim 1241 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises FTA-ABS.

### Claim 1242 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Gamma glutamyl transferase (GGT).

### Claim 1243 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Gastrin.

### Claim 1244 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises GGTP (Gamma glutamyl transferase).

### Claim 1245 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Glucose.

### Claim 1246 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Growth hormone.

### Claim 1247 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Haptoglobin.

### Claim 1248 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises HBeAg (Hepatitis Be antigen).

### Claim 1249 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises HBs-Ag (Hepatitis B surface antigen).

### Claim 1250 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Helicobacter pylori.

### Claim 1251 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Hematocrit.

### Claim 1252 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Hematocrit (HCT).

### Claim 1253 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Hemoglobin.

### Claim 1254 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Hemoglobin A1C.

### Claim 1255 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Hemoglobin electrophoresis.

### Claim 1256 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Hepatitis A antibodies.

### Claim 1257 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Hepatitis C antibodies.

### Claim 1258 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises IAT (Indirect antiglobulin test).

### Claim 1259 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Immunofixation (IFE).

### Claim 1260 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Iron.

### Claim 1261 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Lactate dehydrogenase (LDH).

### Claim 1262 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Lactic acid (lactate).

### Claim 1263 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises LDH.

### Claim 1264 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises LH (Leutinizing hormone.

### Claim 1265 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Lipase.

### Claim 1266 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Lupus anticoagulant.

### Claim 1267 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Lymphocyte.

### Claim 1268 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Magnesium.

### Claim 1269 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises MCH (mean corpuscular hemoglobin.

### Claim 1270 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises MCHC (mean corpuscular hemoglobin concentration).

### Claim 1271 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises MCV (mean corpuscular volume).

### Claim 1272 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Methylmalonate.

### Claim 1273 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Monocyte.

### Claim 1274 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises MPV (mean platelet volume).

### Claim 1275 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Myoglobin.

### Claim 1276 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Neutrophil.

### Claim 1277 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Parathyroid hormone (PTH).

### Claim 1278 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Phosphorus.

### Claim 1279 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Platelets (plt).

### Claim 1280 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Potassium.

### Claim 1281 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Prealbumin.

### Claim 1282 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Prolactin.

### Claim 1283 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Prostate specific antigen (PSA).

### Claim 1284 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Protein C.

### Claim 1285 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Protein S.

### Claim 1286 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises PSA (prostate specific antigen).

### Claim 1287 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises PT (Prothrombin time).

### Claim 1288 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises PTT (Partial thromboplastin time).

### Claim 1289 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises RDW (red cell distribution width).

### Claim 1290 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Renin.

### Claim 1291 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Rennin.

### Claim 1292 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Reticulocyte count.

### Claim 1293 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises reticulocytes.

### Claim 1294 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Rheumatoid factor (RF).

### Claim 1295 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Sed Rate.

### Claim 1296 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Serum glutamic-pyruvic transaminase (SGPT).

### Claim 1297 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Serum protein electrophoresis (SPEP).

### Claim 1298 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Sodium.

### Claim 1299 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises T3-resin uptake (T3RU).

### Claim 1300 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises T4, Free.

### Claim 1301 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Thrombin time.

### Claim 1302 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Thyroid stimulating hormone (TSH).

### Claim 1303 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Thyroxine (T4).

### Claim 1304 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Total iron binding capacity (TIBC).

### Claim 1305 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Total protein.

### Claim 1306 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Transferrin.

### Claim 1307 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Transferrin saturation.

### Claim 1308 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Triglyceride (TG).

### Claim 1309 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Troponin.

### Claim 1310 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Uric acid.

### Claim 1311 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Vitamin B12.

### Claim 1312 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises White blood cells (WBC).

### Claim 1313 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Widal test.

### Claim at position 1311

1314-1400. (canceled)

### Claim 1328 (depends on 1127)

The invention of claim 1127, wherein said diagnostic test material comprises Bilirubin, direct.

### Claim 1401

A filled package comprising:
a vessel having a lumen defined at least in part by a wall, the wall having an interior surface facing the lumen, an outer surface, and a coating set on the interior surface comprising a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer;
the tie coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.9 and y is from about 0.6 to about 3, the tie coating or layer having an interior surface facing the lumen and an outer surface facing the wall interior surface;
the barrier coating or layer comprising SiOx, wherein x is from 1.5 to 2.9, from 2 to 1000 nm thick, the barrier coating or layer of SiOx having an interior surface facing the lumen and an outer surface facing the interior surface of the tie coating or layer, the barrier coating or layer being effective to reduce the ingress of atmospheric gas into the lumen compared to an vessel without a barrier coating or layer;
the pH protective coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the pH protective coating or layer having an interior surface facing the lumen and an outer surface facing the interior surface of the barrier coating or layer,
the combination of the tie coating or layer and the pH protective coating or layer being effective to increase the calculated shelf life of the package (total Si/Si dissolution rate); and
a fluid composition contained in the lumen and having a pH between 5 and 9; wherein the calculated shelf life of the package is more than six months at a storage temperature of 4° C.

### Claim 1402

(canceled)

### Claim 1403

An article comprising:
a wall having a surface and a coating set on the surface comprising a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer;
the tie coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the tie coating or layer having an outer surface facing the wall surface and the tie coating or layer having an interior surface;
the barrier coating or layer comprising SiOx, wherein x is from 1.5 to 2.9, from 2 to 1000 nm thick, the barrier coating or layer of SiOx having an outer surface facing the interior surface of the tie coating or layer and the barrier coating or layer of SiOx having an interior surface, the barrier coating or layer being effective to reduce the ingress of atmospheric gas through the wall compared to an uncoated wall; and
the pH protective coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, on the barrier coating or layer, the pH protective coating or layer being formed by chemical vapor deposition of a precursor selected from an acyclic siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors; and
in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH at some point between 5 and 9, is less than the rate of erosion of the barrier coating or layer, if directly contacted by the fluid composition.

### Claim 1404

A vessel comprising:
a thermoplastic wall having an interior surface enclosing a lumen;
a fluid contained in the lumen having a pH greater than 5 disposed in the lumen;
a tie coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the tie coating or layer having an outer surface facing the wall surface and the tie coating or layer having an interior surface;
a barrier coating or layer of SiOx, in which x is between 1.5 and 2.9, the barrier coating or layer applied by PECVD, positioned between the interior surface of the tie coating or layer and the fluid, and supported by the thermoplastic wall, the barrier coating or layer having the characteristic of being subject to being measurably diminished in barrier improvement factor in less than six months as a result of attack by the fluid; and
a pH protective coating or layer of SiOxCy, in which x is between 0.5 and 2.4 and y is between 0.6 and 3, the pH protective coating or layer applied by PECVD, positioned between the barrier coating or layer and the fluid and supported by the thermoplastic wall, the pH protective coating or layer and tie coating or layer together being effective to keep the barrier coating or layer at least substantially undissolved as a result of attack by the fluid for a period of at least six months.

### Claim 1405

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises:
a polyolefin,
a polyester or
a combination of a polyolefin and a polyester.

### Claim 1406

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a polyolefin.

### Claim 1407

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a polyolefin.

### Claim 1408

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a cyclic olefin polymer.

### Claim 1409

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a cyclic olefin polymer.

### Claim 1410

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a cyclic olefin copolymer.

### Claim 1411

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a cyclic olefin copolymer.

### Claim 1412

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises polypropylene.

### Claim 1413

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of polypropylene.

### Claim 1414

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a polyester.

### Claim 1415

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a polyester.

### Claim 1416

The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises polyethylene terephthalate.

### Claim 1417

The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of polyethylene terephthalate.

### Claim 1418

The invention of any preceding claim, in which the vessel comprises a syringe barrel.

### Claim 1419 (depends on 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417)

The invention of any preceding claims 1401 to 1417, in which the vessel comprises a vial.

### Claim 1420 (depends on 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417)

The invention of any preceding claims 1401 to 1417, in which the vessel comprises a blister package.

### Claim 1421 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1420, in which the fluid composition has a pH between 5 and 6.

### Claim 1422 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1420, in which the fluid composition has a pH between 6 and 7.

### Claim 1423 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1420, in which the fluid composition has a pH between 7 and 8.

### Claim 1424 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1420, in which the fluid composition has a pH between 8 and 9.

### Claim 1425

The invention of any preceding claim, in which the fluid composition has a pH between 6.5 and 7.5.

### Claim 1426

The invention of any preceding claim, in which the fluid composition has a pH between 7.5 and 8.5.

### Claim 1427

The invention of any preceding claim, in which the fluid composition has a pH between 8.5 and 9.

### Claim 1428

The invention of any preceding claim, in which the fluid composition is a liquid at 20° C. and 760 mm Hg. atmospheric pressure.

### Claim 1429

The invention of any preceding claim, in which the fluid composition is an aqueous liquid.

### Claim 1430 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429)

The invention of any preceding claim 1401 or 1403-1429, in which the barrier coating or layer is from 4 nm to 500 nm thick.

### Claim 1431 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429)

The invention of any preceding claim 1401 or 1403-1429, in which the barrier coating or layer is from 7 nm to 400 nm thick.

### Claim 1432 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429)

The invention of any preceding claim 1401 or 1403-1429, in which the barrier coating or layer is from 10 nm to 300 nm thick.

### Claim 1433 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429)

The invention of any preceding claim 1401 or 1403-1429, in which the barrier coating or layer is from 20 nm to 200 nm thick.

### Claim 1434 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429)

The invention of any preceding claim 1401 or 1403-1429, in which the barrier coating or layer is from 30 nm to 100 nm thick.

### Claim 1435

The invention of any preceding claim, in which the pH protective coating or layer comprises SiOxCy.

### Claim 1436

The invention of any preceding claim, in which the pH protective coating or layer consists essentially of SiOxCy.

### Claim 1437

The invention of any preceding claim, in which the pH protective coating or layer comprises SiNxCy.

### Claim 1438

The invention of any preceding claim, in which the pH protective coating or layer consists essentially of SiNxCy.

### Claim 1439

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising an acyclic siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim 1440

The invention of any preceding claim, in which in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising an acyclic siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a silatrane, a silquasilatrane, a silproatrane, or a combination of any two or more of these precursors.

### Claim 1441

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising a monocyclic siloxane.

### Claim 1442

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising octamethylcyclotetrasiloxane (OMCTS).

### Claim 1443

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD of a precursor feed consisting essentially of octamethylcyclotetrasiloxane (OMCTS).

### Claim 1444

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD of a precursor feed comprising a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim at position 1357 (depends on 1439, 1440, 1441, 1442, 1443, 1444)

1444A. The invention of any preceding claim 1439-1444, in which the precursor feed further comprises oxygen.

### Claim at position 1358 (depends on 1439, 1440, 1441, 1442, 1443, 1444)

1444B. The invention of any preceding claim 1439-1444A, in which the precursor feed further comprises a carrier gas.

### Claim at position 1359 (depends on 44)

1444C. The invention of claim 44B, in which the carrier gas comprises argon.

### Claim at position 1360 (depends on 1439, 1440, 1441, 1442, 1443, 1444)

1444D. The invention of any preceding claim 1439-1444C, in which the precursor feed comprises:
from 0.5 to 10 standard volumes of the organosilicon precursor;
from 0.1 to 10 standard volumes of oxygen; and
from 1 to 100 sccm of a carrier gas.

### Claim at position 1361 (depends on 1439, 1440, 1441, 1442, 1443, 1444)

1444E. The invention of any preceding claim 1439-1444D, in which the precursor feed comprises:
from 0.5 to 10 standard volumes of octamethylenecyclotetrasiloxane;
from 0.1 to 10 standard volumes of oxygen; and
from 1 to 100 sccm of argon.

### Claim 1445

The invention of any preceding claim, in which the pH protective coating or layer as applied is between 10 and 1000 nm thick.

### Claim 1446

The invention of any preceding claim, in which the pH protective coating or layer as applied is between 50 and 800 nm thick.

### Claim 1447

The invention of any preceding claim, in which the pH protective coating or layer as applied is between 100 and 700 nm thick.

### Claim 1448

The invention of any preceding claim, in which the pH protective coating or layer as applied is between 300 and 600 nm thick.

### Claim 1449 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1448, in which the pH protective coating or layer contacting the fluid composition is between 10 and 1000 nm thick two years after the invention is assembled.

### Claim 1450 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1448, in which the pH protective coating or layer contacting the fluid composition is between 20 and 700 nm thick two years after the invention is assembled.

### Claim 1451 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1448, in which the pH protective coating or layer contacting the fluid composition is between 50 and 500 nm thick two years after the invention is assembled.

### Claim 1452 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1448, in which the pH protective coating or layer contacting the fluid composition is between 100 and 400 nm thick two years after the invention is assembled.

### Claim 1453 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1448, in which the pH protective coating or layer contacting the fluid composition is between 150 and 300 nm thick two years after the invention is assembled.

### Claim 1454 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453)

The invention of any preceding claim 1401 or 1403-1453, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 20% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 1455 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453)

The invention of any preceding claim 1401 or 1403-1453, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 15% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 1456 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453)

The invention of any preceding claim 1401 or 1403-1453, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 10% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 1457 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453)

The invention of any preceding claim 1401 or 1403-1453, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 7% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 1458 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453)

The invention of any preceding claim 1401 or 1403-1453, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 20% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 1459 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453)

The invention of any preceding claim 1401 or 1403-1453, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 15% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 1460 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453)

The invention of any preceding claim 1401 or 1403-1453, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 10% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 1461 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453)

The invention of any preceding claim 1401 or 1403-1453, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 7% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.

### Claim 1462 (depends on 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458, 1459)

The invention of any preceding claim 1401 or 1403-1459, in which the pH protective coating or layer is at least coextensive with the barrier coating or layer.

### Claim 1463 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1462, having a shelf life, after the invention is assembled, of at least one year.

### Claim 1464 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1462, having a shelf life, after the invention is assembled, of at least two years.

### Claim at position 1382 (depends on 1401, 1402)

1464A. The invention of any preceding claim 1401, 1402, or 1404-1462, having a shelf life, after the invention is assembled, of at least three years.

### Claim at position 1383 (depends on 1401, 1402)

1464B. The invention of any preceding claim 1401, 1402, or 1404-1462, having a shelf life, after the invention is assembled, of at least four years.

### Claim at position 1384 (depends on 1401, 1402)

1464C. The invention of any preceding claim 1401, 1402, or 1404-1462, having a shelf life, after the invention is assembled, of at least five years.

### Claim at position 1385 (depends on 1401, 1402)

1464D. The invention of any preceding claim 1401, 1402, or 1404-1462, having a shelf life, after the invention is assembled, of at least six years.

### Claim at position 1386 (depends on 1401, 1402)

1464E. The invention of any preceding claim 1401, 1402, or 1404-1462, having a shelf life, after the invention is assembled, of at least seven years.

### Claim at position 1387 (depends on 1401, 1402)

1464F. The invention of any preceding claim 1401, 1402, or 1404-1462, having a shelf life, after the invention is assembled, of at least eight years.

### Claim at position 1388 (depends on 1401, 1402)

1464G. The invention of any preceding claim 1401, 1402, or 1404-1462, having a shelf life, after the invention is assembled, of at least nine years.

### Claim at position 1389 (depends on 1463, 1464)

1464H. The invention of any preceding claim 1463-1464G, having a shelf life, after the invention is assembled, of at most ten years.

### Claim 1465 (depends on 1463, 1464)

The invention of any preceding claim 1463-1464H, in which the shelf life is determined at 3° C.

### Claim 1466 (depends on 1463, 1464)

The invention of any preceding claim 1463-1464H, in which the shelf life is determined at 4° C.

### Claim 1467 (depends on 1463, 1464)

The invention of any preceding claim 1463-1464H, in which the shelf life is determined at 20° C.

### Claim 1468 (depends on 1463, 1464)

The invention of any preceding claim 1463-1464H, in which the shelf life is determined at 23° C.

### Claim 1469 (depends on 1463, 1464)

The invention of any preceding claim 1463-1464H, in which the shelf life is determined at 40° C.

### Claim 1470 (depends on 1463, 1464, 1465, 1466, 1467, 1468, 1469)

The invention of any preceding claim 1463-1469, in which the pH of the fluid composition is between 5 and 6 and the thickness of the pH protective coating or layer is at least 80 nm at the end of the shelf life.

### Claim 1471 (depends on 1463, 1464, 1465, 1466, 1467, 1468, 1469)

The invention of any preceding claim 1463-1469, in which the pH of the fluid composition is between 6 and 7 and the thickness of the pH protective coating or layer is at least 80 nm at the end of the shelf life.

### Claim 1472 (depends on 1463, 1464, 1465, 1466, 1467, 1468, 1469)

The invention of any preceding claim 1463-1469, in which the pH of the fluid composition is between 7 and 8 and the thickness of the pH protective coating or layer is at least 80 nm at the end of the shelf life.

### Claim 1473 (depends on 1463, 1464, 1465, 1466, 1467, 1468, 1469)

The invention of any preceding claim 1463-1469, in which the pH of the fluid composition is between 8 and 9 and the thickness of the pH protective coating or layer is at least 80 nm at the end of the shelf life.

### Claim 1474 (depends on 1463, 1464, 1465, 1466, 1467, 1468, 1469)

The invention of any preceding claim 1463-1469, in which the pH of the fluid composition is between 5 and 6 and the thickness of the pH protective coating or layer is at least 150 nm at the end of the shelf life.

### Claim 1475 (depends on 1463, 1464, 1465, 1466, 1467, 1468, 1469)

The invention of any preceding claim 1463-1469, in which the pH of the fluid composition is between 6 and 7 and the thickness of the pH protective coating or layer is at least 150 nm at the end of the shelf life.

### Claim 1476 (depends on 1463, 1464, 1465, 1466, 1467, 1468, 1469)

The invention of any preceding claim 1463-1469, in which the pH of the fluid composition is between 7 and 8 and the thickness of the pH protective coating or layer is at least 150 nm at the end of the shelf life.

### Claim 1477 (depends on 1463, 1464, 1465, 1466, 1467, 1468, 1469)

The invention of any preceding claim 1463-1469, in which the pH of the fluid composition is between 8 and 9 and the thickness of the pH protective coating or layer is at least 150 nm at the end of the shelf life.

### Claim 1478

The invention of any preceding claim, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 44 hours of contact with the fluid composition.

### Claim 1479

The invention of any preceding claim, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 88 hours of contact with the fluid composition.

### Claim 1480

The invention of any preceding claim, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 175 hours of contact with the fluid composition.

### Claim 1481

The invention of any preceding claim, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 250 hours of contact with the fluid composition.

### Claim 1482

The invention of any preceding claim, in which the fluid composition removes the pH protective coating or layer at a rate of 1 nm or less of pH protective coating or layer thickness per 350 hours of contact with the fluid composition.

### Claim 1483

The invention of any preceding claim, in which the pH protective coating or layer is effective to provide a lower frictional resistance than the uncoated interior surface.

### Claim 1484 (depends on 1483)

The invention of claim 1483 wherein the frictional resistance is reduced by at least 25% in comparison to the uncoated interior surface.

### Claim 1485 (depends on 1483)

The invention of claim 1483 wherein the frictional resistance is reduced by at least 45% in comparison to the uncoated interior surface.

### Claim 1486 (depends on 1483)

The invention of claim 1483 wherein the frictional resistance is reduced by at least 60% in comparison to the uncoated interior surface.

### Claim 1487

The invention of any preceding claim, in which the pH protective coating or layer is effective to reduce the frictional resistance between a portion of the wall contacted by the fluid composition and a relatively sliding part after the invention is assembled.

### Claim 1488

The invention of any preceding claim, in which the pH protective coating or layer is effective to reduce the frictional resistance between the wall and a relatively sliding part at least two years after the invention is assembled.

### Claim 1489 (depends on 1483, 1484, 1485, 1486, 1487, 1488)

The invention of any preceding claim 1483-1488, in which the invention is a syringe.

### Claim 1490 (depends on 1483, 1484, 1485, 1486, 1487, 1488)

The invention of any preceding claim 1483-1488, in which the invention is a syringe comprising a syringe barrel.

### Claim 1491 (depends on 1483, 1484, 1485, 1486, 1487, 1488)

The invention of any preceding claim 1483-1488, in which the invention is a syringe comprising a plunger.

### Claim 1492 (depends on 1483, 1484, 1485, 1486, 1487, 1488)

The invention of any preceding claim 1483-1488, in which the invention is a syringe comprising a syringe barrel and a plunger.

### Claim 1493 (depends on 1483, 1484, 1485, 1486, 1487, 1488)

The invention of any preceding claim 1483-1488, in which the invention is a syringe comprising a syringe barrel and a plunger and the wall defines at least a portion of the syringe barrel.

### Claim 1494 (depends on 1483, 1484, 1485, 1486, 1487, 1488)

The invention of any preceding claim 1483-1488, in which the invention is a syringe comprising a syringe barrel and a plunger, the wall defines at least a portion of the syringe barrel, and the relatively sliding part comprises the syringe plunger.

### Claim 1495

The invention of any preceding claim, further comprising
a lubricity coating or layer applied between the pH protective coating or layer and the lumen;
optionally, a further coating or layer applied adjacent to the inner surface of the pH protective coating or layer, the further coating or layer having an outer surface facing the interior surface of the thermoplastic wall and an inner surface facing the lumen; and
fluid in contact with the pH protective coating or layer.

### Claim 1496

The invention of any preceding claim, in which an FTIR absorbance spectrum of the pH protective coating or layer has a ratio greater than 0.75 between:
the maximum amplitude of the Si—O—Si symmetrical stretch peak between about 1000 and 1040 cm−1, and
the maximum amplitude of the Si—O—Si assymmetric stretch peak between about 1060 and about 1100 cm−1.

### Claim 1497 (depends on 1496)

The invention of claim 1496, in which the ratio is at least 0.8.

### Claim 1498 (depends on 1496)

The invention of claim 1496, in which the ratio is at least 0.9.

### Claim 1499 (depends on 1496)

The invention of claim 1496, in which the ratio is at least 1.

### Claim 1500 (depends on 1496)

The invention of claim 1496, in which the ratio is at least 1.1.

### Claim 1501 (depends on 1496)

The invention of claim 1496, in which the ratio is at least 1.2.

### Claim 1502 (depends on 1496, 1497, 1498, 1499, 1500, 1501)

The invention of any preceding claims 1496 to 1501, in which the ratio is at most 1.7.

### Claim 1503 (depends on 1496, 1497, 1498, 1499, 1500, 1501)

The invention of any preceding claims 1496 to 1501, in which the ratio is at most 1.6.

### Claim 1504 (depends on 1496, 1497, 1498, 1499, 1500, 1501)

The invention of any preceding claims 1496 to 1501, in which the ratio is at most 1.5.

### Claim 1505 (depends on 1496, 1497, 1498, 1499, 1500, 1501)

The invention of any preceding claims 1496 to 1501, in which the ratio is at most 1.4.

### Claim 1506 (depends on 1496, 1497, 1498, 1499, 1500, 1501)

The invention of any preceding claims 1496 to 1501, in which the ratio is at most 1.3.

### Claim 1507

The invention of any preceding claim, in which the pH protective coating or layer has a non-oily appearance.

### Claim 1508

The invention of any preceding claim, in which the silicon dissolution rate by a 50 mM potassium phosphate buffer diluted in water for injection, adjusted to pH 8 with concentrated nitric acid, and containing 0.2 wt. % polysorbate-80 surfactant from the vessel is less than 170 ppb/day.

### Claim 1509 (depends on 1508)

The invention of claim 1508, in which the silicon dissolution rate is less than 160 ppb/day.

### Claim 1510 (depends on 1508)

The invention of claim 1508, in which the silicon dissolution rate is less than 140 ppb/day.

### Claim 1511 (depends on 1508)

The invention of claim 1508, in which the silicon dissolution rate is less than 120 ppb/day.

### Claim 1512 (depends on 1508)

The invention of claim 1508, in which the silicon dissolution rate is less than 100 ppb/day.

### Claim 1513 (depends on 1508)

The invention of claim 1508, in which the silicon dissolution rate is less than 90 ppb/day.

### Claim 1514 (depends on 1508)

The invention of claim 1508, in which the silicon dissolution rate is less than 80 ppb/day.

### Claim 1515 (depends on 1401, 1403, 1514)

The invention of any preceding claim 1401 or 1403-1514, in which the total silicon content of the pH protective coating or layer and barrier coating or layer, upon dissolution into 0.1 N potassium hydroxide aqueous solution at 40° C. from the vessel, is less than 66 ppm.

### Claim 1516 (depends on 1515)

The invention of claim 1515, in which the total silicon content is less than 60 ppm.

### Claim 1517 (depends on 1515)

The invention of claim 1515, in which the total silicon content is less than 50 ppm.

### Claim 1518 (depends on 1515)

The invention of claim 1515, in which the total silicon content is less than 40 ppm.

### Claim 1519 (depends on 1515)

The invention of claim 1515, in which the total silicon content is less than 30 ppm.

### Claim 1520 (depends on 1515)

The invention of claim 1515, in which the total silicon content is less than 20 ppm.

### Claim 1521 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1520, in which the calculated shelf life (total Si/Si dissolution rate) is more than 1 year.

### Claim 1522 (depends on 1401, 1402)

The invention of claim 1401, 1402, or 1404-1520, in which the calculated shelf life (total Si/Si dissolution rate) is more than 18 months.

### Claim 1523 (depends on 1401, 1402)

The invention of claim 1401, 1402, or 1404-1520, in which the calculated shelf life (total Si/Si dissolution rate) is more than 2 years.

### Claim 1524 (depends on 1401, 1402)

The invention of claim 1401, 1402, or 1404-1520, in which the calculated shelf life (total Si/Si dissolution rate) is more than 2½ years.

### Claim 1525 (depends on 1401, 1402)

The invention of claim 1401, 1402, or 1404-1520, in which the calculated shelf life (total Si/Si dissolution rate) is more than 3 years.

### Claim 1526 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1525, in which the calculated shelf life (total Si/Si dissolution rate) is less than 4 years.

### Claim 1527 (depends on 1401, 1402)

The invention of any preceding claim 1401, 1402, or 1404-1525, in which the calculated shelf life (total Si/Si dissolution rate) is less than 5 years.

### Claim 1528

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 22,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1529

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 30,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1530

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 40,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1531

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 50,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1532

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 60,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1533

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 62,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1534

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 70,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1535

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of more than 80,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1536

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of less than 100,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1537

The invention of any preceding claim, in which the pH protective coating or layer is applied by PECVD at a power level per of less than 90,000 kJ/kg of mass of polymerizing gases in the PECVD reaction chamber.

### Claim 1538 (depends on 1401, 1537)

The invention of any preceding claim 1401-1537, in which the pH protective coating or layer is applied by PECVD at a power level per of from 0.1 to 500 W.

### Claim at position 1464 (depends on 1401, 1537)

1538A. The invention of any preceding claim 1401-1537, in which the pH protective coating or layer is applied by PECVD at a power level per of from 0.1 to 400 W.

### Claim 1539 (depends on 1401, 1537)

The invention of any preceding claim 1401-1537, in which the pH protective coating or layer is applied by PECVD at a power level per of from 1 to 250 W.

### Claim 1540 (depends on 1401, 1537)

The invention of any preceding claim 1401-1537, in which the pH protective coating or layer is applied by PECVD at a power level per of from 1 to 200 W.

### Claim 1541 (depends on 1401, 1537)

The invention of any preceding claim 1401-1537, in which the pH protective coating or layer is applied by PECVD at a power level per of from 10 to 150 W.

### Claim 1542 (depends on 1401, 1537)

The invention of any preceding claim 1401-1537, in which the pH protective coating or layer is applied by PECVD at a power level per of from 20 to 150 W.

### Claim 1543 (depends on 1401, 1537)

The invention of any preceding claim 1401-1537, in which the pH protective coating or layer is applied by PECVD at a power level per of from 40 to 150 W.

### Claim 1544 (depends on 1401, 1537)

The invention of any preceding claim 1401-1537, in which the pH protective coating or layer is applied by PECVD at a power level per of from 60 to 150 W.

### Claim 1545

The invention of any preceding claim, in which the ratio of the electrode power to the plasma volume is from 1 W/ml to 100 W/ml.

### Claim 1546 (depends on 1545)

The invention of claim 1545, in which the ratio of the electrode power to the plasma volume is from 5 W/ml to 75 W/ml.

### Claim 1547 (depends on 1545)

The invention of claim 1545, in which the ratio of the electrode power to the plasma volume is from 6 W/ml to 60 W/ml.

### Claim 1548 (depends on 1545)

The invention of claim 1545, in which the ratio of the electrode power to the plasma volume is from 10 W/ml to 50 W/ml.

### Claim 1549 (depends on 1545)

The invention of claim 1545, in which the ratio of the electrode power to the plasma volume is from 20 W/ml to 40 W/ml.

### Claim at position 1476

1549H. The invention of any preceding claim, further comprising a lubricity coating or layer between the lumen and the pH protective coating or layer, the lubricity coating comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the lubricity coating or layer being effective to increase the lubricity of the coating set above that of a coating set having a pH protective coating as the layer confronting the lumen.

### Claim at position 1477

1549A. The invention of any preceding claim, in which the pH protective coating or layer has an RMS surface roughness value (measured by AFM) of from about 5 to about 9.

### Claim at position 1478

1549B. The invention of any preceding claim, in which the pH protective coating or layer has an RMS surface roughness value (measured by AFM) of from about 6 to about 8.

### Claim at position 1479 (depends on 1401, 1549)

1549C. The invention of any preceding claim 1401-1549, in which the pH protective coating or layer has an RMS surface roughness value (measured by AFM) of from about 4 to about 6.

### Claim at position 1480 (depends on 1401, 1549)

1549D. The invention of any preceding claim 1401-1549, in which the pH protective coating or layer has an RMS surface roughness value (measured by AFM) of from about 4.6 to about 5.8.

### Claim at position 1481

1549E. The invention of any preceding claim, in which the pH protective coating or layer has an Rmax surface roughness value of the pH protective coating or layer, measured by AFM, from about 70 to about 160.

### Claim at position 1482

1549F. The invention of any preceding claim, in which the pH protective coating or layer has an Rmax surface roughness value of the pH protective coating or layer, measured by AFM, from about 84 to about 142.

### Claim at position 1483

1549G. The invention of any preceding claim, in which the pH protective coating or layer has an Rmax surface roughness value of the pH protective coating or layer, measured by AFM, from about 90 to about 130.

### Claim 1550

The invention of any preceding claim, comprising a syringe barrel coated on its interior wall with a pH protective coating or layer, the invention further comprising a plunger positioned for sliding in the barrel and a lubricity coating or layer on at least a portion of the plunger.

### Claim 1551 (depends on 1550)

The invention of claim 1550, in which the lubricity coating or layer is configured to provide a lower piston sliding force or breakout force than the uncoated substrate

### Claim 1552 (depends on 1550)

The invention of claim 1550, in which the lubricity coating or layer has one of the following atomic ratios, measured by X-ray photoelectron spectroscopy (XPS), SiwOxCy (or its equivalent SiOxCy) or SiwNxCy (or its equivalent SiNxCy) where w is 1, x in this formula is from about 0.5 to 2.4, and y is from about 0.6 to about 3.

### Claim 1553 (depends on 1550)

The invention of claim 1550, in which the lubricity coating or layer the lubricity coating or layer having a thickness by transmission electron microscopy (TEM) between 10 and 500 nm;

### Claim 1554 (depends on 1550)

The invention of claim 1550, in which the lubricity coating or layer the lubricity coating or layer deposited by plasma enhanced chemical vapor deposition (PECVD).

### Claim 1555 (depends on 1550)

The invention of claim 1550, in which the lubricity coating or layer is deposited under conditions effective to form a coating or layer from a precursor selected from a linear siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a linear silazane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim 1556 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a linear siloxane.

### Claim 1557 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a monocyclic siloxane.

### Claim 1558 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a polycyclic siloxane.

### Claim 1559 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a polysilsesquioxane.

### Claim 1560 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a linear silazane.

### Claim 1561 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a monocyclic silazane.

### Claim 1562 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a polycyclic silazane.

### Claim 1563 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a polysilsesquiazane.

### Claim 1564 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a silatrane.

### Claim 1565 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a silquasilatrane.

### Claim 1566 (depends on 1550)

The invention of claim 1550, in which the precursor comprises a silproatrane.

### Claim 1567 (depends on 1550)

The invention of claim 1550, in which the precursor comprises an azasilatrane.

### Claim 1568 (depends on 1550)

The invention of claim 1550, in which the precursor comprises an azasilquasiatrane.

### Claim 1569 (depends on 1550)

The invention of claim 1550, in which the precursor comprises an azasilproatrane.

### Claim 1570

The invention of any preceding claim, wherein the pH protective coating or layer shows an O-Parameter measured with attenuated total reflection (ATR) of less than 0.4, measured as:
O
⁢
-
⁢
Parameter
=
Intensity
⁢
⁢
at
⁢
⁢
1253
⁢
⁢
cm
-
1
Maximum
⁢
⁢
intensity
⁢
⁢
in
⁢
⁢
the
⁢
⁢
range
⁢
⁢
1000
⁢
⁢
to
⁢
⁢
1100
⁢
⁢
cm
-
1
.

### Claim 1571 (depends on 1570)

The invention of claim 1570, in which the O-parameter has a value of from 0.1 to 0.39.

### Claim 1572 (depends on 170)

The invention of claim 170, in which the O-parameter has a value of from 0.15 to 0.37.

### Claim 1573 (depends on 1570)

The invention of claim 1570, in which the O-parameter has a value of from 0.17 to 0.35.

### Claim 1574

The invention of any preceding claim, wherein the pH protective coating or layer shows an N-Parameter measured with attenuated total reflection (ATR) of less than 0.7, measured as:
N
⁢
-
⁢
Parameter
=
Intensity
⁢
⁢
at
⁢
⁢
840
⁢
⁢
cm
-
1
Intensity
⁢
⁢
at
⁢
⁢
799
⁢
⁢
cm
-
1
.

### Claim 1575 (depends on 1574)

The invention of claim 1574, in which the N-parameter has a value of at least 0.3.

### Claim 1576 (depends on 1574)

The invention of claim 1574, in which the N-parameter has a value of 0.4 to 0.6.

### Claim 1577

A composite material comprising:
a substrate,
a barrier coating or layer over the substrate, and
a passivation coating or layer over the barrier coating or layer, wherein the passivation coating or layer shows an FTIR absorbance ratio of greater than 0.75 between:
the maximum amplitude of the Si—O—Si symmetrical stretch peak of an FTIR spectrum between about 1000 and 1040 cm−1, and
the maximum amplitude of the Si—O—Si assymmetric stretch peak of the FTIR spectrum between about 1060 and about 1100 cm−1.

### Claim 1578

The invention of any preceding claim, in which x is between 0.5 and 1.5 and y is between 0.9 and 2.

### Claim 1579

The invention of any preceding claim, in which x is between 0.7 and 1.3 and y is between 0.9 and 2.

### Claim 1580

The invention of any preceding claim, in which x is between 0.8 and 1.2 and y is between 0.9 and 1.5.

### Claim 1581

The invention of any preceding claim, in which x is between 0.9 and 1.2 and y is between 0.9 and 1.4.

### Claim 1582

The invention of any preceding claim, in which x is between 0.92 and 1.07 and y is between 1.16 and 1.33.

### Claim 1583

The invention of any preceding claim, in which the RMS surface roughness value of the pH protective coating or layer, measured by atomic force microscopy, is from about 5 to about 9, optionally from about 6 to about 8, optionally from about 6.4 to about 7.8.

### Claim 1584

The invention of any preceding claim, in which the Ra surface roughness value of the pH protective coating or layer, measured by atomic force microscopy, is from about 4 to about 6, optionally from about 4.6 to about 5.8.

### Claim 1585

The invention of any preceding claim, in which the Rmax surface roughness value of the pH protective coating or layer, measured by atomic force microscopy, is from about 70 to about 160, optionally from about 84 to about 142, optionally from about 90 to about 130.

### Claim at position 1520

1586-1634. (canceled)

### Claim 1635

The invention of any preceding claim, in which the tie coating or layer comprises SiOxCy.

### Claim 1636

The invention of any preceding claim, in which the tie coating or layer consists essentially of SiOxCy.

### Claim 1637

The invention of any preceding claim, in which the tie coating or layer comprises SiNxCy.

### Claim 1638

The invention of any preceding claim, in which the tie coating or layer consists essentially of SiNxCy.

### Claim 1639

The invention of any preceding claim, in which the tie coating or layer is applied by PECVD of a precursor feed comprising an acyclic siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim 1640

The invention of any preceding claim, in which in which the tie coating or layer is applied by PECVD of a precursor feed comprising an acyclic siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a silatrane, a silquasilatrane, a silproatrane, or a combination of any two or more of these precursors.

### Claim 1641

The invention of any preceding claim, in which the tie coating or layer is applied by PECVD of a precursor feed comprising a monocyclic siloxane.

### Claim 1642

The invention of any preceding claim, in which the tie coating or layer is applied by PECVD of a precursor feed comprising octamethylcyclotetrasiloxane (OMCTS).

### Claim at position 1529

1642a. The invention of any preceding claim, in which the tie coating or layer is applied by PECVD of a precursor feed comprising tetramethyldisiloxane (TMDSO).

### Claim at position 1530

1642b. The invention of any preceding claim, in which the tie coating or layer is applied by PECVD of a precursor feed comprising hexamethyldisiloxane (HMDSO).

### Claim 1643

The invention of any preceding claim, in which the tie coating or layer is applied by PECVD of a precursor feed consisting essentially of octamethylcyclotetrasiloxane (OMCTS).

### Claim at position 1532

1643a. The invention of any preceding claim, in which the tie coating or layer is applied by PECVD of a precursor feed consisting essentially of tetramethyldisiloxane (TMDSO).

### Claim at position 1533

1643b. The invention of any preceding claim, in which the tie coating or layer is applied by PECVD of a precursor feed consisting essentially of hexamethyldisiloxane (HMDSO).

### Claim 1644

The invention of any preceding claim, in which the tie coating or layer is applied by PECVD of a precursor feed comprising a acyclic silazane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.

### Claim at position 1535 (depends on 1639, 1640, 1641, 1642, 1643, 1644)

1644A. The invention of any preceding claim 1639-1644, in which the precursor feed for the tie coating or layer further comprises oxygen.

### Claim at position 1536 (depends on 1639, 1640, 1641, 1642, 1643, 1644)

1644B. The invention of any preceding claim 1639-1644A, in which the precursor feed for the tie coating or layer further comprises a carrier gas.

### Claim at position 1537 (depends on 1644)

1644C. The invention of any preceding claim 1644B, in which the carrier gas for the tie coating or layer comprises argon.

### Claim at position 1538 (depends on 1639, 1640, 1641, 1642, 1643, 1644)

1644D. The invention of any preceding claim 1639-1644C, in which the precursor feed for the tie coating or layer comprises:
from 0.5 to 10 standard volumes of the organosilicon precursor;
from 0.1 to 10 standard volumes of oxygen; and
from 1 to 120 sccm of a carrier gas.

### Claim at position 1539 (depends on 1639, 1640, 1641, 1642, 1643, 1644)

1644E. The invention of any preceding claim 1639-1644D, in which:
the organosilicon precursor for the tie coating or layer comprises TMDSO; and
the carrier gas for the tie coating or layer comprises Argon.

### Claim at position 1540 (depends on 1639, 1640, 1641, 1642, 1643, 1644)

1644F. The invention of any preceding claim 1639-1644D, in which:
the organosilicon precursor for the tie coating or layer comprises HMDSO; and
the carrier gas for the tie coating or layer comprises Argon.

### Claim 1645

The invention of any preceding claim, in which the tie coating or layer is on average between 5 and 200 nm thick.

### Claim 1646

The invention of any preceding claim, in which the tie coating or layer on average is between 5 and 100 nm thick.

### Claim 1647

The invention of any preceding claim, in which the tie coating or layer on average is between 10 and 100 nm thick.

### Claim 1648

The invention of any preceding claim, in which the tie coating or layer on average is between 10 and 50 nm thick.

### Claim 1649 (depends on 1401, 1403, 1659)

The invention of any preceding claim 1401 or 1403-1659, in which the tie coating or layer is at least coextensive with the barrier coating or layer.

### Claim 1650

The invention of any preceding claim in which the barrier coating or layer on average is between 10 and 200 nm thick.

### Claim 1651

The invention of any preceding claim in which the barrier coating or layer on average is between 10 and 100 nm thick.

### Claim 1652

The invention of any preceding claim in which the pH protective coating or layer on average is between 50 and 400 nm thick.

### Claim 1653

The invention of any preceding claim in which the pH protective coating or layer on average is between 50 and 250 nm thick.

### Claim 1654

The invention of any preceding claim, in which the range of thickness of the tie coating or layer is between 5 and 200 nm thick.

### Claim 1655

The invention of any preceding claim, in which the range of thickness of the tie coating or layer is between 5 and 100 nm thick.

### Claim 1656

The invention of any preceding claim, in which the range of thickness of the tie coating or layer is between 10 and 100 nm thick.

### Claim 1657

The invention of any preceding claim, in which the range of thickness of the tie coating or layer is between 10 and 50 nm thick.

### Claim 1658

The invention of any preceding claim in which the range of thickness of the barrier coating or layer is between 10 and 200 nm thick.

### Claim 1660

The invention of any preceding claim in which the range of thickness of the barrier coating or layer is between 10 and 100 nm thick.

### Claim 1661

The invention of any preceding claim in which the range of thickness of the pH protective coating or layer is between 50 and 400 nm thick.

### Claim 1662

The invention of any preceding claim in which the range of thickness of the pH protective coating or layer is between 50 and 250 nm thick.

### Claim 1663

The invention of any preceding claim, in which the fluid comprises a member selected from the group consisting of:
INHALATION ANESTHETICS
Aliflurane
Chloroform
Cyclopropane
Desflurane (Suprane)
Diethyl Ether
Enflurane (Ethrane)
Ethyl Chloride
Ethylene
Halothane (Fluothane)
Isoflurane (Forane, Isoflo)
Isopropenyl vinyl ether
Methoxyflurane
methoxyflurane,
Methoxypropane
Nitrous Oxide
Roflurane
Sevoflurane (Sevorane, Ultane, Sevoflo)
Teflurane
Trichloroethylene
Vinyl Ether
Xenon
INJECTABLE DRUGS
Ablavar (Gadofosveset Trisodium Injection)
Abarelix Depot
Abobotulinumtoxin A Injection (Dysport)
ABT-263
ABT-869
ABX-EFG
Accretropin (Somatropin Injection)
Acetadote (Acetylcysteine Injection)
Acetazolamide Injection (Acetazolamide Injection)
Acetylcysteine Injection (Acetadote)
Actemra (Tocilizumab Injection)
Acthrel (Corticorelin Ovine Triflutate for Injection)
Actummune
Activase
Acyclovir for Injection (Zovirax Injection)
Adacel
Adalimumab
Adenoscan (Adenosine Injection)
Adenosine Injection (Adenoscan)
Adrenaclick
AdreView (Iobenguane I 123 Injection for Intravenous Use)
Afluria
Ak-Fluor (Fluorescein Injection)
Aldurazyme (Laronidase)
Alglucerase Injection (Ceredase)
Alkeran Injection (Melphalan Hcl Injection)
Allopurinol Sodium for Injection (Aloprim)
Aloprim (Allopurinol Sodium for Injection)
Alprostadil
Alsuma (Sumatriptan Injection)
ALTU-238
Amino Acid Injections
Aminosyn
Apidra
Apremilast
Alprostadil Dual Chamber System for Injection (Caverject Impulse)
AMG 009
AMG 076
AMG 102
AMG 108
AMG 114
AMG 162
AMG 220
AMG 221
AMG 222
AMG 223
AMG 317
AMG 379
AMG 386
AMG 403
AMG 477
AMG 479
AMG 517
AMG 531
AMG 557
AMG 623
AMG 655
AMG 706
AMG 714
AMG 745
AMG 785
AMG 811
AMG 827
AMG 837
AMG 853
AMG 951
Amiodarone HCl Injection (Amiodarone HCl Injection)
Amobarbital Sodium Injection (Amytal Sodium)
Amytal Sodium (Amobarbital Sodium Injection)
Anakinra
Anti-Abeta
Anti-Beta7
Anti-Beta20
Anti-CD4
Anti-CD20
Anti-CD40
Anti-IFNalpha
Anti-IL13
Anti-OX40L
Anti-oxLDS
Anti-NGF
Anti-NRP1
Arixtra
Amphadase (Hyaluronidase Inj)
Ammonul (Sodium Phenylacetate and Sodium Benzoate Injection)
Anaprox
Anzemet Injection (Dolasetron Mesylate Injection)
Apidra (Insulin Glulisine [rDNA origin] Inj)
Apomab
Aranesp (darbepoetin alfa)
Argatroban (Argatroban Injection)
Arginine Hydrochloride Injection (R-Gene 10)
Aristocort
Aristospan
Arsenic Trioxide Injection (Trisenox)
Articane HCl and Epinephrine Injection (Septocaine)
Arzerra (Ofatumumab Injection)
Asclera (Polidocanol Injection)
Ataluren
Ataluren-DMD
Atenolol Inj (Tenormin I.V. Injection)
Atracurium Besylate Injection (Atracurium Besylate Injection)
Avastin
Azactam Injection (Aztreonam Injection)
Azithromycin (Zithromax Injection)
Aztreonam Injection (Azactam Injection)
Baclofen Injection (Lioresal Intrathecal)
Bacteriostatic Water (Bacteriostatic Water for Injection)
Baclofen Injection (Lioresal Intrathecal)
Bal in Oil Ampules (Dimercarprol Injection)
BayHepB
BayTet
Benadryl
Bendamustine Hydrochloride Injection (Treanda)
Benztropine Mesylate Injection (Cogentin)
Betamethasone Injectable Suspension (Celestone Soluspan)
Bexxar
Bicillin C-R 900/300 (Penicillin G Benzathine and Penicillin G Procaine Injection)
Blenoxane (Bleomycin Sulfate Injection)
Bleomycin Sulfate Injection (Blenoxane)
Boniva Injection (Ibandronate Sodium Injection)
Botox Cosmetic (OnabotulinumtoxinA for Injection)
BR3-FC
Bravelle (Urofollitropin Injection)
Bretylium (Bretylium Tosylate Injection)
Brevital Sodium (Methohexital Sodium for Injection)
Brethine
Briobacept
BTT-1023
Bupivacaine HCl
Byetta
Ca-DTPA (Pentetate Calcium Trisodium Inj)
Cabazitaxel Injection (Jevtana)
Caffeine Alkaloid (Caffeine and Sodium Benzoate Injection)
Calcijex Injection (Calcitrol)
Calcitrol (Calcijex Injection)
Calcium Chloride (Calcium Chloride Injection 10%)
Calcium Disodium Versenate (Edetate Calcium Disodium Injection)
Campath (Altemtuzumab)
Camptosar Injection (Irinotecan Hydrochloride)
Canakinumab Injection (Ilaris)
Capastat Sulfate (Capreomycin for Injection)
Capreomycin for Injection (Capastat Sulfate)
Cardiolite (Prep kit for Technetium Tc99 Sestamibi for Injection)
Carticel
Cathflo
Cefazolin and Dextrose for Injection (Cefazolin Injection)
Cefepime Hydrochloride
Cefotaxime
Ceftriaxone
Cerezyme
Carnitor Injection
Caverject
Celestone Soluspan
Celsior
Cerebyx (Fosphenytoin Sodium Injection)
Ceredase (Alglucerase Injection)
Ceretec (Technetium Tc99m Exametazime Injection)
Certolizumab
CF-101
Chloramphenicol Sodium Succinate (Chloramphenicol Sodium Succinate Injection)
Chloramphenicol Sodium Succinate Injection (Chloramphenicol Sodium Succinate)
Cholestagel (Colesevelam HCL)
Choriogonadotropin Alfa Injection (Ovidrel)
Cimzia
Cisplatin (Cisplatin Injection)
Clolar (Clofarabine Injection)
Clomiphine Citrate
Clonidine Injection (Duraclon)
Cogentin (Benztropine Mesylate Injection)
Colistimethate Injection (Coly-Mycin M)
Coly-Mycin M (Colistimethate Injection)
Compath
Conivaptan Hcl Injection (Vaprisol)
Conjugated Estrogens for Injection (Premarin Injection)
Copaxone
Corticorelin Ovine Triflutate for Injection (Acthrel)
Corvert (Ibutilide Fumarate Injection)
Cubicin (Daptomycin Injection)
CF-101
Cyanokit (Hydroxocobalamin for Injection)
Cytarabine Liposome Injection (DepoCyt)
Cyanocobalamin
Cytovene (ganciclovir)
D.H.E. 45
Dacetuzumab
Dacogen (Decitabine Injection)
Dalteparin
Dantrium IV (Dantrolene Sodium for Injection)
Dantrolene Sodium for Injection (Dantrium IV)
Daptomycin Injection (Cubicin)
Darbepoietin Alfa
DDAVP Injection (Desmopressin Acetate Injection)
Decavax
Decitabine Injection (Dacogen)
Dehydrated Alcohol (Dehydrated Alcohol Injection)
Denosumab Injection (Prolia)
Delatestryl
Delestrogen
Delteparin Sodium
Depacon (Valproate Sodium Injection)
Depo Medrol (Methylprednisolone Acetate Injectable Suspension)
DepoCyt (Cytarabine Liposome Injection)
DepoDur (Morphine Sulfate XR Liposome Injection)
Desmopressin Acetate Injection (DDAVP Injection)
Depo-Estradiol
Depo-Provera 104 mg/ml
Depo-Provera 150 mg/ml
Depo-Testosterone
Dexrazoxane for Injection, Intravenous Infusion Only (Totect)
Dextrose/Electrolytes
Dextrose and Sodium Chloride Inj (Dextrose 5% in 0.9% Sodium Chloride)
Dextrose
Diazepam Injection (Diazepam Injection)
Digoxin Injection (Lanoxin Injection)
Dilaudid-HP (Hydromorphone Hydrochloride Injection)
Dimercarprol Injection (Bal in Oil Ampules)
Diphenhydramine Injection (Benadryl Injection)
Dipyridamole Injection (Dipyridamole Injection)
DMOAD
Docetaxel for Injection (Taxotere)
Dolasetron Mesylate Injection (Anzemet Injection)
Doribax (Doripenem for Injection)
Doripenem for Injection (Doribax)
Doxercalciferol Injection (Hectorol Injection)
Doxil (Doxorubicin Hcl Liposome Injection)
Doxorubicin Hcl Liposome Injection (Doxil)
Duraclon (Clonidine Injection)
Duramorph (Morphine Injection)
Dysport (Abobotulinumtoxin A Injection)
Ecallantide Injection (Kalbitor)
EC-Naprosyn (naproxen)
Edetate Calcium Disodium Injection (Calcium Disodium Versenate)
Edex (Alprostadil for Injection)
Engerix
Edrophonium Injection (Enlon)
Eliglustat Tartate
Eloxatin (Oxaliplatin Injection)
Emend Injection (Fosaprepitant Dimeglumine Injection)
Enalaprilat Injection (Enalaprilat Injection)
Enlon (Edrophonium Injection)
Enoxaparin Sodium Injection (Lovenox)
Eovist (Gadoxetate Disodium Injection)
Enbrel (etanercept)
Enoxaparin
Epicel
Epinepherine
Epipen
Epipen Jr.
Epratuzumab
Erbitux
Ertapenem Injection (Invanz)
Erythropoieten
Essential Amino Acid Injection (Nephramine)
Estradiol Cypionate
Estradiol Valerate
Etanercept
Exenatide Injection (Byetta)
Evlotra
Fabrazyme (Adalsidase beta)
Famotidine Injection
FDG (Fludeoxyglucose F 18 Injection)
Feraheme (Ferumoxytol Injection)
Feridex I.V. (Ferumoxides Injectable Solution)
Fertinex
Ferumoxides Injectable Solution (Feridex I.V.)
Ferumoxytol Injection (Feraheme)
Flagyl Injection (Metronidazole Injection)
Fluarix
Fludara (Fludarabine Phosphate)
Fludeoxyglucose F 18 Injection (FDG)
Fluorescein Injection (Ak-Fluor)
Follistim AQ Cartridge (Follitropin Beta Injection)
Follitropin Alfa Injection (Gonal-f RFF)
Follitropin Beta Injection (Follistim AQ Cartridge)
Folotyn (Pralatrexate Solution for Intravenous Injection)
Fondaparinux
Forteo (Teriparatide (rDNA origin) Injection)
Fostamatinib
Fosaprepitant Dimeglumine Injection (Emend Injection)
Foscarnet Sodium Injection (Foscavir)
Foscavir (Foscarnet Sodium Injection)
Fosphenytoin Sodium Injection (Cerebyx)
Fospropofol Disodium Injection (Lusedra)
Fragmin
Fuzeon (enfuvirtide)
GA101
Gadobenate Dimeglumine Injection (Multihance)
Gadofosveset Trisodium Injection (Ablavar)
Gadoteridol Injection Solution (ProHance)
Gadoversetamide Injection (OptiMARK)
Gadoxetate Disodium Injection (Eovist)
Ganirelix (Ganirelix Acetate Injection)
Gardasil
GC1008
GDFD
Gemtuzumab Ozogamicin for Injection (Mylotarg)
Genotropin
Gentamicin Injection
GENZ-112638
Golimumab Injection (Simponi Injection)
Gonal-f RFF (Follitropin Alfa Injection)
Granisetron Hydrochloride (Kytril Injection)
Gentamicin Sulfate
Glatiramer Acetate
Glucagen
Glucagon
HAE1
Haldol (Haloperidol Injection)
Havrix
Hectorol Injection (Doxercalciferol Injection)
Hedgehog Pathway Inhibitor
Heparin
Herceptin
hG-CSF
Humalog
Human Growth Hormone
Humatrope
HuMax
Humegon
Humira
Humulin
Ibandronate Sodium Injection (Boniva Injection)
Ibuprofen Lysine Injection (NeoProfen)
Ibutilide Fumarate Injection (Corvert)
Idamycin PFS (Idarubicin Hydrochloride Injection)
Idarubicin Hydrochloride Injection (Idamycin PFS)
Ilaris (Canakinumab Injection)
Imipenem and Cilastatin for Injection (Primaxin I.V.)
Imitrex
Incobotulinumtoxin A for Injection (Xeomin)
Increlex (Mecasermin [rDNA origin] Injection)
Indocin IV (Indomethacin Inj)
Indomethacin Inj (Indocin IV)
Infanrix
Innohep
Insulin
Insulin Aspart [rDNA origin] Inj (NovoLog)
Insulin Glargine [rDNA origin] Injection (Lantus)
Insulin Glulisine [rDNA origin] Inj (Apidra)
Interferon alfa-2b, Recombinant for Injection (Intron A)
Intron A (Interferon alfa-2b, Recombinant for Injection)
Invanz (Ertapenem Injection)
Invega Sustenna (Paliperidone Palmitate Extended-Release Injectable Suspension)
Invirase (saquinavir mesylate)
Iobenguane I 123 Injection for Intravenous Use (AdreView)
Iopromide Injection (Ultravist)
Ioversol Injection (Optiray Injection)
Iplex (Mecasermin Rinfabate [rDNA origin] Injection)
Iprivask
Irinotecan Hydrochloride (Camptosar Injection)
Iron Sucrose Injection (Venofer)
Istodax (Romidepsin for Injection)
Itraconazole Injection (Sporanox Injection)
Jevtana (Cabazitaxel Injection)
Jonexa
Kalbitor (Ecallantide Injection)
KCL in DSNS (Potassium Chloride in 5% Dextrose and Sodium Chloride Injection)
KCL in D5 W
KCL in NS
Kenalog 10 Injection (Triamcinolone Acetonide Injectable Suspension)
Kepivance (Palifermin)
Keppra Injection (Levetiracetam)
Keratinocyte
KFG
Kinase Inhibitor
Kineret (Anakinra)
Kinlytic (Urokinase Injection)
Kinrix
Klonopin (clonazepam)
Kytril Injection (Granisetron Hydrochloride)
lacosamide Tablet and Injection (Vimpat)
Lactated Ringer's
Lanoxin Injection (Digoxin Injection)
Lansoprazole for Injection (Prevacid I.V.)
Lantus
Leucovorin Calcium (Leucovorin Calcium Injection)
Lente (L)
Leptin
Levemir
Leukine Sargramostim
Leuprolide Acetate
Levothyroxine
Levetiracetam (Keppra Injection)
Lovenox
Levocarnitine Injection (Carnitor Injection)
Lexiscan (Regadenoson Injection)
Lioresal Intrathecal (Baclofen Injection)
Liraglutide [rDNA] Injection (Victoza)
Lovenox (Enoxaparin Sodium Injection)
Lucentis (Ranibizumab Injection)
Lumizyme
Lupron (Leuprolide Acetate Injection)
Lusedra (Fospropofol Disodium Injection)
Maci
Magnesium Sulfate (Magnesium Sulfate Injection)
Mannitol Injection (Mannitol IV)
Marcaine (Bupivacaine Hydrochloride and Epinephrine Injection)
Maxipime (Cefepime Hydrochloride for Injection)
MDP Multidose Kit of Technetium Injection (Technetium Tc99m Medronate Injection)
Mecasermin [rDNA origin] Injection (Increlex)
Mecasermin Rinfabate [rDNA origin] Injection (Iplex)
Melphalan Hcl Injection (Alkeran Injection)
Methotrexate
Menactra
Menopur (Menotropins Injection)
Menotropins for Injection (Repronex)
Methohexital Sodium for Injection (Brevital Sodium)
Methyldopate Hydrochloride Injection, Solution (Methyldopate Hcl)
Methylene Blue (Methylene Blue Injection)
Methylprednisolone Acetate Injectable Suspension (Depo Medrol)
MetMab
Metoclopramide Injection (Reglan Injection)
Metrodin (Urofollitropin for Injection)
Metronidazole Injection (Flagyl Injection)
Miacalcin
Midazolam (Midazolam Injection)
Mimpara (Cinacalet)
Minocin Injection (Minocycline Inj)
Minocycline Inj (Minocin Injection)
Mipomersen
Mitoxantrone for Injection Concentrate (Novantrone)
Morphine Injection (Duramorph)
Morphine Sulfate XR Liposome Injection (DepoDur)
Morrhuate Sodium (Morrhuate Sodium Injection)
Motesanib
Mozobil (Plerixafor Injection)
Multihance (Gadobenate Dimeglumine Injection)
Multiple Electrolytes and Dextrose Injection
Multiple Electrolytes Injection
Mylotarg (Gemtuzumab Ozogamicin for Injection)
Myozyme (Alglucosidase alfa)
Nafcillin Injection (Nafcillin Sodium)
Nafcillin Sodium (Nafcillin Injection)
Naltrexone XR Inj (Vivitrol)
Naprosyn (naproxen)
NeoProfen (Ibuprofen Lysine Injection)
Nandrol Decanoate
Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection)
NEO-GAA
NeoTect (Technetium Tc 99m Depreotide Injection)
Nephramine (Essential Amino Acid Injection)
Neulasta (pegfilgrastim)
Neupogen (Filgrastim)
Novolin
Novolog
NeoRecormon
Neutrexin (Trimetrexate Glucuronate Inj)
NPH (N)
Nexterone (Amiodarone HCl Injection)
Norditropin (Somatropin Injection)
Normal Saline (Sodium Chloride Injection)
Novantrone (Mitoxantrone for Injection Concentrate)
Novolin 70/30 Innolet (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection)
NovoLog (Insulin Aspart [rDNA origin] Inj)
Nplate (romiplostim)
Nutropin (Somatropin (rDNA origin) for Inj)
Nutropin AQ
Nutropin Depot (Somatropin (rDNA origin) for Inj)
Octreotide Acetate Injection (Sandostatin LAR)
Ocrelizumab
Ofatumumab Injection (Arzerra)
Olanzapine Extended Release Injectable Suspension (Zyprexa Relprevv)
Omnitarg
Omnitrope (Somatropin [rDNA origin] Injection)
Ondansetron Hydrochloride Injection (Zofran Injection)
OptiMARK (Gadoversetamide Injection)
Optiray Injection (Ioversol Injection)
Orencia
Osmitrol Injection in Aviva (Mannitol Injection in Aviva Plastic Vessel)
Osmitrol Injection in Viaflex (Mannitol Injection in Viaflex Plastic Vessel)
Osteoprotegrin
Ovidrel (Choriogonadotropin Alfa Injection)
Oxacillin (Oxacillin for Injection)
Oxaliplatin Injection (Eloxatin)
Oxytocin Injection (Pitocin)
Paliperidone Palmitate Extended-Release Injectable Suspension (Invega Sustenna)
Pamidronate Disodium Injection (Pamidronate Disodium Injection)
Panitumumab Injection for Intravenous Use (Vectibix)
Papaverine Hydrochloride Injection (Papaverine Injection)
Papaverine Injection (Papaverine Hydrochloride Injection)
Parathyroid Hormone
Paricalcitol Injection Fliptop Vial (Zemplar Injection)
PARP Inhibitor
Pediarix
PEGIntron
Peginterferon
Pegfilgrastim
Penicillin G Benzathine and Penicillin G Procaine
Pentetate Calcium Trisodium Inj (Ca-DTPA)
Pentetate Zinc Trisodium Injection (Zn-DTPA)
Pepcid Injection (Famotidine Injection)
Pergonal
Pertuzumab
Phentolamine Mesylate (Phentolamine Mesylate for Injection)
Physostigmine Salicylate (Physostigmine Salicylate (injection))
Physostigmine Salicylate (injection) (Physostigmine Salicylate)
Piperacillin and Tazobactam Injection (Zosyn)
Pitocin (Oxytocin Injection)
Plasma-Lyte 148 (Multiple Electrolytes Inj)
Plasma-Lyte 56 and Dextrose (Multiple Electrolytes and Dextrose Injection in Viaflex
Plastic Vessel)
PlasmaLyte
Plerixafor Injection (Mozobil)
Polidocanol Injection (Asclera)
Potassium Chloride
Pralatrexate Solution for Intravenous Injection (Folotyn)
Pramlintide Acetate Injection (Symlin)
Premarin Injection (Conjugated Estrogens for Injection)
Prep kit for Technetium Tc99 Sestamibi for Injection (Cardiolite)
Prevacid I.V. (Lansoprazole for Injection)
Primaxin I.V. (Imipenem and Cilastatin for Injection)
Prochymal
Procrit
Progesterone
ProHance (Gadoteridol Injection Solution)
Prolia (Denosumab Injection)
Promethazine HCl Injection (Promethazine Hydrochloride Injection)
Propranolol Hydrochloride Injection (Propranolol Hydrochloride Injection)
Quinidine Gluconate Injection (Quinidine Injection)
Quinidine Injection (Quinidine Gluconate Injection)
R-Gene 10 (Arginine Hydrochloride Injection)
Ranibizumab Injection (Lucentis)
Ranitidine Hydrochloride Injection (Zantac Injection)
Raptiva
Reclast (Zoledronic Acid Injection)
Recombivarix HB
Regadenoson Injection (Lexiscan)
Reglan Injection (Metoclopramide Injection)
Remicade
Renagel
Renvela (Sevelamer Carbonate)
Repronex (Menotropins for Injection)
Retrovir IV (Zidovudine Injection)
rhApo2L/TRAIL
Ringer's and 5% Dextrose Injection (Ringers in Dextrose)
Ringer's Injection (Ringers Injection)
Rituxan
Rituximab
Rocephin (ceftriaxone)
Rocuronium Bromide Injection (Zemuron)
Roferon-A (interferon alfa-2a)
Romazicon (flumazenil)
Romidepsin for Injection (Istodax)
Saizen (Somatropin Injection)
Sandostatin LAR (Octreotide Acetate Injection)
Sclerostin Ab
Sensipar (cinacalcet)
Sensorcaine (Bupivacaine HCl Injections)
Septocaine (Articane HCl and Epinephrine Injection)
Serostim LQ (Somatropin (rDNA origin) Injection)
Simponi Injection (Golimumab Injection)
Sodium Acetate (Sodium Acetate Injection)
Sodium Bicarbonate (Sodium Bicarbonate 5% Injection)
Sodium Lactate (Sodium Lactate Injection in AVIVA)
Sodium Phenylacetate and Sodium Benzoate Injection (Ammonul)
Somatropin (rDNA origin) for Inj (Nutropin)
Sporanox Injection (Itraconazole Injection)
Stelara Injection (Ustekinumab)
Stemgen
Sufenta (Sufentanil Citrate Injection)
Sufentanil Citrate Injection (Sufenta)
Sumavel
Sumatriptan Injection (Alsuma)
Symlin
Symlin Pen
Systemic Hedgehog Antagonist
Synvisc-One (Hylan G-F 20 Single Intra-articular Injection)
Tarceva
Taxotere (Docetaxel for Injection)
Technetium Tc 99m
Telavancin for Injection (Vibativ)
Temsirolimus Injection (Torisel)
Tenormin I.V. Injection (Atenolol Inj)
Teriparatide (rDNA origin) Injection (Forteo)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Propionate
Tev-Tropin (Somatropin, rDNA Origin, for Injection)
tgAAC94
Thallous Chloride
Theophylline
Thiotepa (Thiotepa Injection)
Thymoglobulin (Anti-Thymocyte Globulin (Rabbit)
Thyrogen (Thyrotropin Alfa for Injection)
Ticarcillin Disodium and Clavulanate Potassium Galaxy (Timentin Injection)
Tigan Injection (Trimethobenzamide Hydrochloride Injectable)
Timentin Injection (Ticarcillin Disodium and Clavulanate Potassium Galaxy)
TNKase
Tobramycin Injection (Tobramycin Injection)
Tocilizumab Injection (Actemra)
Torisel (Temsirolimus Injection)
Totect (Dexrazoxane for Injection, Intravenous Infusion Only)
Trastuzumab-DM1
Travasol (Amino Acids (Injection))
Treanda (Bendamustine Hydrochloride Injection)
Trelstar (Triptorelin Pamoate for Injectable Suspension)
Triamcinolone Acetonide
Triamcinolone Diacetate
Triamcinolone Hexacetonide Injectable Suspension (Aristospan Injection 20 mg)
Triesence (Triamcinolone Acetonide Injectable Suspension)
Trimethobenzamide Hydrochloride Injectable (Tigan Injection)
Trimetrexate Glucuronate Inj (Neutrexin)
Triptorelin Pamoate for Injectable Suspension (Trelstar)
Twinject
Trivaris (Triamcinolone Acetonide Injectable Suspension)
Trisenox (Arsenic Trioxide Injection)
Twinrix
Typhoid Vi
Ultravist (Iopromide Injection)
Urofollitropin for Injection (Metrodin)
Urokinase Injection (Kinlytic)
Ustekinumab (Stelara Injection)
Ultralente (U)
Valium (diazepam)
Valproate Sodium Injection (Depacon)
Valtropin (Somatropin Injection)
Vancomycin Hydrochloride (Vancomycin Hydrochloride Injection)
Vancomycin Hydrochloride Injection (Vancomycin Hydrochloride)
Vaprisol (Conivaptan Hcl Injection)
VAQTA
Vasovist (Gadofosveset Trisodium Injection for Intravenous Use)
Vectibix (Panitumumab Injection for Intravenous Use)
Venofer (Iron Sucrose Injection)
Verteporfin Inj (Visudyne)
Vibativ (Telavancin for Injection)
Victoza (Liraglutide [rDNA] Injection)
Vimpat (lacosamide Tablet and Injection)
Vinblastine Sulfate (Vinblastine Sulfate Injection)
Vincasar PFS (Vincristine Sulfate Injection)
Victoza
Vincristine Sulfate (Vincristine Sulfate Injection)
Visudyne (Verteporfin Inj)
Vitamin B-12
Vivitrol (Naltrexone XR Inj)
Voluven (Hydroxyethyl Starch in Sodium Chloride Injection)
Xeloda
Xenical (orlistat)
Xeomin (Incobotulinumtoxin A for Injection)
Xolair
Zantac Injection (Ranitidine Hydrochloride Injection)
Zemplar Injection (Paricalcitol Injection Fliptop Vial)
Zemuron (Rocuronium Bromide Injection)
Zenapax (daclizumab)
Zevalin
Zidovudine Injection (Retrovir IV)
Zithromax Injection (Azithromycin)
Zn-DTPA (Pentetate Zinc Trisodium Injection)
Zofran Injection (Ondansetron Hydrochloride Injection)
Zingo
Zoledronic Acid for Inj (Zometa)
Zoledronic Acid Injection (Reclast)
Zometa (Zoledronic Acid for Inj)
Zosyn (Piperacillin and Tazobactam Injection)
Zyprexa Relprevv (Olanzapine Extended Release Injectable Suspension)
LIQUID DRUGS (NON-INJECTABLE)
Abilify
AccuNeb (Albuterol Sulfate Inhalation Solution)
Actidose Aqua (Activated Charcoal Suspension)
Activated Charcoal Suspension (Actidose Aqua)
Advair
Agenerase Oral Solution (Amprenavir Oral Solution)
Akten (Lidocaine Hydrochloride Ophthalmic Gel)
Alamast (Pemirolast Potassium Ophthalmic Solution)
Albumin (Human) 5% Solution (Buminate 5%)
Albuterol Sulfate Inhalation Solution
Alinia
Alocril
Alphagan
Alrex
Alvesco
Amprenavir Oral Solution
Analpram-HC
Arformoterol Tartrate Inhalation Solution (Brovana)
Aristospan Injection 20 mg (Triamcinolone Hexacetonide Injectable Suspension)
Asacol
Asmanex
Astepro
Astepro (Azelastine Hydrochloride Nasal Spray)
Atrovent Nasal Spray (Ipratropium Bromide Nasal Spray)
Atrovent Nasal Spray 0.06
Augmentin ES-600
Azasite (Azithromycin Ophthalmic Solution)
Azelaic Acid (Finacea Gel)
Azelastine Hydrochloride Nasal Spray (Astepro)
Azelex (Azelaic Acid Cream)
Azopt (Brinzolamide Ophthalmic Suspension)
Bacteriostatic Saline
Balanced Salt
Bepotastine
Bactroban Nasal
Bactroban
Beclovent
Benzac W
Betimol
Betoptic S
Bepreve
Bimatoprost Ophthalmic Solution
Bleph 10 (Sulfacetamide Sodium Ophthalmic Solution 10%)
Brinzolamide Ophthalmic Suspension (Azopt)
Bromfenac Ophthalmic Solution (Xibrom)
Bromhist
Brovana (Arformoterol Tartrate Inhalation Solution)
Budesonide Inhalation Suspension (Pulmicort Respules)
Cambia (Diclofenac Potassium for Oral Solution)
Capex
Carac
Carboxine-PSE
Carnitor
Cayston (Aztreonam for Inhalation Solution)
Cellcept
Centany
Cerumenex
Ciloxan Ophthalmic Solution (Ciprofloxacin HCL Ophthalmic Solution)
Ciprodex
Ciprofloxacin HCL Ophthalmic Solution (Ciloxan Ophthalmic Solution)
Clemastine Fumarate Syrup (Clemastine Fumarate Syrup)
CoLyte (PEG Electrolytes Solution)
Combiven
Comtan
Condylox
Cordran
Cortisporin Ophthalmic Suspension
Cortisporin Otic Suspension
Cromolyn Sodium Inhalation Solution (Intal Nebulizer Solution)
Cromolyn Sodium Ophthalmic Solution (Opticrom)
Crystalline Amino Acid Solution with Electrolytes (Aminosyn Electrolytes)
Cutivate
Cuvposa (Glycopyrrolate Oral Solution)
Cyanocobalamin (CaloMist Nasal Spray)
Cyclosporine Oral Solution (Gengraf Oral Solution)
Cyclogyl
Cysview (Hexaminolevulinate Hydrochloride Intravesical Solution)
DermOtic Oil (Fluocinolone Acetonide Oil Ear Drops)
Desmopressin Acetate Nasal Spray
DDAVP
Derma-Smoothe/FS
Dexamethasone Intensol
Dianeal Low Calcium
Dianeal PD
Diclofenac Potassium for Oral Solution (Cambia)
Didanosine Pediatric Powder for Oral Solution (Videx)
Differin
Dilantin 125 (Phenytoin Oral Suspension)
Ditropan
Dorzolamide Hydrochloride Ophthalmic Solution (Trusopt)
Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution (Cosopt)
Dovonex Scalp (Calcipotriene Solution)
Doxycycline Calcium Oral Suspension (Vibramycin Oral)
Efudex
Elaprase (Idursulfase Solution)
Elestat (Epinastine HCl Ophthalmic Solution)
Elocon
Epinastine HCl Ophthalmic Solution (Elestat)
Epivir HBV
Epogen (Epoetin alfa)
Erythromycin Topical Solution 1.5% (Staticin)
Ethiodol (Ethiodized Oil)
Ethosuximide Oral Solution (Zarontin Oral Solution)
Eurax
Extraneal (Icodextrin Peritoneal Dialysis Solution)
Felbatol
Feridex I.V. (Ferumoxides Injectable Solution)
Flovent
Floxin Otic (Ofloxacin Otic Solution)
Flo-Pred (Prednisolone Acetate Oral Suspension)
Fluoroplex
Flunisolide Nasal Solution (Flunisolide Nasal Spray 0.025%)
Fluorometholone Ophthalmic Suspension (FML)
Flurbiprofen Sodium Ophthalmic Solution (Ocufen)
FML
Foradil
Formoterol Fumarate Inhalation Solution (Perforomist)
Fosamax
Furadantin (Nitrofurantoin Oral Suspension)
Furoxone
Gammagard Liquid (Immune Globulin Intravenous (Human) 10%)
Gantrisin (Acetyl Sulfisoxazole Pediatric Suspension)
Gatifloxacin Ophthalmic Solution (Zymar)
Gengraf Oral Solution (Cyclosporine Oral Solution)
Glycopyrrolate Oral Solution (Cuvposa)
Halcinonide Topical Solution (Halog Solution)
Halog Solution (Halcinonide Topical Solution)
HEP-LOCK U/P (Preservative-Free Heparin Lock Flush Solution)
Heparin Lock Flush Solution (Hepflush 10)
Hexaminolevulinate Hydrochloride Intravesical Solution (Cysview)
Hydrocodone Bitartrate and Acetaminophen Oral Solution (Lortab Elixir)
Hydroquinone 3% Topical Solution (Melquin-3 Topical Solution)
IAP Antagonist
Isopto
Ipratropium Bromide Nasal Spray (Atrovent Nasal Spray)
Itraconazole Oral Solution (Sporanox Oral Solution)
Ketorolac Tromethamine Ophthalmic Solution (Acular LS)
Kaletra
Lanoxin
Lexiva
Leuprolide Acetate for Depot Suspension (Lupron Depot 11.25 mg)
Levobetaxolol Hydrochloride Ophthalmic Suspension (Betaxon)
Levocarnitine Tablets, Oral Solution, Sugar-Free (Carnitor)
Levofloxacin Ophthalmic Solution 0.5% (Quixin)
Lidocaine HCl Sterile Solution (Xylocaine MPF Sterile Solution)
Lok Pak (Heparin Lock Flush Solution)
Lorazepam Intensol
Lortab Elixir (Hydrocodone Bitartrate and Acetaminophen Oral Solution)
Lotemax (Loteprednol Etabonate Ophthalmic Suspension)
Loteprednol Etabonate Ophthalmic Suspension (Alrex)
Low Calcium Peritoneal Dialysis Solutions (Dianeal Low Calcium)
Lumigan (Bimatoprost Ophthalmic Solution 0.03% for Glaucoma)
Lupron Depot 11.25 mg (Leuprolide Acetate for Depot Suspension)
Megestrol Acetate Oral Suspension (Megestrol Acetate Oral Suspension)
MEK Inhibitor
Mepron
Mesnex
Mestinon
Mesalamine Rectal Suspension Enema (Rowasa)
Melquin-3 Topical Solution (Hydroquinone 3% Topical Solution)
MetMab
Methyldopate Hcl (Methyldopate Hydrochloride Injection, Solution)
Methylin Oral Solution (Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL)
Methylprednisolone Acetate Injectable Suspension (Depo Medrol)
Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL (Methylin Oral Solution)
Methylprednisolone sodium succinate (Solu Medrol)
Metipranolol Ophthalmic Solution (Optipranolol)
Migranal
Miochol-E (Acetylcholine Chloride Intraocular Solution)
Micro-K for Liquid Suspension (Potassium Chloride Extended Release Formulation for Liquid Suspension)
Minocin (Minocycline Hydrochloride Oral Suspension)
Nasacort
Neomycin and Polymyxin B Sulfates and Hydrocortisone
Nepafenac Ophthalmic Suspension (Nevanac)
Nevanac (Nepafenac Ophthalmic Suspension)
Nitrofurantoin Oral Suspension (Furadantin)
Noxafil (Posaconazole Oral Suspension)
Nystatin (oral) (Nystatin Oral Suspension)
Nystatin Oral Suspension (Nystatin (oral))
Ocufen (Flurbiprofen Sodium Ophthalmic Solution)
Ofloxacin Ophthalmic Solution (Ofloxacin Ophthalmic Solution)
Ofloxacin Otic Solution (Floxin Otic)
Olopatadine Hydrochloride Ophthalmic Solution (Pataday)
Opticrom (Cromolyn Sodium Ophthalmic Solution)
Optipranolol (Metipranolol Ophthalmic Solution)
Patanol
Pediapred
PerioGard
Phenytoin Oral Suspension (Dilantin 125)
Phisohex
Posaconazole Oral Suspension (Noxafil)
Potassium Chloride Extended Release Formulation for Liquid Suspension (Micro-K for Liquid Suspension)
Pataday (Olopatadine Hydrochloride Ophthalmic Solution)
Patanase Nasal Spray (Olopatadine Hydrochloride Nasal Spray)
PEG Electrolytes Solution (CoLyte)
Pemirolast Potassium Ophthalmic Solution (Alamast)
Penlac (Ciclopirox Topical Solution)
PENNSAID (Diclofenac Sodium Topical Solution)
Perforomist (Formoterol Fumarate Inhalation Solution)
Peritoneal Dialysis Solution
Phenylephrine Hydrochloride Ophthalmic Solution (Neo-Synephrine)
Phospholine Iodide (Echothiophate Iodide for Ophthalmic Solution)
Podofilox (Podofilox Topical Solution)
Pred Forte (Prednisolone Acetate Ophthalmic Suspension)
Pralatrexate Solution for Intravenous Injection (Folotyn)
Pred Mild
Prednisone Intensol
Prednisolone Acetate Ophthalmic Suspension (Pred Forte)
Prevacid
PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution)
ProAir
Proglycem
ProHance (Gadoteridol Injection Solution)
Proparacaine Hydrochloride Ophthalmic Solution (Alcaine)
Propine
Pulmicort
Pulmozyme
Quixin (Levofloxacin Ophthalmic Solution 0.5%)
QVAR
Rapamune
Rebetol
Relacon-HC
Rotarix (Rotavirus Vaccine, Live, Oral Suspension)
Rotavirus Vaccine, Live, Oral Suspension (Rotarix)
Rowasa (Mesalamine Rectal Suspension Enema)
Sabril (Vigabatrin Oral Solution)
Sacrosidase Oral Solution (Sucraid)
Sandimmune
Sepra
Serevent Diskus
Solu Cortef (Hydrocortisone Sodium Succinate)
Solu Medrol (Methylprednisolone sodium succinate)
Spiriva
Sporanox Oral Solution (Itraconazole Oral Solution)
Staticin (Erythromycin Topical Solution 1.5%)
Stalevo
Starlix
Sterile Hemofiltration Hemodiafiltration Solution (PrismaSol Solution)
Stimate
Sucralfate (Carafate Suspension)
Sulfacetamide Sodium Ophthalmic Solution 10% (Bleph 10)
Synarel Nasal Solution (Nafarelin Acetate Nasal Solution for Endometriosis)
Taclonex Scalp (Calcipotriene and Betamethasone Dipropionate Topical Suspension)
Tamiflu
Tobi
TobraDex
Tobradex ST (Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05%)
Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05% (Tobradex ST)
Timolol
Timoptic
Travatan Z
Treprostinil Inhalation Solution (Tyvaso)
Trusopt (Dorzolamide Hydrochloride Ophthalmic Solution)
Tyvaso (Treprostinil Inhalation Solution)
Ventolin
Vfend
Vibramycin Oral (Doxycycline Calcium Oral Suspension)
Videx (Didanosine Pediatric Powder for Oral Solution)
Vigabatrin Oral Solution (Sabril)
Viokase
Viracept
Viramune
Vitamin K1 (Fluid Colloidal Solution of Vitamin K1)
Voltaren Ophthalmic (Diclofenac Sodium Ophthalmic Solution)
Zarontin Oral Solution (Ethosuximide Oral Solution)
Ziagen
Zyvox
Zymar (Gatifloxacin Ophthalmic Solution)
Zymaxid (Gatifloxacin Ophthalmic Solution)
DRUG CLASSES
5-alpha-reductase inhibitors
5-aminosalicylates
5HT3 receptor antagonists
adamantane antivirals
adrenal cortical steroids
adrenal corticosteroid inhibitors
adrenergic bronchodilators
agents for hypertensive emergencies
agents for pulmonary hypertension
aldosterone receptor antagonists
alkylating agents
alpha-adrenoreceptor antagonists
alpha-glucosidase inhibitors
alternative medicines
amebicides
aminoglycosides
aminopenicillins
aminosalicylates
amylin analogs
Analgesic Combinations
Analgesics
androgens and anabolic steroids
angiotensin converting enzyme inhibitors
angiotensin II inhibitors
anorectal preparations
anorexiants
antacids
anthelmintics
anti-angiogenic ophthalmic agents
anti-CTLA-4 monoclonal antibodies
anti-infectives
antiadrenergic agents, centrally acting
antiadrenergic agents, peripherally acting
antiandrogens
antianginal agents
antiarrhythmic agents
antiasthmatic combinations
antibiotics/antineoplastics
anticholinergic antiemetics
anticholinergic antiparkinson agents
anticholinergic bronchodilators
anticholinergic chronotropic agents
anticholinergics/antispasmodics
anticoagulants
anticonvulsants
antidepressants
antidiabetic agents
antidiabetic combinations
antidiarrheals
antidiuretic hormones
antidotes
antiemetic/antivertigo agents
antifungals
antigonadotropic agents
antigout agents
antihistamines
antihyperlipidemic agents
antihyperlipidemic combinations
antihypertensive combinations
antihyperuricemic agents
antimalarial agents
antimalarial combinations
antimalarial quinolines
antimetabolites
antimigraine agents
antineoplastic detoxifying agents
antineoplastic interferons
antineoplastic monoclonal antibodies
antineoplastics
antiparkinson agents
antiplatelet agents
antipseudomonal penicillins
antipsoriatics
antipsychotics
antirheumatics
antiseptic and germicides
antithyroid agents
antitoxins and antivenins
antituberculosis agents
antituberculosis combinations
antitussives
antiviral agents
antiviral combinations
antiviral interferons
anxiolytics, sedatives, and hypnotics
aromatase inhibitors
atypical antipsychotics
azole antifungals
bacterial vaccines
barbiturate anticonvulsants
barbiturates
BCR-ABL tyrosine kinase inhibitors
benzodiazepine anticonvulsants
benzodiazepines
beta-adrenergic blocking agents
beta-lactamase inhibitors
bile acid sequestrants
biologicals
bisphosphonates
bone resorption inhibitors
bronchodilator combinations
bronchodilators
calcitonin
calcium channel blocking agents
carbamate anticonvulsants
carbapenems
carbonic anhydrase inhibitor anticonvulsants
carbonic anhydrase inhibitors
cardiac stressing agents
cardioselective beta blockers
cardiovascular agents
catecholamines
CD20 monoclonal antibodies
CD33 monoclonal antibodies
CD52 monoclonal antibodies
central nervous system agents
cephalosporins
cerumenolytics
chelating agents
chemokine receptor antagonist
chloride channel activators
cholesterol absorption inhibitors
cholinergic agonists
cholinergic muscle stimulants
cholinesterase inhibitors
CNS stimulants
coagulation modifiers
colony stimulating factors
contraceptives
corticotropin
coumarins and indandiones
cox-2 inhibitors
decongestants
dermatological agents
diagnostic radiopharmaceuticals
dibenzazepine anticonvulsants
digestive enzymes
dipeptidyl peptidase 4 inhibitors
diuretics
dopaminergic antiparkinsonism agents
drugs used in alcohol dependence
echinocandins
EGFR inhibitors
estrogen receptor antagonists
estrogens
expectorants
factor Xa inhibitors
fatty acid derivative anticonvulsants
fibric acid derivatives
first generation cephalosporins
fourth generation cephalosporins
functional bowel disorder agents
gallstone solubilizing agents
gamma-aminobutyric acid analogs
gamma-aminobutyric acid reuptake inhibitors
gamma-aminobutyric acid transaminase inhibitors
gastrointestinal agents
general anesthetics
genitourinary tract agents
GI stimulants
glucocorticoids
glucose elevating agents
glycopeptide antibiotics
glycoprotein platelet inhibitors
glycylcyclines
gonadotropin releasing hormones
gonadotropin-releasing hormone antagonists
gonadotropins
group I antiarrhythmics
group II antiarrhythmics
group III antiarrhythmics
group IV antiarrhythmics
group V antiarrhythmics
growth hormone receptor blockers
growth hormones
H. pylori eradication agents
H2 antagonists
hematopoietic stem cell mobilizer
heparin antagonists
heparins
HER2 inhibitors
herbal products
histone deacetylase inhibitors
hormone replacement therapy
hormones
hormones/antineoplastics
hydantoin anticonvulsants
illicit (street) drugs
immune globulins
immunologic agents
immunosuppressive agents
impotence agents
in vivo diagnostic biologicals
incretin mimetics
inhaled anti-infectives
inhaled corticosteroids
inotropic agents
insulin
insulin-like growth factor
integrase strand transfer inhibitor
interferons
intravenous nutritional products
iodinated contrast media
ionic iodinated contrast media
iron products
ketolides
laxatives
leprostatics
leukotriene modifiers
lincomycin derivatives
lipoglycopeptides
local injectable anesthetics
loop diuretics
lung surfactants
lymphatic staining agents
lysosomal enzymes
macrolide derivatives
macrolides
magnetic resonance imaging contrast media
mast cell stabilizers
medical gas
meglitinides
metabolic agents
methylxanthines
mineralocorticoids
minerals and electrolytes
miscellaneous agents
miscellaneous analgesics
miscellaneous antibiotics
miscellaneous anticonvulsants
miscellaneous antidepressants
miscellaneous antidiabetic agents
miscellaneous antiemetics
miscellaneous antifungals
miscellaneous antihyperlipidemic agents
miscellaneous antimalarials
miscellaneous antineoplastics
miscellaneous antiparkinson agents
miscellaneous antipsychotic agents
miscellaneous antituberculosis agents
miscellaneous antivirals
miscellaneous anxiolytics, sedatives and hypnotics
miscellaneous biologicals
miscellaneous bone resorption inhibitors
miscellaneous cardiovascular agents
miscellaneous central nervous system agents
miscellaneous coagulation modifiers
miscellaneous diuretics
miscellaneous genitourinary tract agents
miscellaneous GI agents
miscellaneous hormones
miscellaneous metabolic agents
miscellaneous ophthalmic agents
miscellaneous otic agents
miscellaneous respiratory agents
miscellaneous sex hormones
miscellaneous topical agents
miscellaneous uncategorized agents
miscellaneous vaginal agents
mitotic inhibitors
monoamine oxidase inhibitors
monoclonal antibodies
mouth and throat products
mTOR inhibitors
mTOR kinase inhibitors
mucolytics
multikinase inhibitors
muscle relaxants
mydriatics
narcotic analgesic combinations
narcotic analgesics
nasal anti-infectives
nasal antihistamines and decongestants
nasal lubricants and irrigations
nasal preparations
nasal steroids
natural penicillins
neuraminidase inhibitors
neuromuscular blocking agents
next generation cephalosporins
nicotinic acid derivatives
nitrates
NNRTIs
non-cardioselective beta blockers
non-iodinated contrast media
non-ionic iodinated contrast media
non-sulfonylureas
nonsteroidal anti-inflammatory agents
norepinephrine reuptake inhibitors
norepinephrine-dopamine reuptake inhibitors
nucleoside reverse transcriptase inhibitors (NRTIs)
nutraceutical products
nutritional products
ophthalmic anesthetics
ophthalmic anti-infectives
ophthalmic anti-inflammatory agents
ophthalmic antihistamines and decongestants
ophthalmic diagnostic agents
ophthalmic glaucoma agents
ophthalmic lubricants and irrigations
ophthalmic preparations
ophthalmic steroids
ophthalmic steroids with anti-infectives
ophthalmic surgical agents
oral nutritional supplements
otic anesthetics
otic anti-infectives
otic preparations
otic steroids
otic steroids with anti-infectives
oxazolidinedione anticonvulsants
parathyroid hormone and analogs
penicillinase resistant penicillins
penicillins
peripheral opioid receptor antagonists
peripheral vasodilators
peripherally acting antiobesity agents
phenothiazine antiemetics
phenothiazine antipsychotics
phenylpiperazine antidepressants
plasma expanders
platelet aggregation inhibitors
platelet-stimulating agents
polyenes
potassium-sparing diuretics
probiotics
progesterone receptor modulators
progestins
prolactin inhibitors
prostaglandin D2 antagonists
protease inhibitors
proton pump inhibitors
psoralens
psychotherapeutic agents
psychotherapeutic combinations
purine nucleosides
pyrrolidine anticonvulsants
quinolones
radiocontrast agents
radiologic adjuncts
radiologic agents
radiologic conjugating agents
radiopharmaceuticals
RANK ligand inhibitors
recombinant human erythropoietins
renin inhibitors
respiratory agents
respiratory inhalant products
rifamycin derivatives
salicylates
sclerosing agents
second generation cephalosporins
selective estrogen receptor modulators
selective serotonin reuptake inhibitors
serotonin-norepinephrine reuptake inhibitors
serotoninergic neuroenteric modulators
sex hormone combinations
sex hormones
skeletal muscle relaxant combinations
skeletal muscle relaxants
smoking cessation agents
somatostatin and somatostatin analogs
spermicides
statins
sterile irrigating solutions
streptomyces derivatives
succinimide anticonvulsants
sulfonamides
sulfonylureas
synthetic ovulation stimulants
tetracyclic antidepressants
tetracyclines
therapeutic radiopharmaceuticals
thiazide diuretics
thiazolidinediones
thioxanthenes
third generation cephalosporins
thrombin inhibitors
thrombolytics
thyroid drugs
tocolytic agents
topical acne agents
topical agents
topical anesthetics
topical anti-infectives
topical antibiotics
topical antifungals
topical antihistamines
topical antipsoriatics
topical antivirals
topical astringents
topical debriding agents
topical depigmenting agents
topical emollients
topical keratolytics
topical steroids
topical steroids with anti-infectives
toxoids
triazine anticonvulsants
tricyclic antidepressants
trifunctional monoclonal antibodies
tumor necrosis factor (TNF) inhibitors
tyrosine kinase inhibitors
ultrasound contrast media
upper respiratory combinations
urea anticonvulsants
urinary anti-infectives
urinary antispasmodics
urinary pH modifiers
uterotonic agents
vaccine
vaccine combinations
vaginal anti-infectives
vaginal preparations
vasodilators
vasopressin antagonists
vasopressors
VEGF/VEGFR inhibitors
viral vaccines
viscosupplementation agents
vitamin and mineral combinations
vitamins
DIAGNOSTIC TESTS
17-Hydroxyprogesterone
ACE (Angiotensin I converting enzyme)
Acetaminophen
Acid phosphatase
ACTH
Activated clotting time
Activated protein C resistance
Adrenocorticotropic hormone (ACTH)
Alanine aminotransferase (ALT)
Albumin
Aldolase
Aldosterone
Alkaline phosphatase
Alkaline phosphatase (ALP)
Alpha1-antitrypsin
Alpha-fetoprotein
Alpha-fetoprotien
Ammonia levels
Amylase
ANA (antinuclear antbodies)
ANA (antinuclear antibodies)
Angiotensin-converting enzyme (ACE)
Anion gap
Anticardiolipin antibody
Anticardiolipin antivbodies (ACA)
Anti-centromere antibody
Antidiuretic hormone
Anti-DNA
Anti-Dnase-B
Anti-Gliadin antibody
Anti-glomerular basement membrane antibody
Anti-HBc (Hepatitis B core antibodies
Anti-HBs (Hepatitis B surface antibody
Antiphospholipid antibody
Anti-RNA polymerase
Anti-Smith (Sm) antibodies
Anti-Smooth Muscle antibody
Antistreptolysin O (ASO)
Antithrombin III
Anti-Xa activity
Anti-Xa assay
Apolipoproteins
Arsenic
Aspartate aminotransferase (AST)
B12
Basophil
Beta-2-Microglobulin
Beta-hydroxybutyrate
B-HCG
Bilirubin
Bilirubin, direct
Bilirubin, indirect
Bilirubin, total
Bleeding time
Blood gases (arterial)
Blood urea nitrogen (BUN)
BUN
BUN (blood urea nitrogen)
CA 125
CA 15-3
CA 19-9
Calcitonin
Calcium
Calcium (ionized)
Carbon monoxide (CO)
Carcinoembryonic antigen (CEA)
CBC
CEA
CEA (carcinoembryonic antigen)
Ceruloplasmin
CH50Chloride
Cholesterol
Cholesterol, HDL
Clot lysis time
Clot retraction time
CMP
CO2
Cold agglutinins
Complement C3
Copper
Corticotrophin releasing hormone (CRH) stimulation test
Cortisol
Cortrosyn stimulation test
C-peptide
CPK (Total)
CPK-MB
C-reactive protein
Creatinine
Creatinine kinase (CK)
Cryoglobulins
DAT (Direct antiglobulin test)
D-Dimer
Dexamethasone suppression test
DHEA-S
Dilute Russell viper venom
Elliptocytes
Eosinophil
Erythrocyte sedimentation rate (ESR)
Estradiol
Estriol
Ethanol
Ethylene glycol
Euglobulin lysis
Factor V Leiden
Factor VIII inhibitor
Factor VIII level
Ferritin
Fibrin split products
Fibrinogen
Folate
Folate (serum
Fractional excretion of sodium (FENA)
FSH (follicle stimulating factor)
FTA-ABS
Gamma glutamyl transferase (GGT)
Gastrin
GGTP (Gamma glutamyl transferase)
Glucose
Growth hormone
Haptoglobin
HBeAg (Hepatitis Be antigen)
HBs-Ag (Hepatitis B surface antigen)
Helicobacter pylori
Hematocrit
Hematocrit (HCT)
Hemoglobin
Hemoglobin A1C
Hemoglobin electrophoresis
Hepatitis A antibodies
Hepatitis C antibodies
IAT (Indirect antiglobulin test)
Immunofixation (IFE)
Iron
Lactate dehydrogenase (LDH)
Lactic acid (lactate)
LDH
LH (Leutinizing hormone
Lipase
Lupus anticoagulant
Lymphocyte
Magnesium
MCH (mean corpuscular hemoglobin
MCHC (mean corpuscular hemoglobin concentration)
MCV (mean corpuscular volume)
Methylmalonate
Monocyte
MPV (mean platelet volume)
Myoglobin
Neutrophil
Parathyroid hormone (PTH)
Phosphorus
Platelets (plt)
Potassium
Prealbumin
Prolactin
Prostate specific antigen (PSA)
Protein C
Protein S
PSA (prostate specific antigen)
PT (Prothrombin time)
PTT (Partial thromboplastin time)
RDW (red cell distribution width)
Renin
Rennin
Reticulocyte count
reticulocytes
Rheumatoid factor (RF)
Sed Rate
Serum glutamic-pyruvic transaminase (SGPT
Serum protein electrophoresis (SPEP)
Sodium
T3-resin uptake (T3RU)
T4, Free
Thrombin time
Thyroid stimulating hormone (TSH)
Thyroxine (T4)
Total iron binding capacity (TIBC)
Total protein
Transferrin
Transferrin saturation
Triglyceride (TG)
Troponin
Uric acid
Vitamin B12
White blood cells (WBC)
Widal test

### Claim 3281 (depends on 332)

The invention of claim 332, wherein said drug comprises Sumatriptan Injection (Alsuma).

### Claim 3321 (depends on 332)

The invention of claim 332, wherein said drug comprises Typhoid Vi.